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I went to the woods because I wished to live deliberately. I wanted to live deep and 
suck out all the marrow of life, to live so sturdily and Spartan-like as to put to rout all 
that was not life. And not, when I came to die, discover that I had not lived. 
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Neuregulin (NRG) 1 contains an epidermal growth factor (EGF)-like signaling domain 
and serves as a ligand for receptor tyrosine kinases of the ErbB family. ErbB4, the 
main neuronal NRG1 receptor in the brain, is enriched in GABAergic interneurons. 
NRG1/ErbB4 signaling regulates different aspects of nervous system development 
and synaptic plasticity in the mature brain. Variants of the human NRG1 and ERBB4 
genes are genetic risk factors for schizophrenia, and inhibitory network dysfunctions 
have been implicated in schizophrenia. For NRG1 most of the at-risk haplotypes are 
located in non-coding regions, implicating that expression of NRG1 isoforms might 
be altered in SZ. In line with this, increased NRG1 expression and ErbB4 
hyperphosphorylation was observed in postmortem brains of schizophrenia patients, 
suggesting that NRG1/ErbB4 hyperstimulation represents a possible 
pathomechanisms in schizophrenia. To test this hypothesis several NRG1 loss- and 
gain-of-function mouse models were employed to examine effects of altered NRG1 
signaling on nervous system development and adult brain functions. 
Conditional ablation of NRG1 in the embryonic cortex (Emx-Cre*Nrg1f/f mice) had no 
effect on cortical development, whereas pan-neuronal overexpression of the CRD-
NRG1 isoform in transgenic mice lead to ErbB4 hyperactivation, altered numbers of 
cortical interneurons, changes in dendritic spine morphology, ventricular 
enlargement, increased anxiety-like behavior, and impaired sensorimotor gating. 
These data suggest that the human NRG1 risk haplotypes exert a gain-of-function 
effect. 
To study NRG1/ErbB4 hyperstimulation in a more selective in vivo model, a 
‚conditional’ transgenic mouse line (Stop-Nrg1) was generated, which allows Cre 
recombinase-mediated CRD-NRG1 overexpression. This mouse line was examined 
in combination with different Cre ‚driver’ lines to model distinct temporal and spatial 
aspects of CRD-NRG1 overexpression in the brain. Postnatal onset of CRD-NRG1 
overexpression had only minor effects on nervous system development and 
behavior, whereas early embryonic onset of NRG1 hyperstimulation lead to 
hyperactivity, consistent with the neurodevelopmental hypothesis of schizophrenia. 
Cortical-restricted CRD-NRG1 overexpression had no effect on ventricular size or 
sensorimotor gating, indicating functions of CRD-NRG1 signaling in subcortical 
networks. Finally, CRD-NRG1 was present in synaptosomal fractions and appears to 
recruit LIMK1-cofilin signaling, providing a potential mechanism for the regulation of 






2.1 The central nervous system 
The human brain is the most complex biological structure on earth. It performs a 
large variety of complex tasks, including the reception, processing, integration and 
storage of information. In addition, by controlling the central and peripheral nervous 
system it controls and adapts body functions and motor behavior.  
In the beginning of the 20th century Santiago Ramón y Cajal layed the foundation for 
our understanding of the nervous system by describing its central information 
processing unit, the neuron. The human brain consists of approximately 1011 neurons 
(Brose, 1999). These neurons are electrically excitable cells that form neuronal 
networks (Fig. 1). In order to achieve higher brain functions, neurons communicate 
with each other via two kinds of elaborations: multiple dendrites, which receive 
incoming informations and send them to the cell soma, and a single axon that passes 
electrical informations on to the next cell.  
If the electrical excitation of a neuron reaches a certain threshold, an action potential 
is generated at the axon hillock and travels along the axon and eventually reaches a 
nerve terminal, the synapse. Neurons communicate via 1014 to 1015 of these 
synapses (Brose, 1999). At the synapse the plasma membranes of two cells come 
into close proximity and form a synaptic cleft. Both, the pre- and the postsynaptic 
membrane are specialized to transmit information from one cell to another. Neurons 
communicate with each other through electrical and chemical signals. Besides rare 
electrical synapses, the majority of neurons in the vertebrate central nervous system 
(CNS) communicate via chemical synapses. During neuronal communication an 
action potential that reaches a synapse triggers the fusion of synaptic vesicles with 
the presynaptic membrane. These vesicles contain neurotransmitters, that are 
released into the synaptic cleft and thereby transform electrical information into 
chemical signals. Neurotransmitters bind to receptors in the postsynapse. Depending 
on the neurotransmitter released and the neurotransmitter receptor it binds to, 
different postsynaptic reactions are triggered. Two kinds of neurotransmitter 
receptors exist in the nervous system, ligand-gated (ionotropic) receptors and G-
protein-coupled (metabotropic) receptors. Ionotropic receptors can either be excited, 
by neurotransmitters like glutamate or aspartate, or inhibited by ligands like GABA or 
glycine. Metabotropic receptors are not directly channel-linked. Upon ligand binding a 
conformational change is induced, which allows the receptor to activate adapter 
molecules, so called G-proteins, by exchanging their bond GDP by GTP. Thereupon, 




lead to ion channel opening or altered gene expression, and therefore can induce 
long-term changes in the activated cell (Kandel, 2013). 
Cortical networks comprise two classes of neurons: excitatory (mostly glutamatergic) 
pyramidal neurons and inhibitory (mostly GABAergic) interneurons (Fig. 1). 
Pyramidal neurons process sensory or motor informations and generate output 
signals, that control other parts of the nervous system and body, including muscles in 
the periphery. Interneurons connect locally between neurons, are typically inhibitory 
and modulate the activity of pyramidal neurons by finetuning their excitability. In line 
with their different function, pyramidal neurons and interneurons also originate from 
different brain regions and progenitor cells. While excitatory neurons derive from 
progenitors in the ventricular zone (VZ) of the pallium and migrate radially into the 
emerging neocortex, inhibitory neurons originate from several progenitor pools in the 
subpallium, from where they migrate along tangential routes to the developing 
neocortex, where they shift from tangential to radial migration and invade different 
neocortical cell layers (Marin, 2013; Marin and Müller, 2014). GABAergic 
interneurons can be classified into nearly 30 different subtypes based on molecular, 
morphological and physiological criteria (DeFelipe et al., 2013). Since they originate 
from distinct progenitor pools and adopt their final cortical position following specific 
rules, interneuronal migration is a highly complex process (Marin, 2013). 
Pyramidal neurons possess two kinds of dendrites. Basal dendrites elaborate from 
the side of the cell body from which also the axon originates. Apical dendrites 
originate from the opposite side. Dendrites of pyramidal neurons possess specific 
synaptic microdomains, the so-called dendritic spines, at which excitatory synapses 
terminate (Fig. 1). Dendritic spines are equipped with a postsynaptic density (PSD), 
which contains neurotransmitter receptors, ion channels and enzymes that serve in 
synaptic neurotransmission (Kennedy, 1997; Ziff, 1997). PSD95 (postsynaptic 
density protein of 95 kDa) is an important component of the PSD, involved in the 
molecular organisation of the postsynaptic complex. Pyramidal neurons form 
synapses with both other excitatory (glutamatergic) pyramidal neurons and inhibitory 
(GABAergic) interneurons (Markram et al., 2004). Excitatory synapses on pyramidal 
neurons are usually formed with dendritic spines. Inhibitory interneuron dendrites 
usually do not form dendritic spines and excitatory synapses on interneurons are less 





Fig. 1: A cortical neuronal microcircuit. A central excitatory pyramidal neuron is innervated 
by different classes of interneurons. Basket cells target the soma and basal dendrites of 
pyramidal cells, whereas chandelier cells synapse on the axon initial segment (AIS). 
Martinotti and neurogliaform cells types contact pyramidal cell dendrites. Bipolar cells are 
specialized in targeting other interneurons (modified from Marin, 2012). 
 
About 20-30% of neocortical neurons are inhibitory interneurons. They are 
morphologically diverse and their precise classification is subject to ongoing 
discussion (see Fig. 1 and DeFelipe et al., 2013). Inhibitory interneurons use GABA 
as their main neurotransmitter. Inhibitory synapses to pyramidal neurons are usually 
formed with dendrites, the soma and the axonal initial segment (Freund and Buzsáki, 
1996; Benes and Berretta, 2001) and constitute up to 16 % of all synapses on 
cortical pyramidal neurons (Markram et al., 2004). Interneurons usually have smooth 
dendrites, without spines, and they receive excitatory and inhibitory synapses to their 
cell soma. Basket cells for instance usually form synapses with the perisomatic 
regions of pyramidal cells (Markram et al., 2004), whereas so-called „Chandelier“-
cells innervate the axonal initial segment and the axon hillock (Somogyi, 1977). 
„Neurogliaform“ and „double-bouquet“-cells on the other hand form synapses with 
dendrites of pyramidal cells (see Fig. 1 and Benes and Berretta, 2001; Markram et 
al., 2004). Apart from these innervation profiles, interneurons can also be classified 
via their molecular properties, the expression of certain marker proteins, usually 




neuropeptides, including somatostatin, cholecystokinin (CCK), neuropeptide Y 
(NPY), and vasoactive intestinal peptide (VIP) (Freund and Buzsáki, 1996; DeFelipe 
et al., 2013). A newly imerging criterium is the origin of interneuron subpopulations, 
whether they originate from the medial ganglionic eminence (MGE), lateral and 
dorsocaudal ganglionic eminence (CGE) or the preoptic area (POA). Yet another is 
the classification via electrical properties. Interneurons exhibit a variety of different 
firing patterns, including “fast-spiking” (FS) and “Non-adapting, non-fast-spiking” (NA-
NFS) cells (reviewed in DeFelipe et al., 2013). Parvalbumin-positive (PV+) 
interneurons for instance are usually fast-spiking interneurons that play an important 
role in the synchronization of pyramidal cell activity and the generation of -
oszillations (Bartos et al., 2007). 
Besides neurons, the nervous system consists of another, even more abundant cell 
type, the glial cells (Fig. 2). In fact glial cells outnumber neurons by 10 to 15 times 
(Kandel, 2013). The name glia comes from the Greek word for glue, because these 
cells were first thought to glue together nervous tissue. In addition to the stabilizing 
function, glial cells have been shown to provide several important functions, including 
myelination and metabolic support of axons. 
Glial cells can be subdivided into two different cell classes, micro- and macroglia. 
While microglia are specialized macrophages, that are mobile, serve immune 
functions and protect the nervous system, CNS macroglia can be further divided into 
oligodendrocytes and astrocytes (Fig. 2).  
The main function of oligodendrocytes is the insulation of axons of the central 
nervous system. By enwrapping axons with multiple layers of extended plasma 
membrane they produce a densly packed insulating sheath, the so-called myelin 
sheath (Fig. 2A). Because voltage-dependent sodium channels are only present at 
the nodes of ranvier, action potentials jump from node to node, in saltatory impulse 
propagation, increasing propagation speed by ~100-fold and reducing space and 
energy consumption (Garbay et al., 2000; Salzer, 2003). Unlike Schwann cells in the 
PNS, one oligodendrocyte can myelinate multiple axonal segments (Fig. 2A). Recent 
results also suggest a metabolic support function for axons, that is required for 
functional integrity and long-term survival (Funfschilling et al., 2012; Saab et al., 
2013). 
Astrocytes are named after the Greek word for star (‚astron’) because of their 
numerous projections giving them a star shape and allow them to connect to blood 
vessels and other cells. They are the most abundant cell type in the human brain and 




nutrients to the nervous tissue and also regulate the external chemical environment 
by removing excess ions, especially K+ ions. Perinodal astrocytes contact the nodes 
of ranvier of CNS myelin, where they are thought to buffer the extracellular ion 
concentrations, but also stabilize the nodes and provide nutrients (see Fig. 2A and 
Black and Waxman, 1988). According to the tripartite synapse theory astrocytic 
processes engulf neuronal synapses and not only recycle neurotransmitters, but are 
also thought to modulate synaptic efficacy by release of „gliotransmitters“, like 
glutamate or ATP (see Fig. 2B and Lalo et al., 2009; Santello and Volterra, 2009). 
 
 
Fig. 2: Glial cells of the central nervous system. (A) Oligodendrocytes are the myelin 
forming cells of the CNS. In contrast to Schwann cells in the PNS, oligodendrocytes engulf 
multiple axonal segments with a myelin sheath. The myelin sheath speeds up neuronal signal 
propagation by saltatory impulse propagation. Perinodal astrocytes contact the nodes of 
ranvier, where they buffer the extracellular ion concentrations, stabilize the nodes and provide 
nutrients (modified from Poliak and Peles, 2003). (B) Astrocyte processes engulf neuronal 
synapses and form the so-called tripartite synapse. Astrocytes recycle neurotransmitters and 
modulate synaptic efficacy by releasing „gliotransmitters“ (modified from Allen and Barres, 
2009). 
 
Taken together the central nervous system is a highly complex and dynamic 
structure, which comprises multiple cell types. By cell-cell communication the 




new synaptic connections are formed or some axonal pathways are strengthened, 
while others are retracted during development. 
Apart from electrical and neurotransmitter-mediated neuronal communication, 
communication modules, consisting of ligands and receptors, regulate essential 
processes of neuronal development and maintenance. These modules are potentially 
involved in functions like neuronal migration, synapse formation and cortical network 
establishment and myelination. Defects in these signaling modules can result in 
impaired neuronal development and abnormalities in synaptic signaling, 
dysconnectivity, neuroinflammation and -degeneration. Ultimately, these processes 
can precipitate neurodegenerative diseases, e.g. Alzheimers disease or 
neuropsychiatric disorders such as schizophrenia. 
 
2.2 Schizophrenia 
Schizophrenia (SZ) is a devastating mental illness that affects an estimated 0.5 to 1 
% of the general population world wide. The estimated financial burden to the 
European health care systems is 30 billion € annually. SZ has been considered a 
neurodegenerative disorder by some, but the most established data suggest that SZ 
is a late onset neurodevelopmental disorder. The age of onset of the disease is 
usually in late adolescence or during early adulthood. Data suggest that SZ is 
affecting glutamatergic, dopaminergic and GABAergic cortical microcircuits directly or 
indirectly, as well as grey and white matter (Harrison and Weinberger, 2005; Owen et 
al., 2005). No clear causal genetic, biochemical or pathophysiological relationships 
have been identified yet. Thus, a clear classification of the disease by hallmark 
biomarkers is not possible. The diagnoses of SZ is based on characterization of 
behavioral phenotypes of patients (Andreasen, 1995; McKenna, 2013). These 
psychological and cognitive impairments can be grouped into positive (delusions, 
hallucinations and thought disorder) and negative symptoms (social withdrawal, 
cognitive deficits) (Harrison, 1999; McGuffin et al., 2004). Problems of establishing 
the validity and boundaries of SZ diagnosis, as in any syndromal diagnosis, exist, 
impacting on research regarding its pathological basis and causative genes 
(Jablensky, 1995; Kennedy, 1996). Although a clear cause of SZ is lacking, twin 
studies suggest a significant genetic component based on a 50 % concordance in 
monozygotic twins. These studies also showed that SZ has a 80 % heritability 
(Gottesman, 1991; McGuffin et al., 2004). In addition to a genetic predisposition, 




Environmental stressors that can occur in early development, during pregnancy or 
childhood, include for instance social stress or drug abuse. During adolescence, 
environmental factors can further damage the brain (Leask, 2004). 
A number of morphological abnormalities have been identified in schizophrenia, 
including ventricular enlargement and reduced cerebral (cortical and hippocampal) 
volume. In addition alterations in synaptic, dendritic and axonal organization have 
been observed. Advances in microscopy enabled extensive studies of dendritic and 
axonal structures as well as synapses in postmortem tissue of SZ patients. These 
studies have shown abnormalities in neuronal processes and reduction of dendritic 
spines in SZ tissue (Moyer et al., 2014), suggesting SZ to be a synaptic disorder. 
These structural changes are supported by functional studies. Aberrant activity in the 
components of cortical circuits, involving the prefrontal cortex (PFC), the 
hippocampus and certain subcortical structures, like the dorsal thalamus, has been 
demonstrated through functional imaging data. Neuronal dysconnectivity between 
aforementioned brain regions is thought to result from functional abnormalities 
(Harrison, 1999).  
Genome-wide association studies (GWAS) have identified multiple candidate genetic 
risk factors for SZ (>100). Alongside the ‚classic’ SZ at-risk locus disrupted in 
schizophrenia-1 (DISC1), the Neuregulin (NRG) 1 gene has emerged as a major risk 
gene for SZ (Harrison, 2015). NRG1 and its major brain receptor ErbB4 (see below) 
are embedded in a pathway of SZ risk factors also comprising PI3K–AKT1. 
Dysregulated expression of such signaling modules could trigger abnormal activity in 
the signaling pathways they are embedded in and thereby ultimately lead to 
morphological and physiological dysfunctions with relevance for neuropsychiatric 
disorders, including SZ. 
Although none of these genes alone is significant in GWAS studies, there is evidence 
for the involvement of all four genes in SZ (Emamian et al., 2004; Harrison and Law, 
2006; Norton et al., 2006a; Nicodemus et al., 2010; Law et al., 2012; Hatzimanolis et 
al., 2013). 
 
2.3 Neuregulin1 isoforms 
The NRG1 gene belongs to a gene family, which includes six members (NRG1, 
NRG2, NRG3, NRG4, NRG5 and NRG6), with NRG1 being the best characterized 
(Falls, 2003; Mei and Nave, 2014). NRG1 is one of the largest mammalian genes 
(1.4 megabases in humans), located on the short arm of chromosome 8. Due to 




family of growth and differentiation factors with more than 30 different isoforms (see 
Fig. 3 and Steinthorsdottir et al., 2004). NRG1 isoforms include secreted and 
transmembrane proteins, all of which share a common epidermal growth factor 
(EGF)-like signaling domain that is necessary and sufficient for the activation of 
receptor-tyrosine kinases of the ErbB family (Falls, 2003). The EGF-like domain exist 
in an -, and -form, with the binding affinity of the β-form being 100-fold stronger 
than the -form (Jones et al., 1999). NRG1 isoforms can be grouped into six main 
classes (types I – VI; see Figure 3 and Mei and Xiong, 2008) based on distinct N-
terminal domains. Types IV to VI have not been extensively characterized and will 




Fig. 3: NRG1 isoforms. (A) Alternative splicing and differential promoter usage give rise to at 
least 30 NRG1 isoforms that can be grouped into six classes based on N-terminal protein 
domains. All NRG1 isoforms share a common EGF-like domain. Ig-NRGs (Type I, II, IV and 
V) carry an immunoglobulin (Ig)-like domain. The N-terminal domain of NRG1 type III 
(cystein-rich domain; CRD) habors a second transmembrane domain (TMn). (B) Most NRG1 
isoforms are produced as transmembrane proteins, also referred to as pro-NRG1s, which 
undergo proteolytic cleavage in the juxtamembrane linker (‚stalk’) region (flash) by proteases 
such as BACE1 or ADAMs metalloproteases, generating soluble („mature“) NRG1s. In case 
of NRG1 type III, the processed form remains membrane thethered due to the second TMn 





NRG1 type I, II, IV and V isoforms contain an immunoglobulin (Ig)-like domain 
between the N-terminal sequence and the EGF-like domain, and are therefore 
referred to as “Ig-NRGs” (see Fig. 3 and Harrison and Law, 2006; Mei and Xiong, 
2008). Members of the type I group were identified independently and originally 
named heregulin (Holmes et al., 1992), acetylcholine receptor-inducing activity 
(ARIA) (Falls, 2003), or neu-differentiation factor (NDF) (Wen et al., 1992). The type 
II isoforms, also referred to as glial growth factor (GGF) (Marchionni et al., 1993), 
harbor a “kringle” domain, located N-terminally to the Ig-like domain. Sensory and 
motor neuron derived factor (SMDF) (Ho et al., 1995), nowadays referred to as 
NRG1 type III, harbors a cystein-rich domain (CRD) that serves as a second 
transmembrane domain (Fig. 3). These isoforms are also known as “CRD-NRGs” 
(Falls, 2003). Additional NRG1 variants are generated by splicing different linkers 
into the juxtamembrane ‘stalk’ region. Finally, the cytoplasmic tail of NRG1 is 
structurally variable, as isoforms of different length (a, b, c) exist (Wen et al., 1994) 
(Fig. 3). 
Further complexity is added to NRG1 signaling by posttranslational modifications, 
e.g. glycosylation (Burgess et al., 1995), and proteolytic processing (Fig. 3B). NRG1 
is cleaved in the stalk region by proteases such as BACE1 (-site APP-cleaving 
enzyme) (Hu et al., 2006, 2008; Willem et al., 2006) and metalloproteases of the 
ADAMs family, ADAMS17 (or tumor-necrosis factor‐ -converting enzyme; TACE), 
and ADAMS19 (or Meltrin beta) (Horiuchi et al., 2005; Yokozeki et al., 2007). While 
processing in the stalk region releases extracellular parts of NRG1 type I and type II 
proproteins from the cell surface for paracrine signaling, the N-terminal fragment of 
the type III isoforms, is thought to remain membrane anchored (Fig. 3B). Their 
signaling is thought to proceed in a juxtacrine fashion (Mei and Xiong, 2008). 
However, it has recently been shown that further processing of type III isoforms 
releases the EGF-like domain, allowing paracrine signaling (Birchmeier and Nave, 
2008; Willem et al., 2009; Fleck et al., 2013). 
In addition to EGF-like domain-mediated ‚forward signaling’ to ErbB4, the intracellular 
C-terminal domain of NRG1 (NRG1-ICD or -CTF) has also been linked to signaling 
processes (Fig. 6). Specifically, it has been shown that after initial extracellular 
cleavage, -secretase can cleave the C-terminal domain, releasing the NRG1-ICD 
(Mei and Xiong, 2008; Talmage, 2008). NRG1-ICD signaling is of relevance for 
neuropsychiatric diseases, as a schizophrenia at risk mutation (substitution at valine 
321) results in a NRG1 type III protein that fails to undergo -secretase-mediated 




that this mutation impairs dendritic development independent of ErbB kinase activity 
(Chen et al., 2010).  
Finally, NRG1 isoform expression has been shown to be differentially regulated 
during development. The most prominant isoforms in the human and rat brain are 
type III and type II isoforms, followed by type I and type V. It is important to note that 
all isoforms show dynamic expression profiles during developmental stages with 
expression peaks during early embryonic stages (embryonic day (E) 13) and around 
postnatal day (P) 5, suggesting functions in early neural development and the 
neonatal critical period. Most of the NRG1 isoforms are expressed by excitatory 
neurons, but are also present in GABAergic interneurons and astrocytes (Liu et al., 
2011). NRG1 expression is also regulated by neuronal activity. Using a rat model of 
epileptic seizures induced by kainic acid (KA) treatment, type I and II isoforms were 
found to be significantly upregulated, while KA treatment had no effect on the 
expression of types III, V and VI isoforms. (Liu et al., 2011), suggesting isoform-
specific  regulation of distinct NRG1 isoforms. 
In 2002, NRG1 was identified as a SZ susceptibility gene by fine mapping of the 
locus on chromosome 8p22 and haplotype association analysis performed in families 
of Icelandic origin. A „core at-risk” region in the 5’ region of the NRG1 gene was 
identified and named the "Icelandic haplotype" by Stefansson et al. (2002). This 
region surrounds an exon that encodes the NRG1 type II-specific domain. Several 
but not all subsequent studies in other populations have replicated the association to 
SZ, hence NRG1 has been on and off the lists of major SZ risk genes since then 
(Harrison and Weinberger, 2005). However, of the 23.094 single nucleotide 
polymorphisms (SNPs) found in the human NRG1 gene approximately 40% have 
been linked to SZ. ErbB4, the most prominent NRG1 receptor in the brain, has as 
well been identified as a SZ at risk gene in several studies (Nicodemus et al., 2006; 
Silberberg et al., 2006; Law et al., 2007). Both genes are on the list of major SZ 
susceptibility genes (for both NRG1 and ErbB4 see Schizophrenia Gene Resource, 
Vanderbilt University; http://bioinfo.mc.vanderbilt.edu/SZGR). 
 
2.4 The ErbB receptor family 
NRG1 signals via its EGF-like domain to receptor tyrosine kinases of the ErbB family 
(Mei and Xiong, 2008). The family name derives from the erythroblastic leukemia 
viral oncogene (v-erbB). ErbB receptors play an important role in the development of 
the heart and in different types of cancer. In the nervous system, ErbB receptors 




processes, including neuronal migration, Schwann cell- and oligodendrocyte-
mediated myelination, axon guidance, synapse and neuromuscular junction 
formation (Mei and Xiong, 2008). 
ErbB receptors are structurally related to the epidermal growth factor receptor 
(EGFR, HER or ErbB1), which was identified in the early 1980s. Since then the ErbB 
family has grown to four members, ErbB1 to 4, which together integrate at least 11 
different ligands (Yarden and Sliwkowski, 2001). ErbB transmembrane receptors 
have similar structures, with a large glycosylated extracellular N-terminal domain that 
carries the ligand binding site (seperated into four subdomains) (Fig. 4, 5). The 
cystein-rich domains II and IV can form 25 disulfide-bridges and play an important 
role in receptor dimerization (Fig. 4). All receptors have a transmembrane domain 
and a cytoplasmic tyrosine kinase domain with several potential tyrosine 
phosphorylation sites (Linggi and Carpenter, 2006). Upon ligand binding 
conformational changes are induced that render a dimerization arm accessible and 
allow the receptors to form homo- and heterodimers (Burgess et al., 2003), followed 
by activation of the intracellular tyrosine kinase domain. Dimerized receptors then 
auto- and transphosphorylate themselves at the C-terminus (Fig. 4). This process 
was shown to depend on receptor endocytosis (Gu et al., 2005; Yang et al., 2005; 
Liu et al., 2007). The intracellular phosphorylated tyrosine-residues then serve as 
binding sites for adaptor proteins that stimulate downstream signaling cascades. 
ErbB receptors differ in their function. ErbB1 does not to bind NRG1, but is activated 
by at least seven other ligands, including EGF, TGF-, and heparin-binding EGF-like 
growth factor (HB-EGF). Also ErbB2 (also known as Her2 or Neu) does not bind 
NRG1, as it has an impaired ligand binding domain and functions only as a 
coreceptor (see Fig. 4 and Klapper et al., 1999). Although ErbB2 can not bind 
ligands, its conformation allows dimerization without ligand binding. ErbB2 is the 
preferred dimerization partner for other ErbBs, as heterodimers involving ErbB2 have 
a higher ligand affinity (Citri et al., 2003). In addition, interaction with ErbB2 allows its 
dimerization partners to bind additional ligands (Citri et al., 2003). 
ErbB3 (also known as Her3) binds NRG1 and NRG2. Since ErbB3 is lacking a 
functional kinase domain, it must form heterodimers with other ErbB receptors in 
order to convey signals (see Fig. 4 and Guy et al., 1994). Thus, ErbB4, which binds 
to all NRGs, epiregulin, betacellulin and HB-EGF, is the only receptor that can form 
functional NRG-binding homodimers (Fig. 5). In addition, it forms heterodimers with 
all other ErbBs (Mei and Xiong, 2008). Although ErbB2 and ErbB3 alone are inactive, 
in vitro studies have shown that they form the most potent heterodimer to regulate 




In summary the following functional ErbB receptor dimers can be activated by NRG1 




Fig. 4: ErbB receptors: ligand binding and receptor dimerization. Binding of NRG 
molecules to ErbB receptors is illustrated for an ErbB2/ErbB3 heterodimer. ErbB2 has an 
inactive ligand-binding site and only functions as a co-receptor. ErbB3 is lacking an active 
intracellular kinase domain and also only functions as a heterodimer. Conformational changes 
are induced by ligand binging and result in receptor dimerization, which leads to auto- and 
transphosphorylation of intracellular tyrosin residues and recruitment of adaptor proteins, and 
activation of downstream signaling cascades (modified from Citri et al., 2003). 
 
Activation of ErbB receptors and recruitment of adaptor proteins triggers intracellular 
signaling pathways that regulate cellular responses, including stimulation or inhibition 
of proliferation, apoptosis, migration, differentiation, and adhesion (Yarden and 
Sliwkowski, 2001). 
 
2.5 The ErbB4 receptor 
Analyses of ErbB receptor expression patterns and functions revealed that ErbB4 is 
the main neuronal receptor for NRG1 in the brain (Fig. 5). ErbB4 is predominantly 
expressed by the majority of PV+ interneurons (Neddens and Buonanno, 2009, 2011; 
Vullhorst et al., 2009; Neddens et al., 2011). Similar to the multimodal signaling 
properties of NRG1, ErbB receptors exhibit different signaling properties. In 
canonical forward signaling, the aforementioned auto- and transphosphorylation and 
recruitment of adaptor proteins triggers intracellular signaling pathways, including the 
Raf–MEK–ERK and PI3K–AKT–S6K pathways (Si et al., 1999; Fu et al., 2001; 
Yarden and Sliwkowski, 2001; Bjarnadottir et al., 2007). 
Similar to NRG1, ErbB4 transcripts are alternatively spliced, resulting in four different 
isoforms by differential pairing of the cytoplasmic C-terminal CYT-1 and CYT-2 




ErbB4 isoforms show distinct tissue- and brain-region-specific expression patterns 
and trigger distinct signaling cascades. Both cytoplasmic isoforms regulate DNA 
synthesis and proliferation by activation of the Shc–Ras–MAPK signaling pathway. 
However, only the CYT‐ 1, but not CYT‐ 2 isoform, can activate PI3K and 
subsequently AKT (see Fig. 5 and Elenius et al., 1999), that regulates chemotaxis 
and apoptosis (Elenius et al., 1997; Sawyer et al., 1998; Junttila et al., 2000; 
Kainulainen et al., 2000; Rio et al., 2000; Lewis et al., 2005; Norton et al., 2006b). 
Both JMa and JMb can bind NRG1, but only JMa is a substrate for TACE-mediated 
cleavage and release of an extracellular domain of ErbB4 (ecto-ErbB4, Fig. 5) 
(Sawyer et al., 1998; Rio et al., 2000; Cheng et al., 2003; Arasada and Carpenter, 
2005). TACE-mediated cleavage is part of non-canonical ErbB4 forward signaling 
(Fig. 6) and mediated by ligand-binging or protein kinase C (PKC) activity (Vecchi et 
al., 1996; Zhou and Carpenter, 2000; Zhu et al., 2000). This first cleavage renders 
the remaining protein fragment accessible to -secretase-mediated cleavage and 
release of the ErbB4 intracellular domain (ErbB4-ICD), similar to NRG1-ICD 
cleavage (Fig. 6). The ErbB4-ICD can be translocated into the nucleus and is thought 
to act as a chaperon that promotes the nuclear transport of transcription factors 
STAT5 (signal transducer and activators of transcription) and YAP1 (Yes-associated 
protein-1), thereby regulating gene expression (Ni et al., 2001; Lee et al., 2002; 
Komuro et al., 2003; Omerovic et al., 2004; Williams et al., 2004; Sardi et al., 2006; 





Fig. 5: Splice isoforms of the ErbB4 receptor. (A) Four different ErbB4 variants are 
produced by alternative splicing of juxtamembrane regions JMa or JMb and the cytoplasmic 
CYT-1 or CYT-2 domains. (B) ErbB4 is produced as a singlepass membrane protein with two 
extracellular cysteine-rich (CRD) domains, important for receptor dimerization. Only the JMa 
region is a substrate of TACE-mediated cleavage (flash) and release of the extracellular 
domain of ErbB4 (ecto-ErbB4). Both cytoplasmic isoforms can activate the Shc-Ras-MAPK 
signaling pathway, but only the CYT‐ 1 containing variant activates PI3K and AKT signaling 
(modified from Mei and Xiong, 2008). 
 
ErbB4, as the only member of the ErbB family, contains a C-terminal T-V-V peptide 
motive that allows the interaction with PDZ-domains of other proteins (Garcia et al., 
2000). PDZ were originally identified in PSD95 (Cho et al., 1992; Kistner et al., 1993) 
and a colocalization of ErbB4 and PSD95 was observed in the excitatory 
postsynapse (Garcia et al., 2000; Huang et al., 2000; Ma et al., 2003). It has been 
suggested that ErbB4/PSD95 signaling could potentially modulate NMDA and AMPA 
receptor functions and K+ channels (Kim and Sheng, 2004). Thus, interactions of 
ErbB4 with synaptic proteins, like the scaffold protein PSD95, could link NRG1/ErbB4 
signaling to synaptic organization by impacting on synaptic integrity and function. 
 
2.6 NRG1/ErbB4 signaling in cortical networks during health and 
disease 
NRG1 and ErbB4 are implicated in regulating various aspects of neural development, 




have been considered relevant for neuropsychiatric disorders, including SZ, as 
reduced numbers of inhibitory interneurons (Benes et al., 1991; Chance et al., 2005; 
Holt et al., 2005; Levitt, 2005; Heckers and Konradi, 2014), as well as reduced 
expression of GAD67 in PV+ interneurons of the dorsolateral prefrontal cortex and 
disturbed inhibitory functions (Benes et al., 1991; Akbarian et al., 1995; Hashimoto et 
al., 2003; Lewis et al., 2005; Farzan et al., 2010; Ongür et al., 2010; Yoon et al., 
2010) have been described in cases of SZ. In addition, alterations in dendritic spines 
(Penzes et al., 2011) and deficits in cortical synchronization were observed in SZ 
(Uhlhaas and Singer, 2010). 
Most of the NRG1 at-risk haplotypes have been mapped to the non-coding region of 
the NRG1 gene (Stefansson et al., 2002; Weickert et al., 2012), suggesting that 
rather than altered protein functions per se, changes in NRG1 expression levels 
could cause abnormal NRG1 functions in SZ. Indeed reduced and increased NRG1 
expression were found in postmortem studies of SZ patients (Law et al., 2006; 
Bertram et al., 2007), including elevated expression of CRD-NRG1, the predominant 
isoform of NRG1 in the human brain (Liu et al., 2011; Weickert et al., 2012). In 
addition, NRG1-induced ErbB4 hyperphosphorylation was observed in postmortem 
brains of SZ patients supporting this idea (Hahn et al., 2006). 
By in situ hybridization and immunostainings, NRG1 expression has been detected in 
pyramidal neurons of the human and rat cortex and hippocampus, for instance in 
hippocampal CA3 pyramidal neurons, that form the Schaffer collaterals by projection 
to CA1 neurons (see Fig. 7 and Law et al., 2004; Okada and Corfas, 2004). ErbB4 
on the other hand is expressed by GABAergic interneurons (see Fig. 7 and Neddens 
and Buonanno, 2009, 2011; Vullhorst et al., 2009; Neddens et al., 2011) and has 
been colocalized with PSD95 in the excitatory postsynapse (Garcia et al., 2000; 
Huang et al., 2000). Interaction of ErbB4 with PSD95 has been shown to increase 
the activation of the receptor by NRG and subsequent MAP-kinase signaling (Huang 
et al., 2000). The postulated localization of NRG1 and ErbB4 suggests a potential 
involvement in the regulation of neuronal migration, synaptic plasticity and pyramidal 
neuron-interneuron interaction (Fig. 6, 7). 
Modelling loss- and gain-of-functions of NRG1 and ErbB4 in cell culture and 
transgenic mouse models has become a valuable tool to study their functions in vitro 
and in vivo. These approaches have delivered important insights into NRG1/ErbB4 
signaling functions during the formation and maintenance of cortical circuitry under 
normal and disease conditions. 
Due to a heart defect, ErbB4 null mutant mice die at E10.5 (Gassmann et al., 1995), 




rescue“, ErbB4-/- HER4heart) the null mutant is viable (Tidcombe et al., 2003). Such 
genetic ablation of ErbB4 in mice was shown to impair GABAergic interneuron 
migration from the subpallium to the cortex (Flames et al., 2004), and thalamo-
cortical axonal pathfinding (López-Bendito et al., 2006). Interneurons ultimately fail to 
reach the cortex, leading to reduced numbers of GABAergic interneurons in ErbB4-/- 
mice (Flames et al., 2004; Neddens and Buonanno, 2009). In line with this, ErbB4-/- 
mutant mice have comprised inhibitory circuits (Neddens and Buonanno, 2009; 
Fazzari et al., 2010; Wen et al., 2010; Del Pino et al., 2013).  
Treatment of hippocampal slices with soluble NRG1 was shown to block LTP (Huang 
et al., 2000; Kwon et al., 2005; Bjarnadottir et al., 2007). Concordantly, acute 
treatment of hippocampal slices from ErbB4-/- mice with soluble NRG1 had no effect 
on LTP (Pitcher et al., 2008). Conversely, acute blocking of ErbB kinase activity in 
hippocampal slices prevented this blockade, and ablation of ErbB4 in ErbB4-/- mice 
was shown to result in enhanced LTP at the Schaffer-collateral CA1 synapse (Pitcher 
et al., 2008; Chen et al., 2010; Shamir et al., 2012). In addition, loss of ErbB4 also 
lead to enhanced limbic epileptogenesis, an effect reversed by soluble NRG1 
incubation (Li et al., 2011; Tan et al., 2011), demonstrating an important role of 
NRG1/ErbB4 signaling in balancing inhibitory circuit activity. 
Further, ErbB4-/- and PV+ interneuron-restricted PV-Cre*ErbB4-/- mice were shown to 
exhibit novelty-induced hyperactivity and deficits in prepulse inhibition (PPI), in line 
with findings in SZ patients. Interestingly, only ErbB4-/- mice, but not PV-Cre*ErbB4-/- 
mutants, showed reduced anxiety-like behavior and impairments of contextual and 
cued fear memory, in line with broad ErbB4 expression in PV- cells of the amygdala 
(Shamir et al., 2012; Yin et al., 2013b). Further, combined ablation of ErbB2 and 
ErbB4 in the CNS of mice impaired NMDA receptor/PSD95 clusters and dendritic 
spine maturation, increased aggressive behavior and reduced PPI (Barros et al., 
2009). 
Many in vitro and slice culture studies on NRG1/ErbB4 signaling have used the 
recombinant EGF-like signaling domain (commonly referred to as “soluble NRG1”). 
These studies have for instance shown that treatment of cultured neurons or brain 
slices with soluble NRG1 modulates glutamatergic, GABAergic cholinergic and 
dopaminergic neurotransmission (Gu et al., 2005; Kwon et al., 2005; Woo et al., 
2007; Ting et al., 2011). For instance, treatment of cultured prefrontal cortex 
pyramidal neurons with the recombinant EGF-like domain was shown to reduce 
NMDA receptor-mediated excitatory postsynaptic currents (EPSC) (Gu et al., 2005), 
and treatment of hippocampal slices resulted in reduced AMPA receptor-mediated 




AMPA receptors (Kwon et al., 2005). Soluble NRG1 also promoted dendritic spine 
maturation (Barros et al., 2009).  
In line with this, Thy1.2-mediated overexpression of CRD-NRG1 in mice (NRG1-tg) 
reduced LTP and altered dendritic spine morphology. Conditional inactivation of 
NRG1 from projection neurons, using CamKII-Cre driver mice, had a similar effect on 
LTP, suggesting an inverted U-shaped model (Agarwal et al., 2014). In line with this, 
a disturbed excitatory/inhibitory (E/I) balance was found CA1 pyramidal neurons in 
both NRG1-tg and CamKII-Cre and Emx1-Cre*Nrg1f/f mutant mice. NRG1 
overexpression lead to increased IPSC frequencies, but not amplitudes, suggesting 
that NRG1 overexpression shifts the E/I synaptic balance towards enhanced 
inhibition, probably by increased GABAergic input (Agarwal et al., 2014). Alterations 
in the E/I balance were suggested to result in deficits in cortical synchronization as 
implicated in SZ (Uhlhaas and Singer, 2010). However, it is important to note that 
studies with isoform-specific mouse mutants revealed that the structural variability of 
NRG1 isoforms and their different expression patterns translate into differential 
functions (Meyer et al., 1997; Wolpowitz et al., 2000). Thus, only overexpression of 
CRD-NRG1 impaired LTP, whereas overexpression of Ig-NRG1 impaired -
oscillations, but not LTP (Deakin et al., 2012). In line with isoform-specific functions 
of NRG1 variants, the migration of GABAergic interneurons from the subpallium to 
the developing cortex is regulated by an interplay of long- and short-range attractive 
signals of distinct NRG1 isoforms and ErbB4 receptors. CRD-NRG1 isoforms form a 
permissive corridor along which interneurons migrate, while Ig-NRGs form a 
diffusible signal attracting them toward the cortex (Flames et al., 2004). 
Alterations in dendritic spines have been observed in several SZ cases (Penzes et 
al., 2011). NRG1/ErbB4 signaling has been linked to synaptogenesis, neurite 
outgrowth and dendritic spine dynamics. Mice lacking BACE1 displayed reduced 
numbers of dendritic spines in hippocampal neurons and exhibit SZ-relevant 
phenotypes, including reduced PPI and novelty-induced hyperactivity (Savonenko et 
al., 2008), suggesting that proteolytic processing of NRG1 is important for its 
signaling functions in cortical networks. In a recent study, the NRG1-ICD and -
secretase subunit APH1B were linked to dendritic spine formation (Fazzari et al., 
2014), indicating that CRD-NRG1 backsignaling might play an important role in the 
regulation of synaptogenesis and synaptic plasticity in vivo. A SZ at-risk mutation in 
NRG1, a valine-to-leucine substitution at valine 321 prevents -secretase-mediated 
NRG1 cleavage, subsequent nuclear localization, and transcriptional activation. 




ErbB receptor kinase activity (Chen et al., 2010), underlining the cell autonomous 
backsignaling properties of CRD-NRG1 and their relevance for SZ (Fig. 6).  
 
 
Fig. 6: Model of canonical and non-canonical NRG1/ErbB4 signaling. Both NRG1 and 
ErbB4 can serve as ligand and receptor. Canonical forward signaling includes cleavage 
(flash) of NRG1 in the stalk-region, followed by paracrine or juxtacrine signaling to ErbB4, 
which triggers downstream signaling cascades (ERK, PI3K). -secretase mediated ErbB4 
cleavage induces ErbB4-CTF-mediated non-canonical forward signaling, including nuclear 
translocation and altered gene expression. TACE-mediated extracellular cleavage of ErbB4 
produces ecto-ErbB4, which can signal to NRG1, possibly inducing -secretase-mediated 
NRG1 cleavage, nuclear translocation of the NRG1-ICD and altered gene expression. 
Interaction of the NRG1-ICD with LIMK1 may also trigger backward signaling possibly 
involved in actin cytoskeleton remodelling and dendritic spine dynamics (modified from Mei 
and Xiong, 2008). 
 
Apart from its functions in transcriptional regulation, interaction of the NRG1-ICD with 
LIM Kinase 1 (LIMK1) was reported (see Fig. 6 and Wang et al., 1998). LIMK1 is a 
LIM and PDZ domain containing kinase, which has been implicated in the modulation 
of dendritic spines by regulating actin cytoskeleton dynamics. Abnormalities in spine 
morphology and synaptic functions have been reported for LIMK1-/- mice (Meng et 
al., 2002, 2003). LIMK1 and its family member LIMK2 are key regulators of the actin 
depolymerizing factor cofilin. LIMK1 itself is regulated via phosphorylation by Rho 
GTPase-associated protein kinases PAK and ROCK (Edwards et al., 1999; 
Maekawa et al., 1999), and thus links Rho GTPases Rac, Rho and Cdc42 (Arber et 
al., 1998; Yang et al., 1998) to actin reorganization. Many of these interaction 




strengthening the importance of LIMK1 interactions with NRG1/ErbB4 signaling in 
the context of dendritic spine remodelling and synaptic plasticity. This is supported by 
a recent study in which it was shown that overexpression of the NRG1 type I isoform 
in transgenic mice alters LIMK1 expression and cofilin phosphorylation. Interestingly, 
these findings were partly independent from ErbB4 (Yin et al., 2013a). 
Taken together the NRG1/ErbB4 signaling module plays a critical role in cortical 
development and synaptic functions in the mature brain. It regulates various aspects 
of neuronal plasticity and connectivity and has been implicated in multiple processes 
that could underlay the pathomechanisms of neuropsychiatric disorders, including 
SZ. As most of the NRG1 at-risk haplotypes have been mapped in the non-coding 
region of the NRG1 gene, chronic changes in NRG1/ErbB4 signaling could confer 
increased risk for SZ. However, the precise pathomechanism underlying SZ 




Fig. 7: NRG1/ErbB4 signaling regulates various aspects of cortical networks. Simplified 
hippocampal microcircuit and possible sites of NRG1/ErbB4 signaling. NRG1 is mainly 
expressed by pyramidal neurons, whereas ErbB4 is predominantly expressed in subsets of 
GABAergic interneurons, including basket cells and chandelier synapse-forming axoaxonic 
interneurons (ACC), and neurogliaform cells. According to this model, NRG1 and ErbB4 in 
different cell types and subcellular locations serve distinct regulatory functions at cortical 
synapses. Question mark indicates the unclear role of soluble NRG1 in paracrine signaling. 
CA3, Schaffer collateral-CA1 projections; EC, input from entorhinal cortex; SLM, Stratum 
lacunosum-moleculare; SO, Stratum oriens; SP, Stratum pyramidale; SR, Stratum radiatum. 





2.7 Aim of this study 
SZ is considered as a disorder of brain disconnectivity. Human NRG1 and ERBB4 
genes are possible genetic risk factors for SZ. NRG1/ErbB4 signaling regulates 
synaptic functions in the brain, but the underlying pathomechanisms linked to SZ 
remain elusive. Reduced and increased expression of NRG1 and ErbB4 
hyperstimulation has been observed in post mortem brain of SZ patients. Thus, 
altered NRG1 expression and ErbB4 activation could represent a possible 
pathomechanism with relevance for SZ. To test this hypothesis, the first aim of the 
PhD project was to systematically investigate loss- and a gain-of-function mouse 
models of NRG1 for changes in brain functions, including development of cortical 
interneurons. 
NRG1 isoforms show dynamic and complex expression patterns in the brain. Thus, 
cell type- or stage-specific changes in NRG1 expression could  differentially affect 
brain functions. Therefore, the second aim of the PhD project was to characterize a 
novel conditional NRG1 transgenic mouse line, and to model cell type- and stage-
specific overexpression of CRD-NRG1 in vivo. The third aim of this project was to 
examine consequences of stage-specific, cortical-restricted overexpression of CRD-
NRG1 on brain development and behavioral functions. Further,  the project aimed at 
obtaining a first insight into molecular pathomechanisms of cortical network 







3.1 Consequences of NRG1 deficiency on interneuronal migration and 
integration 
GABAergic interneurons control the excitatory-inhibitory balance in cortical networks 
and mediate the precise gating of information (Vogels and Abbott, 2009; Marin, 
2012). Abnormal inhibitory functions have been reported in schizophrenia (SZ) 
patients (Lewis et al., 2005; Farzan et al., 2010; Ongür et al., 2010; Yoon et al., 
2010). ErbB4, the main neuronal receptor for NRG1 in the brain, is expressed in 
GABAergic interneurons (Neddens and Buonanno, 2009, 2011; Vullhorst et al., 2009; 
Fazzari et al., 2010), and plays an important role for interneuronal development 
(Flames et al., 2004; Neddens and Buonanno, 2009). The human NRG1 gene is a 
major SZ susceptibility gene (Li et al., 2006; Ayalew et al., 2012). Virtually all of the 
„at-risk“ haplotypes are located in non-coding regions of the gene (Stefansson et al., 
2002; Weickert et al., 2012), suggesting that altered expression of NRG1 may 
represent a component of SZ pathology. Both, reduced and increased expression of 
NRG1 variants was found in post-mortem brains of SZ patients (Law et al., 2006; 
Bertram et al., 2007).   
To investigate the effects of NRG1 deficiency on interneuronal migration and 
integration into the cortical network, we examined conditional NRG1 mutants. To 
delete NRG1 from all forebrain progenitor cells beginning at embryonic day (E) 10 
(Fig. 8A) we crossbred floxed Nrg1 mice (Li et al., 2002) to EMX1-Cre driver mice 
(Gorski et al., 2002, referred to as Emx-Cre mice). The cell population derived from 
the Emx1 cell lineage includes radial glia, Cajal-Retzius cells, glutamatergic neurons, 
astrocyes and oligodendrocytes, but not interneurons. The Emx-Cre recombination 
pattern is shown by X-Gal histochemistry on a brain section of an Emx-Cre*R26R-
floxLacZ double-transgenic mouse at postnatal day (P) 46 (Fig. 8A). This approach 
lead to a ~80 % reduction of NRG1 protein in the forebrain of Emx-Cre*Nrg1f/f mice 
(Agarwal et al., 2014).  
To determine the number of GABAergic interneurons in the postnatal brain of NRG1 
deficient mice, coronal paraffin sections of Emx-Cre*Nrg1f/f mice and controls at P14 
were stained for the interneuron marker GAD67 and  interneuron numbers were 
quantified in the somatosensory cortex and hippocampus (bregma -1.7). Total 
interneuron numbers in the hippocampus of Emx-Cre*Nrg1f/f mice were not altered 
compared to controls (Fig. 8D).  In addition, the subcortical distribution of GAD67+ 
interneurons showed no differences in Emx-Cre*Nrg1f/f mice compared to controls 





Fig. 8: Embryonic NRG1 signaling is dispensable for cortex lamination and 
interneuronal migration. (A) Using the Emx1-Cre driver line, NRG1 elimination can be 
achieved in embryonic stages, overlapping with network integration of cortical interneurons 
(IN). X-gal histochemistry on a 20 µm coronal cryo-brain section from an Emx-Cre*R26R-
floxLacZ double-transgenic mouse (P46) shows Cre-mediated recombination of lacZ reporter 
in forebrain projection neurons and glial cells. Scale bar, 1 mm. (B to E) Normal numbers and 
cortical positions of GAD67
+
 interneurons in Emx*Nrg1
f/f
 mutants during cortical maturation. 





 and WT) at P14. Higher magnifications (right) show the hippocampal 
CA1 region (boxed in overviews). Scale bars, 500 mm and 50 mm (CA1 region). (C) 




normal layering (I–VI, cortical layers) and interneuron positions in the somatosensory cortex 
of Emx*Nrg1
f/f
 mutants in comparison to controls (Nrg1
f/f 
and WT). Bregma -1.7; scale bars, 
50 mm (NeuN), 100 mm (GAD67). (D) Quantification of GAD67
+
 interneurons in the 
hippocampus shows no difference in interneuron numbers at P14 (marked area D in B) of 
Emx*Nrg1
f/f 
mutants and controls (Nrg1
f/f 
and WT). n = 6/genotype. (E) Quantification of 
GAD67
+
 interneurons per layer in the neocortex of Emx*NRG1
f/f 
mutants and controls (Nrg1
f/f
 
and WT) at P14 reveals no difference in interneuron numbers and layering (boxed area E in 
B). n = 6/genotype. Error bars represent SEM. (F) Normal cortical lamination in Emx-Nrg1
f/f 
mutants. Relative cortical layer width was determined based on GAD67 immunostainings on 
coronal paraffin brain sections (left panel, representative micrograph from Nrg1
f/f 
mice, 
bregma -1.7; n=6 per genotype; error bars represent SEM). 
 
normal in Emx-Cre*Nrg1f/f mice at P14 compared to controls (Fig. 8F). Similar 
findings were obtained at one year of age (data not shown). 
Taken together, NRG1 signaling appeared to be dispensible for interneuron 
migration and their integration into cortical layers, and NRG1 mutants did not 
phenocopy the ErbB4 null mutation. 
 
3.2 Elevated CRD-NRG1 expression leads to sustained ErbB4 
hyperstimulation, altered interneuron functions, and abnormal 
behavior 
In a complementary approach, we tested whether chronically increased NRG1 
expression could affect interneuronal migration and neocortical network assembly. 
CRD-NRG1 is the most prominant NRG1 isoform in the brain (Liu et al., 2011) and 
elevated CRD-NRG1 expression has been reported in post-mortem tissue of SZ 
patients (Weickert et al., 2012). To test whether CRD-NRG1 serves as a signal for 
ErbB-receptor-mediated cortical network regulation, we examined Nrg1-tg mice that 
express CRD-NRG1 under control of the neuronal Thy1.2 promoter (Fig. 9A) 
(Michailov et al., 2004). In these mice transgene expression is initiated around E16 
and CRD-NRG1 accumulates on the surface of projection neurons in the neocortex 
and hippocampus, but is absent from interneurons, astrocytes, and oligodendrocytes 
(Agarwal et al., 2014). 
First, we tested whether chronic CRD-NRG1 overexpression alters ErbB4 receptor 
activation. A western blot analysis of hippocampus protein lysates from Nrg1-tg mice 
revealed CRD-NRG1 overexpression at 4 months of age. CRD-NRG1 was 
expressed as a full length protein (~140 kDa) and a processed form (~60 kDa; 
presumably the NRG1 CTF after stalk region cleavage) (Fig. 9B). Phosphorylation of 
ErbB4 was detected using an antibody directed against the phosphorylated tyrosin 
residue Tyr1284, a binding site for the adapter protein ‚SH2 domains containing 





Fig. 9: Elevated CRD-NRG1 expression results in ErbB4 hyperphosphorylation and 
altered numbers of GABAergic interneurons. (A) Structure of the Thy1.2 transgene 
cassette used in Nrg1-tg mice (grey box, CRD-NRG1 cDNA; white boxes, exons I-IV of the 
Thy1.2 gene). (B) Overexpression of CRD-NRG1 results in a chronic ErbB4 
hyperphosphorylation in the hippocampus of Nrg1-tg mice. Western blot analysis of 




Densitometric quantification of phosphorylated ErbB4 (Tyr1284) bands. Integrated density 
values were normalized to -actin loading control (n = 3/genotype; *p < 0.05; Mann-Whitney 
U test). CTF, NRG1 C-terminal fragment; FL, full length; kDa, kilodalton. (C) (Left) 
Immunostaining for GAD67 on 5 µm coronal paraffin sections from brains of WT and Nrg1-tg 
mice at P14 (somatosensory cortex; bregma -1.7). Scale bars, 100 mm. (Right) Quantification 
of GAD67
+
 interneurons reveals a loss of interneurons in layer IV of the cortex (n = 
6/genotype; *p < 0.05, Mann-Whitney U test). I–VI, cortical layers; WM, white matter. (D) 
(Left) Immunostaining for Parvalbumin (PV) as in (C). Scale bars, 100 mm. (Right) 
Quantification of PV
+
 interneurons across all cortical layers shows no difference in total cell 
numbers (n = 6/genotype; Mann-Whitney U test). (E) (Left) 2P-LSM of PV-GFP*Nrg1-tg and 
PV-GFP control mice at 3 months of age. Depicted are 3D projections-rendered live-imaging 
stacks of a cortical column (250x250x500 µm (0.03125 mm
3
); 2 µm stack interval) from the 
MZ to layer V. (Right) Quantification of GFP
+
 interneurons in layers I–V from 2P-LSM live-
imaging stacks reveals an overall loss of cells and more specifically in layers II/III and V. Note 
that parts of layers V and VI could not be imaged. (PV-GFP*Nrg1-tg, n = 6; PV-GFP, n = 5; *p 
< 0.05; Student’s t test). 
 
a significant increase in the steady-state level of phosphorylated ErbB4 (Fig. 9B). 
Thus, Nrg1-tg mice represent a model for CRD-NRG1 overexpression-mediated 
ErbB4 hyperstimulation beginning at late embryonic stages. 
Interneurons migrate along a chemo-attractive corridor towards the cortex. It has 
been shown in vitro that CRD-NRG1 provides one of the permissive signals for this 
migration (Flames et al., 2004), suggesting that interneuron migration could be 
affected in Nrg1-tg mice. Similar to the loss-of-function study above, we performed 
chromogenic immunostainings for GAD67 on coronal paraffin sections of the 
somatosensory cortex and hippocampus (bregma -1.7) of Nrg1-tg mice and WT 
controls at P14. The analysis revealed minor changes in the cortical distribution of 
GAD67+ cells in Nrg1-tg mice, as we found a reduced number of GAD67+ cells in the 
cortical layer IV, but no change in the total number of hippocampal interneurons (Fig. 
9C). We also quantified the number of neocortical and hippocampal PV+ interneurons 
in chromogenic stainings for parvalbumin and found no significant changes in PV+ 
interneuron numbers for both regions in Nrg1-tg mice at P14 (Fig. 9D). 
To visualize PV+ interneurons in vivo, we crossbred Nrg1-tg mice to PV-GFP 
transgenic mice that express GFP under control of regulatory sequences of the PV 
gene (Meyer et al., 2002). In vivo imaging of PV-GFP*Nrg1-tg double-transgenic 
mice at the age of 3 months by two-photon laser scanning microscopy (2P-LSM) 
revealed a lower number of GFP+ cells in cortical layers II/III and V and a reduction in 
the total number of GFP+ cells in the cortex by ~20 % compared to PV-GFP single 
transgenic controls (Fig. 9E). These findings were confirmed in a second transgenic 
mouse line (HA-Nrg1-tg), which expresses a N-terminally hemagglutinin (HA) 
epitope-tagged variant of CRD-NRG1 under control of the same Thy1.2 cassette as 




Taken together CRD-NRG1 serves only minor permissive functions, as cortical 
layering of GAD67+ interneurons is only mildly altered at P14. However, chronic 
overexpression of CRD-NRG1 and hyperstimulation of ErbB4 affects the survival of 
PV+ interneurons or the expression of the parvalbumin promoter in 3 months old PV-
GFP*NRG1-tg and PV-GFP*HA-NRG1-tg mice.  
Next, we tested whether hyperstimulated CRD-NRG1/ErbB4 signaling causes 
behavioral dysfunctions. The neuromuscular junction in Nrg1-tg mice is severely 
compromised (W.J. Thompson, personal communication), which prevents behavioral 
analyses. Thus, we examined behavior in HA-Nrg1-tg mice (Velanac et al., 2011; 
Fig. 10A). Similar to Nrg1-tg mice, we observed HA-NRG1 expression all over the 
brain, in the neocortex and hippocampus, but also in subcortical regions, such as the 
thalamus, striatum and amygdala (Fig. 10B). Fluorescent immunostaining 
demonstrated that HA-NRG1 accumulates on the surface of cortical projection 
neurons, but was absent from GABAergic interneurons, GFAP+ astrocytes and Olig2+ 
oligodendrocytes (Fig. 10C). 
To assess general locomotor activity and anxiety, we performed the open field test. 
Mice are neophobic and find open spaces aversive, thus normal mice prefer to stay 
close to the walls of the open field arena (thigmotaxis). Time spent in the corners or 
the center of the arena can be quantified as a measure of anxiety. Mice were placed 
into the open field arena for 10 minutes and movements were tracked automatically. 
HA-Nrg1-tg mice showed normal locomotor activity, as the distance travelled in the 
open field test was unaltered (WT: 44.17 ± 1.93, HA-Nrg1-tg: 42.49 ± 2.21; Fig. 10E). 
However, HA-Nrg1-tg mice spent less time in the center of the open field arena (WT: 
24.16 % ± 3.77 %, HA-Nrg1-tg: 10.61 % ± 2.13 %) and performed fewer rearings, 
when compared to WT controls (WT: 56.28 ± 3.86, HA-Nrg1-tg: 39 ± 4.64), 
suggesting diminished exploratory behavior. In addition they displayed more frequent 
defecation (WT: 1.778 ± 0.586; HA-Nrg1-tg: 4.13 ± 0.72), in line with increased 
anxiety (Fig. 10E). 
Disrupted sensorimotor gating is implicated in the neuropathology of SZ and has 
frequently been found in rodent models for SZ. Its disruption in SZ may be related to 
the processes of sensory flooding and cognitive fragmentation and could underlie the 
positive symptoms of the disease (Braff et al., 2001; Swerdlow et al., 2008). Prepulse 
inhibition (PPI) is considered a psychometric measure of sensorimotor gating and 
can be studied both in rodents and humans (Braff and Geyer, 1990). To assess the 
effect of NRG1 overexpression on sensorimotor gating, we performed the prepulse 
inhibition test, where HA-Nrg1-tg mice showed a profound PPI deficit in comparison 






Fig. 10: HA-Nrg1-tg mice exhibit SZ-relevant behavior reduced numbers of 
interneurons in the cortex. (A) In HA-NRG1-tg mice two HA epitope tags are located at the 
N-terminus of CRD-NRG1, that can be detected via anti-HA antibody reactivity. The NRG1 C-
Term antibody binds to the C-terminal cytoplasmatic tail. CRD, cystein-rich domain; EGF, 
epidermal growth factor-like domain; HA, hemagglutinin epitope tag; TM, transmembrane 
domain. Structure of the Thy1.2 transgene cassette (red box, HA epitope; grey box, full-length 
CRD-NRG1 cDNA; white boxes, exons I-IV of the Thy1.2 gene). (B) Chromogenic NRG1 
immunostaining (HA-NRG1) on 5 µm coronal paraffin brain sections from wildtype (WT) and 
HA-Nrg1-tg mice at 4 months of age. Note enlarged lateral ventricle in the HA-Nrg1-tg brain. 




markers (neurons, NeuN; interneurons, PARV; oligodedrocytes, Olig2; astrocytes, GFAP) on 
coronal brain sections from HA-Nrg1-tg mice (age 4 months) show projection neuron-specific 
HA-NRG1 overexpression. Scalebars, 25 μm (PARV, 20 μm). (D) HA-Nrg1-tg mice show 
reduced PPI (Effect of genotype F(1,32) = 4.31; *p < 0.05; two-way ANOVA; Bonferroni’s 
multiple comparison test), and increased startle responses to 120 dB pulses (WT, n = 18; HA-
Nrg1-tg mice, n = 16; **p < 0.01; Mann-Whitney U test. AU, arbitrary units, Error bars 
represent SEM). (E) HA-Nrg1-tg mice display anxiety-like behavior in the open field test. 
Distance travelled was similar in HA-Nrg1-tg and WT male mice, but HA-Nrg1-tg mice spent 
less time in the center of the open field arena, performed less rearings and showed increased 
defecation in the open field test compared to WT controls (age 2-3 months, p = 0.5575, 
Mann-Whitney test; error bars represent SEM). (F) Reduced overall number of GFP
+
 
interneurons in a cortical column of 250*250*500 μm (0.03125 mm
3
) of PV-GFP*HA-Nrg1-tg 
mice (n=2) and PV-GFP controls (n=5) obtained by 2P-LSM in vivo imaging (*p < 0.05; 
Student’s t test). 
 
39.56, HA-Nrg1-tg: 344.9 ± 42.07) (Fig. 10D). 
In summary, CRD-NRG1 overexpression triggers SZ-relevant behavior. Enhanced 
CRD-NRG1/ErbB4 signaling impacts on anxiety-related pathways in the brain of HA-
Nrg1-tg mice and impairs sensorimotor gating, indicating that enhanced 
NRG1/ErbB4 signaling could contribute to SZ pathology. 
 
3.3 Generation of a conditional CRD-NRG1 transgenic mouse line 
The human NRG1 gene encodes for more than 30 isoforms (Falls, 2003; Mei and 
Xiong, 2008). Additional complexity of NRG1 signaling is added by posttranslational 
modifications and dynamic expression patterns in the brain (Liu et al., 2011). The 
expression of CRD-NRG1 is regulated during development and peaks at E13 and P5 
suggesting roles in neural development and in the neonatal critical period (Liu et al., 
2011). Nrg1-tg and HA-Nrg1-tg mice show endophenotypes associated with SZ, but 
the Thy1.2-based transgene cassette offers no chance to manipulate the temporal 
and spatial aspects of NRG1 overexpression. 
To match the complexity of endogenous NRG1 biology and to model different 
scenarios of NRG1 overexpression, a more sophisticated mouse model was 
generated by oocyte injection to manipulate cell type-specific, temporal and spatial 
aspects of NRG1 overexpression. Stop-Nrg1 transgenic mice harbor an expression 
cassette that is driven by a ubiquitously expressed chicken -actin promoter and 
contains a GFP-Stop cassette flanked by loxP sites followed by the same HA-tagged 
CRD-NRG1 variant (HA-NRG1) as in HA-Nrg1-tg mice. Crossbreeding Stop-Nrg1 
mice to Cre recombinase expressing mouse lines (‘driver’ lines) results in Cre-
mediated removal of the GFP-Stop cassette and HA-NRG1 expression in the cell 







Fig. 11: A -actin GFP-Stop-flox transgene cassette allows Cre-mediated transgene 
expression. (A) Basic principle of the -actin Stop-flox transgene cassette used in Stop-Nrg1 
mice. Using a fragment of the chicken -actin promoter, a GFP-Stop cassette (Stop) is 
expressed, that is flanked by loxP sides. Upon Cre recombinase-mediated excision of the 
GFP-Stop-flox cassette, a tagged downstream transgene is expressed. (B) Different Cre 
driver mouse lines define the celltype-specificity and start of recombination in Stop-Nrg1 
double transgenic mice. NEX-Cre driver mice enable early embryonic cortical projection 
neuron-restricted overexpression starting at E12 (Goebbels et al., 2006), while CamKII-Cre 
driver mice express Cre recombinase in cortical projection neurons starting at P5 (Minichiello 
et al., 1999). NEX-CreERT2 driver mice enable tamoxifen-induced acute stimulation of Cre 
recombination and transgene expression in mice of all stages (Agarwal et al., 2011). 
 
Since CRD-NRG1 is mainly expressed by cortical projection neurons (Liu et al., 
2011), we chose NEX-Cre mice harboring Cre recombinase as a ‘knock-in’ into the 
NeuroD6 locus as a driver line for Cre-mediated recombination in cortical projection 
neurons starting at E12 (Goebbels et al., 2006), and CamKII-Cre driver mice with a 
similar expression pattern as in NEX-Cre mice, but a recombination onset at P5 
(Minichiello et al., 1999). These two Cre driver lines allow the separation of 
embryonic from postnatal aspects of NRG1 signaling. A third mouse line (NEX-
CreERT2) represents a modification of the original NEX-Cre driver line and 
expresses a tamoxifen-inducible variant of Cre recombinase (CreERT2). 
Administration of tamoxifen, a synthetic estrogen receptor (ER) ligand, induces the 
dissociation of CreERT2 from HSP90, nuclear import of CreERT2, and the site-
specific recombination of loxP site-flanked target genes, enabling tamoxifen induced 








Fig. 12: Stop-Nrg1 mice express the -actin GFP-Stop-flox transgene in virtually all 
tissues. (A) (left) Structure of -actin GFP-Stop-flox HA-CRD-NRG1 transgene cassette used 
in Stop-Nrg1 mice with location of genotyping primers (1 and 2). (right) Genotyping PCR on 
tail biopsy genomic DNA shows genomic insertion of the Stop-Nrg1 cassette in Stop-Nrg1 
mice (tg) compared to WT littermates. -Actin PCR was used as DNA quality control. (B) 
Stop-Nrg1 mice display green fluorescence in virtually all tissues due to GFP expression in 
the GFP-Stop-flox cassette. Brightfield and epifluorescence images of organs of Stop-Nrg1 
mice and a tail biopsy of a WT littermate. Scale bars, 1 mm (brain, spinal cord, dorsal root 
ganglia (DRG), heart and tailtip), 2 mm (femur muscles). 
 
Injection of the Stop-Nrg1 transgene cassette into C57bl6n oocytes produced one 
founder mouse line (Fig. 12A). Stop-Nrg1 mice were viable and produced offspring 
according to Mendelian ratios. Since the Stop-Nrg1 transgene harbors a GFP-
expressing Stop cassette, transgene expression (in the absence of Cre 
recombinase) can be assessed by fluorescent light microscopy. When examined 
under fluorescent excitation all tested tissues were green fluorescent (Fig. 12B), 
suggesting that the -actin promoter is expressed in most tissues. This also enabled 




To examine which neural cell types in the brain of Stop-Nrg1 mice express the 
transgene cassette, we performed fluorescent co-immunostainings on coronal cryo-
sections (Bregma -1.7) from Stop-Nrg1 mice for GFP and cell type-specific markers. 
Confocal laser microscopy revealed a predominant expression of the Stop-Nrg1 
transgene in neurons and oligodendrocytes, as shown by co-staining for GFP and 
neuronal marker NeuN and oligodendroglial marker Olig2, respectively (Fig. 13A, B). 
Co-immunostaining for GFP and the projection neuron marker neurogranin (NRGN) 
and the interneuronal marker GAD67 revealed that the Stop-Nrg1 cassette was 
predominantly expressed by projection neurons (Fig. 6A). In contrast, only few 
GAD67+ interneurons expressed the Stop-Nrg1 cassette (Fig. 13A). Among glial 
cells, Stop-Nrg1 was preferentially expressed in oligodendrocytes, whereas only few 
astrocytes and microglia expressed the transgene (Fig. 13B), showing that the -
actin promoter was not ubiquitously expressed on the cellular level. Outside the 
brain, spinal cord motoneurons showed prominent Stop-Nrg1 expression (Fig. 13B). 
 
3.4 NEX-Cre mediated recombination of Stop-Nrg1 restricts HA-NRG1 
expression to cortical projection neurons 
To model cortical HA-NRG1 overexpression (Fig. 14A), we crossbred Stop-Nrg1 
mice to NEX-Cre driver mice, in which Cre is selectively expressed by projection 
neurons of the neocortex and hippocampus (Goebbels et al., 2006; Fig. 14A). Cre 
expression starts at E12, allowing for early embryonic initiation HA-NRG1 
overexpression (Fig. 14A). Western blot analysis of hippocampal protein lysates 
showed a pronounced overexpression of HA-NRG1 in 4 months old Stop-Nrg1*NEX-
Cre mice compared to parental controls (Stop-Nrg1 single transgenic and NEX-Cre 
heterozygous mice) (Fig. 14B). As indicated by increased expression of a ~60 kDa 
CTF, transgene-derived full length HA-NRG1 was normally processed in the stalk 
region. In addition, western blot analysis with the phospho-ErbB4 antibody (Tyr1284) 
confirmed sustained ErbB4 hyperphosphorylation in the hippocampus of Stop- 
Nrg1*NEX-Cre mice (Fig. 14B). 
Chromogenic immunostaining on coronal paraffin sections (bregma -1.7) confirmed 
that HA-NRG1 expression was restricted to neocortex, hippocampus, amygdala and 
a few hypothalamic neurons in Stop-Nrg1*NEX-Cre mice mimicking the 
recombination pattern in NEX-Cre mice (Fig. 14C). In contrast to HA-Nrg1-tg mice 
(compare Fig. 10B), no HA-NRG1 expression was detected in subcortical regions, 






Fig. 13: The Stop-Nrg1 transgene is predominantly expressed in projection neurons. 
(A) Confocal images of immunostaings on 14 µm thick coronal Cryo sections of brains from 
Stop-Nrg1 mice at 3 months of age stained for neuronal markers. GFP fluorescence co-
immunostained for NeuN reveals expression of the Stop-Nrg1 transgene in neurons of the 
cortex and hippocampus of Stop-Nrg1 mice. Expression of Stop-Nrg1 is present in projection 
neurons (filled arrowheads), indicated by collocalization with Neurogranin (NRGN), but only 
minor expression is found in cortical interneurons (GAD67; empty arrowheads). Scale bars, 
20 µm (NeuN, GAD67 Hipp), 15 µm (NRGN, GAD67 Cx). (B) Immunostainings for glial 
markers reveals expression of the Stop-Nrg1 cassette in oligodendrocytes (Olig2) and 
partially in astrocytes (GFAP). Co-immunostaining with IBA1 reveals only minor expression in 
microglia. Ventral horn spinal cord motoneurons (ChaT) express the -actin GFP-Stop-flox 
transgene cassette. Scale bars, 25 µm, 20 µm (GFAP Cx). 
 
expressed HA-NRG1 (Fig. 14C), in line with transient Cre expression in postmitotic 
granule cells in NEX-Cre mice (Goebbels et al., 2006). To validate projection neuron-
specific HA-NRG1 overexpression, we co-immunostained coronal paraffin sections 
(Bregma -1.7) of 4 months old Stop-Nrg1*NEX-Cre mice and controls for HA-NRG1 
and the neuronal markers NeuN, NRGN and GAD67 (Fig. 14D). Similar to Thy1.2 
HA-Nrg1-tg mice, HA-NRG1 accumulated in the somato-dendritic compartment 
(compare with Fig. 10C). In addition, co-immunostaining for the HA epitope and the 
NRG1 CTF almost completely overlapped (Fig. 14D), indicating highly similar 
subcellular localization of the N-terminal fragment (NTF) and the CTF after 






Fig. 14: NEX-Cre-mediated activation of Stop-Nrg1 restricts HA-NRG1 expression to 
cortical projection neurons. (A) In Stop-Nrg1 mice two HA epitope tags are located at the 
N-terminus of CRD-NRG1, that can be detected via anti-HA antibody reactivity. The NRG1 C-
Term antibody binds to the C-terminal cytoplasmatic tail. CRD, cystein-rich domain; EGF, 
epidermal growth factor-like domain; HA, hemagglutinin epitope tag; TM, transmembrane 
domain. Structure of Stop-Nrg1 transgene cassette and NEX-Cre-mediated recombination of 
the GFP-Stop cassette. Schematic expression profile of HA-NRG1 in Stop-Nrg1*NEX-Cre 
mice. Endogenous CRD-NRG1 expression peaks at P10 and returns to low expression levels 
in adult mice. In Stop-Nrg1*NEX-Cre mice expression of HA-NRG1 starts after Cre-mediated 
removal of the GFP-Stop cassette at E12 and persists at high levels into adulthood. Structure 
of the targeting construct used for homologous recombination of Cre into exon 2 of the murine 
NEX gene in NEX-Cre mice. X-gal histochemistry indicates NEX-Cre activity in cortical 
projection neurons of a NEX-Cre*R26R-floxLacZ mouse (E1, Exon1; E2, Exon2; Neo, 
Neomycin resistance cassette; adapted from Goebbels et al., 2006). In NEX-Cre mice Cre 
expression starts at E12. (B) Western blotting of hippocampal protein lysates with the NRG1 
C-Term and p-ErbB4 antibody reveals HA-NRG1 overexpression in Stop-Nrg1*NEX-Cre mice 




as loading control. CTF, NRG1 C-terminal fragment; FL, full length; kDa, kilodalton. (C) 
Chromogenic immunostaining for HA-NRG1 on coronal paraffin sections reveals cortex-
restricted HA-NRG1 overexpression in Stop-Nrg1*NEX-Cre mice, consistent with NEX-Cre 
expression profile. Expression is present in neurons of the cortex, hippocampus, amygdala, 
but only few hypothalamic neurons, striatal and thalamic regions. Boxes indicate positions of 
high magnification images. Note that in NEX-Cre mice only the outer dentate gyrus granule 
cells are HA-NRG1-positive. Scale bars, 500 µm, 50µm (Zoom). A, Amygdala; Hy, 
Hypothalamus; St, Striatum; Th, Thalamus. (D) Fluorescent immunostaining on coronal 
paraffin section of Stop-Nrg1*NEX-Cre mice for NRG1 and neuronal markers. HA-NRG1 
expression is restricted to cortical projection neurons (NRGN, NeuN) but absent from GAD67
+
 




Taken together, Stop-Nrg1*NEX-Cre mice allow conditional HA-NRG1 
overexpression in cortical projection neurons, which leads to sustained 
hyperstimulation of ErbB4 receptors. 
 
3.5 Stop-Nrg1*NEX-Cre mice model HA-NRG1 overexpression in the 
embryonic cortex 
NRG1 has been suggested to play an important role in interneuronal migration 
(Flames et al., 2004) and the establishment of cortical circuits (Mei and Xiong, 2008). 
In line with this, the expression of CRD-NRG1 isoforms peaks at early embryonic 
stages (Liu et al., 2011). Thus, elevated CRD-NRG1 expression during embryonic 
stages could impact on a variety of developmental processes. By employing NEX-
Cre driver mice, we wanted to model early embryonic overexpression of CRD-NRG1 
(Fig. 15A).  
To verify expression onset of HA-CRD-NRG1 in Stop-Nrg1*NEX-Cre mice during 
early embryonic stages, we performed immunohistochemistry on coronal 
cryosections of embryonic brains at E16 (Fig. 15B). The cryofixation preserved the 
GFP fluorescence in this approach. Consecutive sections of the cortical plate were 
immunostained for Cre and HA-NRG1. By confocal microscopy Cre-expressing 
neurons of the cortical plate and subplate were identified (imaged areas depicted in 
Fig. 15B), whereas GFP fluorescence was markedly reduced in Cre-expressing 
regions of Stop-Nrg1*NEX-Cre mice, due to recombination of the GFP-Stop cassette 
(Fig. 15C). As expected, in cortical areas with Cre expression and concomitantly 
reduced GFP fluorescence we observed staining for HA-NRG1 (Fig. 15C, D).  
Taken together, breeding to Stop-Nrg1*NEX-Cre mice initiates HA-NRG1 
overexpression during early embryonic stages, and allows to study the effects of 







Fig. 15: NEX-Cre-mediated recombination of Stop-Nrg1 allows early embryonic 
overexpression of HA-NRG1. (A) In NEX-Cre mice Cre expression starts at E12. Structure 
of the targeting construct used for homologous recombination of Cre into exon 2 of the murine 
NEX gene in NEX-Cre mice. (E1, Exon1; E2, Exon2; Neo, Neomycin resistance cassette; 
adapted from Goebbels et al., 2006). Structure of the Stop-Nrg1 cassette and NEX-Cre-
mediated recombination of the GFP-Stop cassette. (B) Schematic drawing of an E16 coronal 
brain section illustrates the position of overview images shown in (C) (dashed blue square 
labelled C) and high magnification images shown in (D) (dashed red square labelled with *D). 
Scale bar, 500 µm. (C) Immunostainings for GFP, Cre recombinase and HA-NRG1 on 
consecutive cryosections of Stop-Nrg1*NEX-Cre and control brains (NEX-Cre and Stop-Nrg1) 
at E16. In Stop-Nrg1*NEX-Cre embryos GFP fluorescence is reduced in the cortical plate, 
subplate and intermediate zone due to NEX-Cre-mediated removal of the GFP-Stop cassette, 
and HA-NRG1 is expressed. Dashed boxes indicate position of high magnification images 
shown in (D). CP, cortical plate; IZ, intermediate zone; LV, lateral ventricle; MZ, marginal 
zone; SP, subplate; SVZ, subventricular zone; VZ, ventricular zone; WM, white matter. Scale 
bars, 100 µm. (D) High magnification images of regions indicated by dashed boxes in (C). 






3.6 CamKII-Cre mice enable postnatal overexpression of HA-NRG1 in 
cortical projection neurons 
SZ is considered a neurodevelopmental disease and first symptoms usually occur in 
early adulthood, between 15 and 25 years of age (Sham et al., 1994). Although most 
of synaptogenesis is completed by two years of age, this process continues until mid-
adolescence in prefrontal and association (temporal and parietal) areas 
(Huttenlocher, 1979; Giedd et al., 1999). Thus, postnatal dysfunctions of signaling 
modules, such as NRG1/ErbB4 could lead to abnormalities in cortical development 
associated with neuropsychiatric disorders, including SZ. 
To distinguish embryonic from postnatal effects of abnormal NRG1/ErbB4 signaling, 
we crossbred Stop-Nrg1 mice to CamKII-Cre driver mice (from now on referred to as 
CKII-Cre mice), which express Cre recombinase under control of the CaMKII 
promoter. Cre activity starts around P5 and is restricted to projection neurons of the 
cortex and hippocampus, but also some subcortical excitatory neurons of the 
striatum, thalamus and hypothalamus express Cre recombinase (Minichiello et al., 
1999; Fig. 16A). Western blot analysis confirmed HA-NRG1 overexpression in 
hippocampus protein lysates. Similar to our previous studies, HA-NRG1 was 
expressed as a full length protein (~140 kDa) and a CTF (60 kDa) (Fig. 16B) as a 
result of proteolytic cleavage in the stalk region. Chromogenic immunostaining 
showed HA-NRG1 overexpression in the neocortex and hippocampus, but minor 
expression was also detected in the striatum and thalamus (Fig. 16C). Higher 
magnification showed that, in contrast to NEX-Cre-mediated HA-NRG1 expression, 
all dentate gyrus granule cells expressed HA-NRG1 (Fig. 16C: DG). Fluorescent 
immunostaining confirmed somato-dendritic accumulation and projection neuron-
specific HA-NRG1 overexpression (Fig. 16D). 
Thus, a comparative analysis of Stop-Nrg1*NEX-Cre and Stop-Nrg1*CKII-Cre mice 
allows to identify possible differences in embryonic versus postnatal effects of HA-







Fig. 16: CKII-Cre-mediated activation of Stop-Nrg1 allows postnatal overexpression of 
HA-NRG1 in cortical projection neurons. (A) In the CKII-Cre driver line Cre activity begins 
at P5. Structure of the CKII–Cre transgene used for generation CKII-Cre mice. Triangle 
represents intronic sequences. pA, polyadenylation signal (adapted from Minichiello et al., 
1999). X-gal histochemistry from a CKII-Cre*R26R-floxLacZ mouse illustrates Cre activity in 
cortical neurons (with kind permission of A. Agarwal). CKII-Cre-mediated activation of Stop-
Nrg1 allows early postnatal onset of HA-NRG1 overexpression. (B) Western blot analysis of 
hippocampal protein lysates of Stop-Nrg1*CKII-Cre and Stop-Nrg1 control mice at 4 months 
of age. NRG1 C-Term antibody immunoreactivity reveals HA-NRG1 overexpression as a full 
length (~140 kDa, FL) and a C-terminal fragment (~60 kDa CTF). -Tubulin was used as a 
loading control. kDa, kilodalton. (C) Chromogenic immunostaining for NRG1 C-Term on a 
paraffin brain section from a Stop-Nrg1*CKII-Cre mouse at 4 months of age reveals 
overexpression of HA-NRG1 in neurons of the cortex and minor overexpression in subcortical 
regions, including striatum (St), thalamus (Th) and hypothalamus (Hy). Boxes indicate 
positions of high magnification images of the cortex (Cx), hippocampal CA1 region (CA1) and 
dentate gyrus (DG). Note that all DG granule cells express HA-NRG1. Scale bars, 1 mm 
(overview), 50 µm (high magnifications). (D) Fluorescent immunostainings for NRG1 C-Term 
and GAD67 on paraffin sections from Stop-Nrg1*CKII-Cre at 4 months of age confirm 
projectionneuron-specific overexpression of HA-NRG1. Cx, cortex; DG, dentate gyrus. Scale 





3.7 Absense of brain pathology in Stop-Nrg1*NEX-Cre and Stop-
Nrg1*CKII-Cre mice 
Overexpression of growth- and differentiation factors could lead to abnormal 
development, neuroinflammation or cell death. Stop-Nrg1*NEX-Cre and Stop-
Nrg1*CKII-Cre mice displayed normal cage behavior compared to control littermates. 
To exclude neuroinflammation or other neuropathology in these mice, we performed 
chromogenic immunostainings for markers of neuropathology and inflammation on 
coronal paraffin sections at 4 months and one year of age. 
Hematoxylin-Eosin (H+E) staining revealed no gross abnormalities in brain 
morphology in both transgenic models (data not shown). Subsequently we tested for 
astrogliosis or microgliosis by chromogenic immunostainings for GFAP, IBA1 and 
MAC3 on coronal paraffin sections (bregma -1.7) (Eng and Ghirnikar, 1994; Hanisch 
and Kettenmann, 2007). Furthermore, we examined brain sections for axonal 
swellings by staining for amyloid precursor protein (APP), and T-cell infiltration by 
staining for the T-cell antigen CD3. 
Stainings for activated microglia, T-cell infiltration, and axonal swellings showed no 
signs of pathology in Stop-Nrg1*NEX-Cre and Stop-Nrg1*CKII-Cre mice at 4 months 
and 1 year of age compared to controls (Fig. 17). Immunostainings for the astrocytic 
marker GFAP were quantified with a semi-automated method, which determined the 
GFAP+ area in relation to the region of interest. Hippocampus and fimbria were 
analyzed as examples for grey and white matter regions, respectively (Fig. 18A). No 
obvious differences in GFAP+ area were observed in the hippocampus of Stop-
Nrg1*NEX-Cre or Stop-Nrg1*CKII-Cre mice. However, the GFAP+ area in the fimbria 
at 4 months was significantly larger in Stop-Nrg1*NEX-Cre (13.41 %  1.49) than in 
Stop-Nrg1*CKII-Cre mice (5.76 %  1.84; *p < 0.05). This effect however, was not 
significant when compared to control mice (Fig. 18B). At 1 year of age there was no 
significant difference detectable in any of the mice tested (Fig. 18C), indicating a 
non-progressive pathology. Taken together, Stop-Nrg1*NEX-Cre and Stop-






Fig. 17: Stop-Nrg1*NEX-Cre and Stop-Nrg1*CKII-Cre mice show no signs of 
neuroinflammation. (A) Chromogenic immunostainings for neuropathology markers on 
coronal paraffin sections (bregma -1.7) of 4 months old Stop-Nrg1*NEX-Cre, Stop-Nrg1*CKII-
Cre and control mice for activated microglia (MAC-3), T-cell infiltration (CD3) and axonal 
swellings (APP), reveal no signs of neuropathology or -inflammation. Insets in CD3 stainings 
show high magnifications of occasionally found CD3
+
 T-cells (indicated by boxes in 
overviews). Sections of CNP
-/-
 mice, which received cryo lesions, were used as positive 
controls (Wieser et al., 2013). Scale bars, 50 µm (overviews), 100 µm (CD3), 10 µm (insets). 
(B) Sustained HA-NRG1 overexpression does not lead to neuroinflammation in aged Stop-
Nrg1*NEX-Cre and Stop-Nrg1*CKII-Cre mice. Chromogenic immunostainings on coronal 
paraffin sections from 1 year old mice for MAC-3, CD3 and APP, as in (A). CA3, hippocampal 
CA3 region; CC, corpus callosum; Fim, fimbria; SO, stratum oriens; SP, stratum pyramidale; 
SR, stratum radiatum. Scale bars, 100 µm (overviews), 20 µm (insets). 
 
Likewise, no changes in activated microglia were found in immunostainings for MAC-




performed (Fig. 19). Similar to GFAP immunostainings, a semi-automated 
quantification of chromogenic IBA1 immunostainings was conducted. Cortex and 
hippocampus were quantified as examples for grey matter, and the corpus callosum 
as an example for white matter regions (quantified regions are illustrated in Fig. 19A, 
C). At 4 months of age no difference in IBA1+ area was detectable in both transgenic 
models. A trend for increased IBA1+ area in the cortex of NEX-Cre controls and Stop-
Nrg1*NEX-Cre mice was not significant (Fig. 19B). Also at 1 year of age no 
significant differences in IBA1+ area were detected in cortex and hippocampus of 
Stop-Nrg1*NEX-Cre and Stop-Nrg1*CKII-Cre mice. However, there was an increase 
in IBA1+ area in the hippocampus of NEX-Cre control mice (7.49 %  1.34) compared 
to CKII-Cre and Stop-Nrg1*CKII-Cre mice (CKII-Cre: 3.03 %  0.56; Stop-Nrg1*CKII-
Cre: 3.23 %  0.35; *p < 0.05), and Stop-Nrg1 mice (2.95 %  0.29; *p < 0.01), but 
not to Stop-Nrg1*NEX-Cre mice (Mean: 4.46 %  1.62), indicating an effect of NEX 
haploinsufficiency (Fig. 19D). 
Taken together, chronically elevated HA-NRG1 expression has no potent 
neurodegenerative or -inflammatory effects when overexpression starts at postnatal 
or even embryonic stages. However, NEX (NeuroD6) haploinsufficiency in 
heterozygous NEX-Cre driver mice is associated with mildly increased microgliosis in 
the hippocampus of aged mice. HA-NRG1 overexpression in Stop-Nrg1*NEX-Cre 







Fig. 18: Stop-Nrg1*NEX-Cre and Stop-Nrg1*CKII-Cre mice show no signs of 
astrogliosis. (A) Chromogenic immunostaining for astrocytes (GFAP) on coronal paraffin 
sections from 4 months old Stop-Nrg1*NEX-Cre, Stop-Nrg1*CKII-Cre and control mice 
(bregma -1.7). Dashed lines mark quantified areas. Square indicates position of high 
magnification image. Fim, fimbria; Hipp, hippocampus. Scale bars, 500 µm. (B) Semi-
automated quantification of GFAP
+ 
area in hippocampus and fimbria of Stop-Nrg1*NEX-Cre, 
Stop-Nrg1*CKII-Cre and control mice at 4 months of age reveals a significant increase in 
GFAP
+
 area in the fimbria of Stop-Nrg1*NEX-Cre
 
mice compared to Stop-Nrg1*CKII-Cre 
mice, that, however, does not differ significantly from control mice. (*p < 0.05, one-way 
ANOVA; Bonferroni’s multiple comparison test; n.s., not significant; n-numbers indicated in 
the graphs). (C) Semi-automated quantification of GFAP
+
 area in hippocampus and fimbria of 
Stop-Nrg1*NEX-Cre, Stop-Nrg1*CKII-Cre and control mice at 1 year of age confirms absence 
of astrogliosis. (One-way ANOVA with Bonferroni’s multiple comparison test; n.s., not 








Fig. 19: Stop-Nrg1*NEX-Cre and Stop-Nrg1*CKII-Cre mice show no signs of 
microgliosis. (A) Chromogenic immunostaining for microglia (IBA1) on coronal paraffin 
sections from 4 months old Stop-Nrg1*NEX-Cre, Stop-Nrg1*CKII-Cre and control mice 
(bregma -1.7). Dashed lines mark quantified areas. Dashed square in thresholded black/white 
image indicates position of high magnification images (Asterisk). Cc, corpus callosum; Cx, 
cortex; Hipp, hippocampus. Scale bars, 500 µm (overvies), 100 µm (high magnifications). (B) 
Semi-automated quantification of IBA1
+
 area in cortex, hippocampus and corpus callosum of 
Stop-Nrg1*NEX-Cre, Stop-Nrg1*CKII-Cre and control mice at 4 months of age reveals 
absence of microgliosis. (One-way ANOVA; Bonferroni’s multiple comparison test; n.s., not 
significant. n-numbers indicated in the graphs). (C) Chromogenic immunostaining for IBA1 on 
1 year old animals as in (A). Scale bars, 500 µm (overviews), 100 µm (high magnifications). 
(D) Semi-automated quantification of IBA1
+
 area in 1 year old animals as in (B), reveals 
significantly increased IBA1
+
 area in the hippocampus of NEX-Cre
 
mice. Note the moderate 
increase of IBA1
+ 
area in Stop-Nrg1*NEX-Cre mice, indicating an effect of NEX 
haploinsufficiency. (One-way ANOVA with Bonferroni’s multiple comparison test; n.s., not 
significant; n-numbers indicated in the graphs). 
 
3.8 Conditional CRD-NRG1 overexpression has no effect on 
interneuronal migration and maintenance 
NRG1 signaling via ErbB4 has been implicated in the migration of cortical 
interneurons (Flames et al., 2004). Interneuron numbers and cortical layering are 
normal in Emx-Cre*Nrg1f/f mice (Fig. 8B-E), but mildly altered in Nrg1-tg mice (Fig. 
9C, E). In addition, the NRG1-ICD has been shown to influence cell survival by 
regulating genes associated with apoptosis (Bao et al., 2003).  
To determine possible effects of chronic CRD-NRG1 overexpression beginning at 
embryonic and postnatal stages on the migration and maintenance of cortical 
neurons, a large-scale quantification of neurons in Stop-Nrg1*NEX-Cre and Stop-
Nrg1*CKII-Cre mice was conducted. Chromogenic immunostainings were performed 
on coronal paraffin sections (bregma -1.7) of 4 months and 1 year old Stop-
Nrg1*NEX-Cre, Stop-Nrg1*CKII-Cre, and parental control mice. Brain sections were 
stained for the pan neuronal marker NeuN and the interneuronal markers GAD67 
and parvalbumin and quantified in the cortex and hippocampus. 
A semi-automated quantification method was employed for counting NeuN+ neuron 
numbers, based on thresholded images, including watershed-based rendering of 
positive signals (Fig. 20A, C). Quantification of NeuN+ neurons in the cortex of 4 
month old Stop-Nrg1*NEX-Cre and Stop-Nrg1*CKII-Cre mice showed no differences 
compared to parental controls, except for a minor difference between Stop-
Nrg1*NEX-Cre mice and CKII-Cre controls, which harbored significantly less NeuN+ 
neurons (*p < 0.05), however, due to small group size (n=3), this finding requires 
cautious interpretation (Fig. 20A, B). At 1 year of age NEX-Cre controls and Stop-






Fig. 20: NEX-Cre and Stop-Nrg1*NEX-Cre mice have reduced numbers of neurons in 
the cortex at 1 year of age. (A and C) Chromogenic immunostaining for the pan-neuronal 
marker NeuN on coronal paraffin sections from 4 months and 1 year old Stop-Nrg1*NEX-Cre, 
Stop-Nrg1*CKII-Cre and control mice (bregma -1.7), and watershed thresholded images used 
for semi-autoated quantification of NeuN
+
 neurons. Scale bars, 50 µm. (B) Semi-automated 
quantification of 500 µm wide columns of the somato-sensory cortex using watershed 
thresholded images at 4 months of age revealed a slight decrease in neuronal numbers in 
CKII-Cre
 
mice compared to Stop-Nrg1*NEX-Cre mice (*p < 0.05, one-way ANOVA; 
Bonferroni’s multiple comparison test; n-numbers indicated in the graph). (D) Semi-automated 
quantification of NeuN
+
 neurons, as in (B), at 1 year of age revealed a ~20 % reduction of 
neurons in the cortex of NEX-Cre and Stop-Nrg1*NEX-Cre mice, indicating an effect of NEX 
haploinsufficiency (*p < 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA; Bonferroni’s multiple 
comparison test; n-numbers indicated in the graph). 
 
compared to other genotypes (Fig. 20C, D). However, this finding emerged from a 
combination of slightly increased cortical size and reduced numbers of NeuN+ cells in 
mice harboring the NEX-Cre allele (data not shown), resulting in a significant 
reduction in cell density. Individually, the number of NeuN+ cells and cortical size 
were not significantly different compared to other genotypes. As above, the 
(modestly) reduced density of NeuN+ neurons was associated with NEX 
haploinsufficiency in NEX-Cre ‘knock-in’ driver mice, rather than Cre expression per 






Fig. 21: NEX-Cre mice show reduced numbers of GAD67
+
 interneurons in the cortex 
and hippocampus at 1 year of age. (A) Chromogenic immunostaining for GAD67 on 




control mice (bregma -1.7). Dashed lines indicate quantified areas. Boxes show location of 
high magnification images. Scale bars, 500 µm (overview), 100 µm (high magnifications). (B) 
Quantification of GAD67
+
 interneurons in the cortex and hippocampus of 4 months old Stop-
Nrg1*NEX-Cre, Stop-Nrg1*CKII-Cre and controls showed no significant differences in 
interneuron numbers (One-way ANOVA; Bonferroni’s multiple comparison test; n.s., not 
significant; n-numbers indicated in the graph). (C and D) A similar analysis of GAD67
+
 
interneurons, as in (A and B), was performed at 1 year of age. (C) Exemplary images of 
GAD67 immunostainings and quantified areas. Scale bars, 500 µm (overview), 100 µm (high 
magnifications). (D) Quantification of GAD67
+
 cells revealed reduced interneuronal numbers 
in the cortex and hippocampus of NEX-Cre mice. Stop-Nrg1*NEX-Cre mice as well showed a 
trend to reduced interneuron numbers. (*p < 0.05, **p < 0.01; one-way ANOVA with 
Bonferroni’s multiple comparison test; n-numbers indicated in the graph). 
 
CKII-Cre or CKII-Cre mice (Fig. 20D). Since the NEX-Cre driver line is a widely used 
tool in neurobiology, possible neuropathological effects of NEX (NeuroD6) 
haploinsufficiency must be carefully considered. 
Next, interneuronal numbers in the somatosensory cortex and hippocampus (bregma 
-1.7) were quantified at 4 months and 1 year of age following immunostaining of 
coronal paraffin sections for GAD67 (Fig. 21A, C, dashed lines mark quantified 
areas). Counting was performed manually, since GAD67 not only stained cell 
somata, but also dendritic and axonal arborizations (Fig. 21A, C, note background 
staining). Again, the results represent cell density (cells/mm2) to normalize the cell 
number to the quantified area. No changes in the number of GAD67+ interneurons 
were observed at 4 months of age (Fig. 21A, B). At 1 year of age a significant 
reduction in the density of GAD67+ interneurons was present in the cortex and 
hippocampus of NEX-Cre controls compared to other genotypes (Fig. 21D). Similar 
as above, increased cortical and hippocampal size, without concomitant increase in 
cell numbers (data not shown), resulted in reduced GAD67+ cell density in NEX-Cre 
controls. In contrast, embryonic (Stop-Nrg1*NEX-Cre) or postnatal (Stop-Nrg1*CKII-
Cre) HA-NRG1 overexpression showed no major effect on interneuron density in the 
cortex or hippocampus (Fig. 21D).  
PV+ interneurons present the largest group of ErbB4 expressing interneurons 
(Neddens and Buonanno, 2009; Vullhorst et al., 2009; Fazzari et al., 2010). To 
specifically examine these cells, coronal paraffin sections were immunostained for 
parvalbumin. Similar to the GAD67 analysis, interneuron numbers were manually 
counted in the hippocampus and cortex (bregma -1.7) of Stop-Nrg1*NEX-Cre, Stop-
Nrg1*CKII-Cre, and parental control mice at 4 months and 1 year of age (Fig. 22A, C, 
dashed lines indicate quantified areas). At 4 months no significant differences in the 
number of PV+ interneurons were observed in the cortex and hippocampus of Stop-







Fig. 22: NEX-Cre and Stop-Nrg1*NEX-Cre mice have reduced numbers of PV
+
 
interneurons in the cortex and hippocampus at one year of age. (A) Chromogenic 




Stop-Nrg1*CKII-Cre and control mice (bregma -1.7). Dashed lines indicate quantified areas. 
Boxes highlight positions of high magnification images. Scale bars, 500 µm (overview), 100 
µm (high magnifications). (B) Quantification of PV
+ 
interneurons in the cortex and 
hippocampus at 4 months of age showed no difference between genotypes. (One-way 
ANOVA; Bonferroni’s multiple comparison test; n.s., not significant; n-numbers indicated in 
the graph). (C) Similar chromogenic immunostaining for PV as in (A) for 1 year old mice. 
Dashed line indicates the area quantified in the hippocampus. Boxes indicate positions of 
high magnification images shown in the lower panel (Asterisk). Scale bars, 500 µm 
(overview), 100 µm (high magnification). (D) Quantification of PV
+
 interneurons at 1 year of 
age in the cortex and hippocampus of NEX-Cre
 
mice revealed reduced numbers of PV
+ 
interneurons. A similar effect in the cortex and a trend in the hippocampus were also 
observed in Stop-Nrg1*NEX-Cre mice, arguing for an effect of NEX haploinsufficiency. Note 
that in the cortex of 1 year old mice only a 500 µm wide column of the somato-sensory cortex 
was quantified. (*p < 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA with Bonferroni’s 
multiple comparison test; n-numbers indicated in the graph). 
 
At 1 year of age a significantly reduced density of PV+ interneurons was detected in 
NEX-Cre controls and Stop-Nrg1*NEX-Cre mice (Fig. 22C, D). As above, a 
combination of increased cortical and hippocampal sizes and mildly reduced 
numbers of PV+ interneurons (data not shown) resulted in a significant reduction of 
cell density. Again, this effect was associated with NEX haploinsufficiency, as it was 
also present in Stop-Nrg1*NEX-Cre mice, but not CamKII-Cre driver mice (Fig. 22D). 
Taken together, HA-NRG1 overexpression in cortical projection neurons (with early 
embryonic or postnatal onset) caused no major abnormalities in cortical interneuron 
migration and/or maintenance. 
At 1 year of age a significantly reduced density of PV+ interneurons was detected in 
NEX-Cre controls and Stop-Nrg1*NEX-Cre mice (Fig. 22C, D). As above, a 
combination of increased cortical and hippocampal sizes and mildly reduced 
numbers of PV+ interneurons (data not shown) resulted in a significant reduction of 
cell density. Again, this effect was associated with NEX haploinsufficiency, as it was 
also present in Stop-Nrg1*NEX-Cre mice, but not CamKII-Cre driver mice (Fig. 22D). 
Taken together, HA-NRG1 overexpression in cortical projection neurons (with early 
embryonic or postnatal onset) caused no major abnormalities in cortical interneuron 
migration and/or maintenance. 
 
3.9 Cortical-restricted HA-NRG1 overexpression is not linked to 
ventricular enlargement observed in Thy1.2 promoter-driven 
transgenic mice 
Ventricular enlargement is a robust and well replicated feature in SZ and Nrg1-tg 
mice with cortical and subcortical HA-NRG1 overexpression show enlarged lateral 






Fig. 23: Lateral ventricles are enlarged in HA-Nrg1-tg, but not in HA-Nrg1
GIEF
 or 
conditional HA-NRG1 overexpressing mice. (A) Representative images of third and lateral 
ventricles of Thy1.2 promoter-driven and conditional HA-Nrg1 transgenic mouse lines and 
controls. Chromogenic immunostaining for GFAP on coronal paraffin sections at bregma -1.7. 
Scale bars, 250 µm. (B) Because ventricles are three dimensional structures with changing 
cross section profile, ventricle sizes of Thy1.2 promoter-driven HA-Nrg1-tg and HA-Nrg1
GIEF
, 
as well as conditional Stop-Nrg1*NEX-Cre, Stop-Nrg1*CKII-Cre mice and controls were 
measured and averaged in at least three coronal paraffin sections per mouse, to increase the 
reliability of the analysis (bregma -1.7). HA-Nrg1-tg mice have enlarged lateral ventricle sizes 
and show a tendency to enlarged third ventricles. (*p < 0.05, **p < 0.01, ***p < 0.001; n.s., not 
significant; one-way ANOVA with Bonferroni’s multiple comparison test; n-numbers indicated 




To systematically compare ventricular sizes in different NRG1 transgenic mouse 
models, sizes of third and lateral ventricles were determined in Thy1.2-driven HA-
Nrg1-tg and HA-Nrg1GIEF mice, as well as in conditional Stop-Nrg1*NEX-Cre and 
Stop-Nrg1*CKII-Cre mice. HA-Nrg1GIEF mice express an HA epitope-tagged variant of 
CRD-NRG1, which mimicks proteolytic cleavage in the juxtamembrane stalk region 
by BASE-1, therefore lacks the CTF, and ends with the amino acid sequence: “GIEF” 
for (Glycine-Isoleucine-Glutamic Acid (E)-Phenylalanine (F)). Similar to HA-Nrg1-tg 
mice, these mice show hypermyelination of the CNS and PNS and express this 
NRG1 variant at high levels in neurons of the brain (Velanac et al., 2011). Ventricular 
size was determined on coronal paraffin sections (bregma -1.7). Representative 
images are shown in Fig. 23A, the dashed lines indicate measured areas. 
As expected, HA-Nrg1-tg mice showed enlarged ventricles, similar to Nrg1-tg mice 
(Agarwal et al., 2014), however the enlargement of the third ventricle was not 
significant, when compared to the other genotypes (Fig. 23B). Analysis of lateral 
ventricles (average of left and right lateral ventricle area) revealed that ventricle size 
in HA-Nrg1-tg mice was almost doubled compared to all other genotypes, however 
this result was not significant when compared to HA-Nrg1GIEF and Stop-Nrg1*CKII-
Cre mice (Fig. 23B). 
It appears that subcortical expression of full length CRD-NRG1 is required for 
ventricular enlargement. However, expression of HA-NRG1GIEF at high levels in 
subcortical regions does not affect ventricular sizes, indicating that the NRG1 CTF 
might be involved in the development of enlarged ventricles. 
 
3.10 Thy1.2-driven NRG1 transgenic mice have reduced body weight 
Intracerebroventricular injections of recombinant NRG1 cause decreased body 
weight in hamsters (Snodgrass-Belt et al., 2005). Furthermore, intraperitoneal 
administration of recombinant NRG1 has recently been shown to trigger decreased 
food intake and results in reduced weight gain in normal-weight mice, by affecting 
leptin levels (Ennequin et al., 2015). When handling our transgenic mice, we 
observed that Nrg1-tg and HA-Nrg1-tg mice were always leaner than their WT 
littermates. To analyze this observation in more detail, the body weight of adult males 
from several NRG1 overexpressing transgenic mouse lines at an age of 12 to 18 
weeks was determined. In line with previous observations, Thy1.2-driven Nrg1-tg and 
HA-Nrg1-tg mice were significantly leaner than controls and Stop-Nrg1*NEX-Cre 
mice, but not than CKII-Cre and Stop-Nrg1*CKII-Cre mice. In fact Stop-Nrg1*CKII-




suggesting that subcortical overexpression of CRD-NRG1, for instance in thalamic 
and hypothalamic regions, is involved in the weight reduction, as Stop-Nrg1*CKII-Cre 
mice show more subcortical expression than Stop-Nrg1*NEX-Cre mice (compare 
Fig. 14, 16). 
 
 
Fig. 24: ‘Global’ Nrg1-tg and HA-Nrg1-tg mice have reduced body weight. Body weight of 
NRG1 transgenic mouse models was determined in male mice at an age of 12 to 18 weeks. 
Thy1.2 promoter-driven Nrg1-tg and HA-Nrg1-tg mice have significantly lower body weight 
than controls and conditional Stop-Nrg1*NEX-Cre mice. CKII-Cre and Stop-Nrg1*CKII-Cre 
were not significantly heavier than Thy1.2 promoter-driven models. Stop-Nrg1*CKII-Cre mice 
were significantly leaner than Stop-Nrg1*NEX-Cre mice. (*p < 0.05, **p < 0.01, ***p < 0.001; 
one-way ANOVA with Bonferroni’s multiple comparison test; n-numbers indicated in the 
graph). 
 
3.11 Stop-Nrg1*NEX-Cre mice show no signs of anxiety-like behavior, 
decreased PPI or cognitive impairments, but exhibit hyperactivity 
Overexpression of full length HA-CRD-NRG1 in HA-Nrg1-tg mice causes behavioral 
changes, such as anxiety-like behavior in the open field test (Fig. 10E) and PPI 
deficits (Fig. 10D). In these mice, pan-neuronal CRD-NRG1 overexpression in the 
brain starts at around E16 and persists at high levels throughout life. In Stop-
Nrg1*NEX-Cre mice moderate HA-CRD-NRG1 overexpression is restricted to 
projection neurons of the neocortex, hippocampus and amygdala, starting at E12.  
To test whether cortical restricted HA-NRG1 overexpression leads to abnormal 
behavior, adult (age 8-25 weeks) Stop-Nrg1*NEX-Cre mice (n = 20) and controls, 
including WT (n = 15), Stop-Nrg1 (n = 11) and NEX-Cre mice (n = 22), were 






Fig. 25: Stop-Nrg1*NEX-Cre mice exhibit novelty-induced hyperactivity and increased 
fighting behavior in the tail suspension test. (A) Stop-Nrg1*NEX-Cre mice are hyperactive 
in the open field test compared to parental controls and show increased time active, distance 
travelled and more corner visits. Distance travelled plotted in 1 min intervals over the length of 
the experiment reveals novelty-induced hyperactivity. No signs of altered anxiety behavior 
were observed. (B) Stop-Nrg1*NEX-Cre males are hyperactive in the hole board test, but 
show similar exploration times and hole visits as controls. Distance travelled plotted as 1 min 
intervals confirms novelty-induced hyperactivity. (C) Stop-Nrg1*NEX-Cre mice show normal 




behavior were observed. (right) Image of the experimental setup. (D) Stop-Nrg1*NEX-Cre 
mice exhibit increased fighting behavior in the first, second and fifth minute of the tail 
suspension test compared to controls. NEX-Cre
 
mice fought more than WT in the first and 
second minute and more than Stop-Nrg1 mice in the second minute of the test. (right) Image 
of a mouse during the experiment. Male mice were tested at an age of 8-25 weeks. Stop-
Nrg1*NEX-Cre mice (n = 20), WT (n = 15), Stop-Nrg1 (n = 11), NEX-Cre
 
(n = 22). (*p < 0.05, 
**p < 0.01, ***p < 0.001; n.s., not significant; one-way ANOVA with Bonferroni’s multiple 
comparison test). 
 
mice were tested in the open field test. While signs for increased anxiety-like 
behavior were not observed (data not shown), Stop-Nrg1*NEX-Cre mice exhibited 
hyperactivity. Stop-Nrg1*NEX-Cre mice were more active (10 % increase) 
compared to WT and Stop-Nrg1 mice, but not to NEX-Cre mice (Fig. 25A). They 
travelled longer distances (30% increase) and visited more corners (44% increase) 
compared to all control groups (Fig. 25A). When the distance travelled was plotted as 
1 minute intervals over the 10 minutes duration of the experiment, Stop-Nrg1*NEX-
Cre mice travelled more distance over the entire course of the experiment (Fig. 25A). 
This effect was highly significant in the first half of the experiment, when compared to 
WT controls and significant in most of the 1 minute intervals compared to the two 
parental control strains (Stop-Nrg1 and NEX-Cre), suggesting novelty induced 
hyperactivity. 
To assess the exploratory drive and anxiety related behavior under different 
conditions, mice were tested in the hole board test. In this test mice explore an open 
arena equipped with holes, which trigger exploratory behavior, i.e. nose poking. 
While Stop-Nrg1*NEX-Cre mice showed no changes in exploratory behavior (Fig. 
25B), they travelled longer distances (35 %). When plotted as 1 minute intervals, 
Stop-Nrg1*NEX-Cre mice travelled longer distances during the first half of the test 
and showed higher activity during the entire experiment compared to controls, similar 
to the hyperactivity phenotype observed in the open field test (Fig. 25B). To examine 
anxiety-related behavior more specifically, the light-dark preference test was 
employed. This test measures the animal’s preference for dark, enclosed places over 
bright, exposed places. Mice that did not enter the dark compartment within 6 
minutes were excluded from the test (two WT and two NEX-Cre mice). Similar to 
open field and hole board tests, Stop-Nrg1*NEX-Cre mice showed no signs of 
increased anxiety (Fig. 25C). 
Next, the tail suspension test was employed, which was developed to assess mood 
levels and as a screening test for potential antidepressant drugs. In this test the mice 
are hung by the tail for 6 minutes and thereupon try to escape this aversive situation 
(Fig. 25D). Longer periods of immobility are considered as depressive-like 




aversive situation compared to WT and Stop-Nrg1 mice (***p < 0.001) and NEX-Cre 
controls (*p < 0.05), thus displaying decreased depressive-like behavior (Fig. 25D). 
When plotted over time, Stop-Nrg1*NEX-Cre mice showed more activity than WT in 
the first, second, and fifth minute of the test (***p < 0.001), in minute 2 more activity 
than Stop-Nrg1 (***p < 0.001) and in minute 5 more activity than NEX-Cre controls 
(***p < 0.001) (Fig. 25D). However, NEX-Cre controls also struggled more than WT 
mice in the first (**p < 0.01) and second minute of the test (*p < 0.05), and in the 
second minute NEX-Cre controls showed more activity than Stop-Nrg1 controls (***p 
< 0.001) (Fig. 25D). This finding again supports the hypothesis that 
haploinsufficiency in NEX-Cre mice could affect brain functions, including behavior. 
NRG1/ErbB4 signaling is involved in both short-term and long-term neural plasticity 
(Li et al., 2007; Woo et al., 2007), CRD-NRG1 overexpression results in impaired 
LTP (Agarwal et al., 2014). In addition, HA-Nrg1-tg mice showed deficits in working 
memory (Wehr et al., in preparation). Ablation of NRG1 in projection neurons, using 
the CKII-Cre driver line caused reduction in contextual and cued fear memory. 
Together, these findings suggest that NRG1 plays a role in learning, memory and 
other cognitive processes. 
To test the influences of cortical restricted HA-NRG1 overexpression on 
hippocampus-dependent learning and memory, Stop-Nrg1*NEX-Cre mice were 
tested in contextual and cued fear conditioning. When mice were placed into the 
shocking chamber for 2 min on the first day, they showed normal baseline behavior 
(normal exploration with no freezing).  
Subsequently, mice were subjected to two pairings of the conditioned stimulus (CS, a 
tone of 80 db, for 30 sec), followed by the aversive unconditioned stimulus (US, mild 
electric foot shock, 0.4 mA for 2 sec) separated by 30 sec. Reaction to both the CS 
and US was comparable in all groups. 24 hours later, the retention of contextual fear 
conditioning was assessed by placing mice back into the fear conditioning context 
box for 2 min. Contextual fear response was scored by measuring the freezing 
response (steady suppression of locomotor or exploratory activity). All genotype 
groups showed comparable freezing behavior as a consequence of exposure to the 
context, however Stop-Nrg1*NEX-Cre mice showed a tendency to reduced freezing 
response (Fig. 26D). 24 hours later mice were placed in a novel context box with no 
similarities to the shocking chamber, and scored for freezing behavior in response to 
the new context for 2 min. All genotypes showed similar freezing responses to the 
new context that were slightly increased over the context baseline, but significantly 






Fig. 26: Stop-Nrg1*NEX-Cre mice show no impairments in working memory and 
sensorimotor gating, but exhibit reduced cued fear memory. (A) Stop-Nrg1*NEX-Cre 
mice show no impairments of working memory in the first and second half, as well as the total 
% alternations compared to controls in the Y-maze spontaneous alternation test. (right) Image 
of the experimental setup. (B) Image of the SR-Lab startle response system used for the PPI 
test. Mice were placed into restraining tubes on a deflection sensitive platform. (C) (left) Stop-
Nrg1*NEX-Cre mice show no differences in the percentage of prepulse inhibition at prepulses 
of 70, 75 and 80 dB and no differences in the startle responses prior, during and after the 
conditioning (right). (D) Stop-Nrg1*NEX-Cre mice display reduced cued fear memory 
compared to WT and NEX-Cre controls. Stop-Nrg1 mice show increased context baseline 
freezing behavior due to two outliers (exclamation mark), illustrated in the scatter plot (right). 
Since these two mice performed normal in all other tasks, they were kept in the analysis. (E) 
Normal pain sensitivity in all genotypes in the hotplate test. (F) Ugo Basile fear conditioning 
system. The striped box on the left was used for contextual, and the clear cylinder on the right 
as novel context for cued fear memory. (G) Genotype color-code of the bargraphs. Male mice 
were tested at an age of 8-25 weeks. Stop-Nrg1*NEX-Cre mice (n = 20), WT (n = 15), Stop-
Nrg1 (n = 11), NEX-Cre
 
(n = 22). (*p < 0.05, **p < 0.01, ***p < 0.001; n.s., not significant; one-
way ANOVA with Bonferroni’s multiple comparison test). 
 




control groups (WT, Stop-Nrg1 and NEX-Cre) showed similar freezing responses, 
Stop-Nrg1*NEX-Cre mice showed a significant reduction in freezing responses 
compared to WT and NEX-Cre controls, but not to Stop-Nrg1 controls (Fig. 26D). 
Impaired fear response in Stop-Nrg1*NEX-Cre mice could not be caused by a deficit 
in detecting auditory stimuli as these mice performed well in the prepulse inhibition 
(PPI) test (Fig. 26C).  
To investigate the effect of cortical HA-CRD-NRG1 overexpression on working 
memory, Stop-Nrg1*NEX-Cre mice were tested in the Y-maze spontaneous 
alternation test. Mice were allowed to explore the maze for 10 min and the number of 
choices and the percentage of alternations were scored. No difference was observed 
between Stop-Nrg1*NEX-cre mice and controls in the number of choices (data not 
shown) and in the percentage of alternations (Fig. 26A). Thus, Stop-Nrg1*NEX-Cre 
mice showed no deficits in working memory in the Y-maze, in contrast to HA-Nrg1-tg 
mice, 
Finally, assessment in the hotplate test (Fig. 26E) and sensorimotor gating by 
employing the PPI test, showed no changes in pain perception as well as normal 
startle responses and no difference in PPI in Stop-Nrg1*NEX-Cre mice (Fig. 26C), in 
contrast to HA-Nrg1-tg mice (Fig. 10, Agarwal et al., 2014).  
 
3.12 Postnatal cortical overexpression of HA-NRG1 in Stop-Nrg1*CKII-
Cre mice has only minor effects on behavior 
SZ is considered a developmental disease with first symptoms occurring in early 
adulthood (Sham et al., 1994). It was shown in previous studies that deletion of 
NRG1 from projection neurons starting at P5 in CKII-Cre*Nrg1f/f mice resulted in 
hypoactivity in the open field test in 3 months old mice and impaired contextual and 
cued fear conditioning in 12 months old mice (Agarwal et al., 2014). Stop-Nrg1*NEX-
Cre mice showed absence of anxiety-like behavior and no PPI impairment (Fig. 10D, 
E), but hyperactivity in the open field and hole board test, and increased fighting 
behavior in the tail suspension test (Fig. 25A, B, D). 
To distinguish embryonic from postnatal effects of NRG1 overexpression on 
behavioral functions, a cohort of Stop-Nrg1*CKII-Cre mice (n=7) and parental 
controls, Stop-Nrg1 (n=19), and CKII-Cre (n=11) was tested at 3 to 6 months of age 
in the same battery of behavioral tests as before. First, locomotor activity and anxiety 
was assessed in the open field test. Here, only minor hyperactivity was observed for 






Fig. 27: Postnatal cortical overexpression of HA-NRG1 in Stop-Nrg1*CKII-Cre mice has 
only minor effects on activity. (A) Stop-Nrg1*CKII-Cre mice show increased distance 
travelled and corner visits in the open field test compared to Stop-Nrg1, but not to CKII-Cre 




hyperactivity, as Stop-Nrg1*CKII-Cre mice show only a minor increase of distance travelled. 
(B) Normal behavior of Stop-Nrg1*CKII-Cre
 
mice in the hole board test. Only minor increases 
in the exploration time, distance travelled and hole visits were observed. When plotted as 1 
min intervals, no difference between genotypes was detected for the distance travelled. (C) 
Stop-Nrg1*CKII-Cre mice show normal behavior in the light-dark preference test. (right) 
Image of the experimental setup. (D) Only minor increase of fighting behavior in Stop-
Nrg1*CKII-Cre mice in the tail suspension test. Plotting the percentage of time active as 1 min 
intervals reveals only minor increases of activity in the second, fourth and last minute of the 
experiment. (right) Image of a mouse during the experiment. Male mice were tested at 3 to 6 
months of age. Stop-Nrg1*CKII-Cre (n = 7), Stop-Nrg1 (n = 19), CKII-Cre
 
(n = 11). (*p < 0.05; 
n.s., not significant; one-way ANOVA with Bonferroni’s multiple comparison test). 
 
compared to Stop-Nrg1 controls, but not to CKII-Cre controls (Fig. 27A). Similarly, 
Stop-Nrg1*CKII-Cre mice showed only tendencies of hyperactivity and increased 
exploratory behavior in the hole board test, but none of these tendencies was 
significant compared to parental controls (Fig. 27B). To more specifically test anxiety-
associated behavior, the light-dark preference test was performed. Both, the number 
of crossings and the time spend in one or the other compartment was unaltered in 
these mice (Fig. 27C), indicating normal exploratory behavior and anxiety levels in 
Stop-Nrg1*CKII-Cre mice. Finally, Stop-Nrg1*CKII-Cre mice showed a non-
significant increase in overall time active in the tail suspension test (Fig. 27D). Thus, 
Stop-Nrg1*CKII-Cre mice showed no signs of depressive-like states, but also no 
increase in motivation to escape the aversive situation. In summary, Stop-Nrg1*CKII-
Cre mice do not replicate the hyperactivity phenotype observed in Stop-Nrg1*NEX-
Cre mice.  
To assess hippocampus-dependent learning and memory, Stop-Nrg1*CKII-Cre mice 
were tested in contextual and cued fear conditioning. Following the same 
experimental procedure as above, Stop-Nrg1*CKII-Cre mice showed no deficits in 
contextual and cued fear memory (Fig. 28D).  
When tested also Stop-Nrg1*CKII-Cre mice and controls in the Y-maze spontaneous 
alternation test, Stop-Nrg1*CKII-Cre mice showed normal exploration behavior, and 
there was no significant difference between Stop-Nrg1*CKII-Cre mice and controls in 
the number of choices (data not shown) and the percentage of alternations (Fig. 
28A). Thus Stop-Nrg1*CKII-Cre mice showed no impairments of working memory in 
this test. 
Finally Stop-Nrg1*CKII-Cre mice and controls showed similar response to pain 
stimuli in the hotplate test (Fig. 28E), and no differences were observed in startle 
response and PPI (Fig. 28C). 
In summary, postnatal conditional overexpression of the same HA-CRD-NRG1 
variant as in HA-Nrg1-tg and Stop-Nrg1*NEX-Cre mice shows only minor effects on 






Fig. 28: Stop-Nrg1*CKII-Cre mice exhibit normal learning and memory as well as 
sensorimotor gating. (A) Stop-Nrg1*CKII-Cre mice show no impairments of working 
memory in the Y-maze spontaneous alternation test compared to parental controls. (right) 
Image of the experimental setup. (B) Image of the SR-Lab startle response system used for 
the PPI test. Mice were placed into restraining tubes on a deflection sensitive platform. (C) 
(left) Stop-Nrg1*CKII-Cre mice show no differences in the percentage of prepulse inhibition at 
prepulses of 70, 75 and 80 dB and no differences in the startle responses prior, during and 
after the conditioning (right). (D) No impairments of learning and memory in Stop-Nrg1*CKII-
Cre mice in contextual and cued fear memory compared to controls. (right) TSE Systems fear 
conditioning setup. The box on the left was used for contextual fear conditioning and the 
triangular box on the right as a novel context for cued fear memory. (E) Normal pain 
sensitivity in all genotypes in the hotplate test. (F) Genotype color-code of the bargraphs. 
Male mice were tested at 3 to 6 months of age. Stop-Nrg1*CKII-Cre (n = 7), Stop-Nrg1 (n = 
19), CKII-Cre
 
(n = 11). (*p < 0.05; n.s., not significant; one-way ANOVA with Bonferroni’s 





3.13 Stop-Nrg1*NEX-CreERT2 mice as a tool for acute overexpression of 
NRG1 in the adult mouse brain  
Acute changes in NRG1/ErbB4 signaling may provide better insight into ‘normal’ 
NRG1 functions in the brain. To model acute overexpression of HA-CRD-NRG1 in 
adult mice, we employed the NEX-CreERT2 driver mouse line (Agarwal et al., 2011). 
This mouse line allows tamoxifen induced, Cre-mediated recombination. Tamoxifen 
is a synthetic estrogen receptor (ER) ligand, which induces the dissociation of 
cytosolic CreERT2 from HSP90, nuclear import of CreERT2, and site-specific 
recombination of loxP-flanked target genes. 
To test the efficiency of different tamoxifen concentrations to induce Cre-
recombination in the brain, we crossbred NEX-CreERT2 mice to R26R-floxtdTomato 
reporter mice (Madisen et al., 2010). Double transgenic mice were injected 
intraperitoneally (IP) for 2 or 10 days with increasing tamoxifen concentrations, 
ranging from 25-100 mg/kg body weight. Tamoxifen injections at 100 mg/kg body 
weight for 10 days were defined as ‘full induction’ protocol. Four weeks after the last 
injection, mice were perfused with 4 % PFA and coronal vibratome sections of the 
brain were prepared. Mice injected for 2 days with tamoxifen at 25 mg/kg body 
weight showed only few recombined cells in the cortex, the hippocampal layers CA1 
and CA3, and the amygdala (Fig. 29A). Mice injected for 2 days with tamoxifen at 50 
mg/kg body weight showed an increased number of recombined cells in these areas, 
but still displayed a single cell recombination pattern (Fig. 29A). Tamoxifen injection 
for 2 days at 100 mg/kg resembled full induction, yet there were still markedly less 
cells recombined than after 10 days tamoxifen injection at 100 mg/kg body weight. 
(Fig. 29A). In summary, protocol 1 and 2 (25-50 mg/kg body weight of tamoxifen for 2 
days) appeared suitable for single cell genetics. 
For biochemical verification of tamoxifen-induced HA-NRG1 expression, Stop-
Nrg1*NEX-CreERT2 and Stop-Nrg1 control mice were injected for 10 days with 
tamoxifen (100 mg/kg body weight) and brain tissue was collected 1 month later. 
Western blot analysis of protein lysates from hippocampus and thalamus with an 
antibody directed against the C-terminus of NRG1 confirmed NRG1 overexpression 
in the hippocampus, but not thalamus (Fig. 29A, B), in line with absence of thalamic 
recombination in NEX-CreERT2 mice. However, NRG1 overexpression levels in 
Stop-Nrg1*NEX-CreERT2 mice did not match the levels of chronic overexpression in 
Stop-Nrg1*NEX-Cre mice (Fig. 29, B). In a similar experiment Stop-Nrg1*NEX-
CreERT2 and control mice were injected for 10 days with tamoxifen (100 mg/kg body 





Fig. 29: Stop-Nrg1*NEX-CreERT2 mice are a tool for tamoxifen-induced acute HA-NRG1 
overexpression in adult mice and in vivo single-cell genetics. (A) Vibratome sections 
(bregma -1.7) of NEX-CreERT2*R26R-floxtdTomato mice that were injected with inclining 
tamoxifen concentrations (ranging from 25-100 mg/kg body weight) for 2 or 10 days at an age 
of 12 weeks and tissue was collected 50 days later. Tamoxifen injection at 100 mg/kg body 
weight for 10 days is considered a full induction. TdTomato reporter fluorescence confirmed 
increasing recombination in perfusion fixed, ranging from single recombined cells to full 
recombination of cortical projection neurons. Higher magnification confocal images of 2 days 
50 mg/kg tamoxifen injected mice show single recombined pyramidal neurons of the cortex 
and hippocampus (locations marked by dashed boxes). Cx, cortex; Hipp, hippocampus. Scale 
bars, 30 µm. (B) Western blot analysis of hippocampus and thalamus protein lysates show 
HA-NRG1 overexpression in the hippocampus, but not in the thalamus of Stop-Nrg1*NEX-
CreERT2, resembling NEX expression pattern. 17 weeks old mice were injected with 
tamoxifen for 10 days at 100 mg/kg body weight and collected 31 days after the last injection. 




kDa, kilodalton. (C) Fluorescent immunostaining for HA-NRG1 and PV on coronal paraffin 
section (bregma -1.7) of 3 months old Stop-Nrg1*NEX-CreERT2 mice, reveals projection 
neuron-specific HA-NRG1 overexpression. Mice were injected with tamoxifen for 10 days at 
100 mg/kg body weight and tissue was collected 1 month after the last injection. Cx, cortex. 
Scale bar, 20µm. (D) For in vivo single cell genetics, 4 months old Stop-Nrg1*tdTomato*NEX-
CreERT2 triple transgenic mice were injected with tamoxifen for 2 days at 50 mg/kg body 
weight and tissue was collected 3 weeks after the last injection. While layer V pyramidal 
neurons of the cortex loose their GFP fluorescence due to recombination of the GFP-Stop-
flox cassette and gain tdTomato fluorescence (asterisk), hippocampal CA1 pyramidal neurons 
only partially loose their GFP fluorescence (#). (E) Acute induction of HA-NRG1 
overexpression in Stop-Nrg1*NEX-CreERT2 mice and western blot analysis of hippocampal 
protein lysates reveals HA-NRG1 overexpression, ErbB4 hyperphosphorylation and activation 
of MAPK signaling. 4 months old mice were injected with tamoxifen for 5 days at 100 mg/kg 
body weight and brain tissue was collected on the day after the last injection. -actin was 
used as a loading control. CTF, NRG1 C-terminal fragment; FL, full length; kDa, kilodalton. 
for HA-NRG1 and cell type specific markers confirmed that HA-NRG1 
overexpression was restricted to cortical projection neurons (Fig. 29C). 
In a pilot experiment to determine parameters for ‘single cell genetics’, Stop-
Nrg1*NEX-CreERT2 mice were bred to R26R-floxtdTomato reporter mice. Triple 
transgenic mice and controls were injected with tamoxifen (2 days, 50 mg/kg), based 
on the assumption that limited numbers of NEX-CreERT2-positive projection neurons 
recombine both the Stop-Nrg1 transgene and the R26R-floxtdTomato reporter, 
resulting in tdTomato fluorescent neurons that were no longer GFP-positive, but 
instead express HA-NRG1. Analysis of vibratome sections 3 weeks after tamoxifen 
injection revealed tdTomato-positive, GFP-negative cortical projection neurons (Fig. 
29D). However, a subset of tdTomato-positive neurons of the hippocampal CA1 
region maintained GFP fluorescence (Fig. 29D). This either suggests incomplete 
Cre-recombination of only one of the floxed cassettes or residual GFP fluorescence 
due to its long half-life. 
To increase the ‘acuteness’ of the approach, western blot analysis was performed on 
protein lysates prepared one day after the last tamoxifen injection (5 days, 100 
mg/kg). Western blotting with the Nrg1 C-terminal antibody revealed overexpression 
of full length and processed NRG1 already at this early timepoint (Fig. 29E). Testing 
for ErbB4 hyperstimulation with the anti-phospho-ErbB4 (Tyr1284) antibody identified 
a weak increase in ErbB4 receptor phosphorylation (Fig. 29E). Next, as a proof of 
concept it was addressed whether this approach allows to identify changes in 
downstream signaling cascades not present in chronic overexpression models (data 
not shown and Fig. 29B). Western blot analysis of hippocampal protein lysates 
showed a small increase in the phosphorylation of Erk1/2 in Stop-Nrg1*NEX-
CreERT2 mice, suggesting activation of the Raf-MEK-ERK signaling cascade (Fig. 
29E). Thus, this ‘acute’ tamoxifen protocol could be suitable to investigate possible 




3.14 Biochemical analysis of CRD-NRG1 signaling in NRG1 transgenic 
mice 
NRG1/ErbB4 signaling has been linked to SZ in numerous studies (Stefansson et al., 
2002, 2003; Yang et al., 2003; Hahn et al., 2006; Law et al., 2007; Chong et al., 
2008). The Icelandic at-risk haplotype (HapICE) (Stefansson et al., 2002) has 
recently been associated with increased CRD-NRG1 expression in postmortem brain 
tissue of SZ patients (Weickert et al., 2012). CRD-NRG1 overexpression leads to 
chronic ErbB4 receptor hyperstimultation, ventricular enlargement, altered E/I 
balance, disrupted LTP, reduced PPI, and abnormal dendritic spine growth in 
transgenic mice (Agarwal et al., 2014). However, the molecular mechanisms of 
neuronal network dysfunctions downstream of NRG1/ErbB4 hyperstimulation have 
not been studied in detail. 
Several mouse models of CRD-NRG1 overexpression based on Thy1.2 promoter-
driven (Fig. 9, 10 and Agarwal et al., 2014) and Cre-dependent conditional activation 
(Fig. 11-28) are available. These mouse models show different phenotypes and allow 
the investigation of different aspects of NRG1 overexpression in vivo. To compare 
the underlying molecular changes side by side, a biochemical analysis was 
performed using conditional Stop-Nrg1 mouse models for embryonic (NEX-Cre-), 
postnatal (CamKII-Cre-) and acute (NEX-CreERT2-mediated) overexpression as well 
as “global” Thy1.2-driven full length HA-Nrg1-tg and BACE1 processed HA-Nrg1GIEF 
mice (Fig. 30B). 
In previous experiments overexpression of CRD-NRG1 was shown to induce chronic 
ErbB4 hyperphosphorylation in several transgenic mouse models (Fig. 9B, 14B, 
29E). To test the hypothesis that the amount of CRD-NRG1 overexpression 
determines the level of ErbB4 stimulation (Fig. 30A) hippocampal protein lysates 
from these mouse models were analyzed side by side by western blotting. This 
analysis revealed major differences in the level of HA-NRG1 overexpression, with the 
highest expression level observed in HA-Nrg1GIEF mice, followed by HA-Nrg1-tg mice, 
whereas NEX-Cre- and CKII-Cre-based conditional mouse models showed moderate 
HA-NRG1 overexpression (Fig. 30C). The processed NTF in lysates derived from full 
length HA-NRG1 overexpressing mouse models matched the size of the HA-NRG1 
variant expressed in HA-Nrg1GIEF mice, indicating in vivo processing in the stalk 
region by proteases, such as BACE1. Acute overexpression of HA-NRG1 in Stop-
Nrg1*NEX-CreERT2 mice after 5 days of tamoxifen injection at 100 mg/kg and 






Fig. 30: NRG1 expression levels correlate with levels of ErbB4 hyperphosphorylation. 
(A) Our working hypothesis suggests that higher levels of NRG1 expression lead to higher 
ErbB4 receptor stimulation. P, phosphorylated tyrosine residues. (B) HA-NRG1 transgenic 
mouse models include conditional models that allow embryonic (NEX-Cre) and postnatal 
(CamKII-Cre) and tamoxifen-induced acute (Stop-Nrg1*NEX-CreERT2) activation of HA-Nrg1 
overexpression. ‘Global’ models use the Thy1.2 promoter expression cassette and show high 
levels of HA-CRD-NRG1 or HA-NRG1
GIEF
 overexpression. Schematic expression curves 
illustrate onset and level of HA-NRG1 overexpression (red curves) in relation to endogenous 
levels (black curve). (C) Western blot analysis of conditional and global HA-NRG1 transgenic 
models side by side reveal different levels of HA-NRG1 overexpression and confirms 
correlating levels of ErbB4 receptor phosphorylation. Note that in all transgenic models ErbB4 
total protein is reduced, indicating receptor internalization and degradation or gene regulation 
upon hyperstimulation. -actin was used as a loading control. FL, full length; kDa, kilodalton; 




to the other models (Fig. 30C). 
In summary, conditional mouse models express HA-NRG1 at more physiological 
levels when compared to Thy1.2-driven “global” transgenic mice (Fig. 30C). In line 
with the hypothesis that ErbB4 receptor phosphorylation correlates with HA-NRG1 
expression (Fig. 30C), the highest ErbB4 phosphorylation level was observed in HA-
Nrg1GIEF mice followed by HA-Nrg1-tg mice. As expected, conditional NRG1 
transgenic models showed moderate ErbB4 phosphorylation levels, with the acute 
model displaying the lowest ErbB4 induction (Fig. 30C). Interestingly, concomitant 
with increased ErbB4 phosphorylation, a reduction in total ErbB4 protein (detected by 
a pan-ErbB4 antibody) was present in all transgenic mouse models, suggesting 
either internalization and degradation after receptor activation, or a downregulation of 
ErbB4 receptor expression upon hyperstimulation (Fig. 30C). 
In summary, NRG1 transgenic mouse models at hand model distinct levels and 
profiles of HA-NRG1 expression and ErbB4 receptor activation. 
 
3.15 NRG1 forward and backsignaling – differential recruitment of 
LIMK1? 
NRG1-mediated canonical forward signaling proceeds via ErbB receptors. In addition 
to canonical forward signaling, backsignaling via the NRG1-ICD has been described 
in cultured cells (Bao et al., 2003; Mei and Xiong, 2008; Talmage, 2008; Chen et al., 
2010; Fazzari et al., 2014; Mei and Nave, 2014). In addition to transcription factor 
functions after nuclear translocation (Bao et al., 2003), direct binding of the NRG-ICD 
to the serine/threonine kinase LIM kinase 1 (LIMK1) was observed (Wang et al., 
1998). LIMK1 phosphorylates the actin depolymerizing factor cofilin and serves as a 
key regulator of actin cytoskeleton dynamics (Arber et al., 1998; Yang et al., 1998). 
LIMK1 has been implicated in synaptic maturation (Huang et al., 2000) and shuttles 
between the cytoplasm and the nucleus (Yang and Mizuno, 1999). 
To further exploit transgenic mouse models, including backsignaling-deficient HA-
Nrg1GIEF mice, for the investigation of forward and backsignaling-associated 
mechanisms, a comparative western blot analysis was performed using conditional 
Stop-Nrg1*NEX-Cre as well as “global” HA-Nrg1-tg and HA-Nrg1GIEF mice. In 
agreement with previous findings, ErbB4 receptor phosphorylation correlated with the 
expression levels of different HA-NRG1 variants. As before, levels of total ErbB4 
protein were reduced in all transgenic samples (Fig. 31A). Western blot analysis of 
hippocampal protein lysates used to examine effects in two major signaling pathways 




forward signaling in cultured cells (Mei and Xiong, 2008; Mei and Nave, 2014), 
showed that in mice with chronic overexpression of full length HA-NRG1 (HA-Nrg1-tg 
and Stop-Nrg1*NEX-Cre mice) MAPK or PI3K signaling was not activated (Fig. 31B). 
However, both pathways were stimulated in HA-Nrg1GIEF mice (Fig. 31B). This finding 
suggests more potent forward signaling functions of NRG1 NTF in HA-Nrg1GIEF mice, 
even under chronic conditions. In line with this finding, the NRG1 NTF was localized 
to axons of projection neurons with a higher abundance than the full length CRD-
NRG1 (Fig. 31B), similar to findings in the PNS (Velanac et al., 2011). Thus, the 
NRG1 NTF more likely reaches presynapses to signal to postsynaptic ErbB4 in 
interneurons. 
Although the precise mechanisms are unknown, perturbed dendrite and axon growth 
of cortical neurons in CRD-NRG1 mouse mutants are thought to be mediated by 
NRG1-ICD backsignaling (Chen et al., 2008, 2010).  
Immunostaining of paraffin sections from Stop-Nrg1*NEX-Cre mice with the anti-HA 
antibody revealed that HA-NRG1 accumulated in the somatodendritic compartment, 
whereas transport into the axonal and presynaptic compartment seemed to be 
limited (Fig. 31C). This lead to the working hypothesis that abnormal accumulation of 
full length HA-NRG1 in the somatodendritic compartment could lead to abnormal 
NRG1-ICD mediated backsignaling (Fig. 24C), with LIMK1 and cofilin as possible 
targets. Thus, hippocampal protein lysates from conditional Stop-Nrg1*NEX-Cre, as 
well as “global” HA-Nrg1-tg and HA-Nrg1GIEF mice were tested for LIMK1 and cofilin 
phosphorylation.  
To verify the identity of the LIMK1 band, protein lysates from LIMK1-/- mice were 
included in the analysis. This analysis revealed that threonine residue 508 (important 
for the regulation of LIMK1 activity) was hypophosphorylated in Stop-Nrg1*NEX-Cre 
mice, indicating reduced LIMK1 activity (Fig. 31C). In contrast, the phosphorylation 
status of T508 was unaltered in HA-Nrg1-tg and HA-Nrg1GIEF mice. Expression of 
LIMK1 protein was unchanged in all transgenic NRG1 mouse models. As expected 
this band was absent in protein lysates from LIMK1-/- mice (Fig. 31C). Examination of 
the phosphorylation status of cofilin at serine 3 revealed increased Ser3 
phosphorylation in all NRG1 transgenic models analyzed (Fig. 31C). Conditional 
Stop-Nrg1*NEX-Cre mice showed stronger Ser3 phosphorylation than “global” HA-
Nrg1-tg mice, which expressed the same HA-NRG1 variant even at higher levels. 
Unexpectedly, backsignaling-deficient HA-Nrg1GIEF mice showed the strongest Ser3 
phosphorylation (Fig. 31C), implicating that NRG1 might regulate cofilin activity also 
via distinct forward directed signaling events. In none of the transgenic mouse 






Fig. 31: A comparative analysis of NRG1 transgenic mouse models reveals differences 
in forward and backsignaling. (A) (left) Western blot analysis of hippocampal protein 
lysates of WT, conditional Stop-Nrg1*NEX-Cre and global HA-Nrg1-tg and HA-Nrg1
GIEF
 mice 
reveals drastic differences in HA-CRD-NRG1 and HA-NRG1
GIEF
 expression levels that 
correlates with ErbB4 receptor hyperphosphorylation levels, in line with our working 
hypothesis (right). ErbB4 total protein is reduced in all NRG1 transgenic mouse models. (B) 
(left) Western blot analysis of hippocampal protein lysates (as in A) shows increased MAPK 
and AKT phosphorylation in HA-Nrg1
GIEF
 mice, but not in full length HA-CRD-NRG1 
transgenic models, suggesting that the processed N-terminal fragment of CRD-NRG1 
(containing the EGF-like domain) is the active part in canonical forward signaling. (Center) 
Illustration demonstration HA-NRG1
GIEF
-mediated canonical forward signaling. (right) In line 
with this hypothesis, the HA-NRG1
GIEF
 fragment was found in axonal structures in HA-
Nrg1
GIEF
 mice (Velanac et al., 2011). (C) (left) Western blot analysis of hippocampal protein 
lysates (as in A,B) reveals reduced LIMK1 phosphorylation in Stop-Nrg1*NEX-Cre mice, but 
not in ‘global’ models. LIMK1
-/-
 brain lysates were used to verify LIMK1 antibody reactivity. 
Cofilin phosphorylation is increased in all HA-NRG1 transgenic models. Total LIMK1 and 
cofilin protein levels are unaltered in HA-NRG1 transgenic models. (Center) LIMK1 is thought 




dendritic spine dynamics by regulating the actin depolymerization activity of cofilin. However, 
backsignaling-deficient HA-Nrg1
GIEF
 mice also show increased cofilin phosphorylation. (right) 
Fluorescent immunostaining for HA-NRG1 on a coronal paraffin section (bregma -1.7) of a 
Stop-Nrg1*NEX-Cre mouse shows accumulation of HA-CRD-NRG1 in the somatodendritic 
compartment and apical dendrites (arrow heads). -actin was used as a loading control in all 
western blot experiments. FL, full length; kDa, kilodalton; IN, interneuron; N-Term, Nrg1 N-
terminal fragment. 
3.16 HA-NRG1 is enriched in synaptosomes of Stop-Nrg1*NEX-Cre mice 
and regulates cofilin phosphorylation 
Chronically high levels of NRG1/ErbB4 hyperstimulation in Thy1.2-driven NRG1 
transgenic mouse models could trigger unphysiological side effects and activate 
compensatory mechanisms that shut down signaling cascades. To specifically 
examine synaptic signaling functions of NRG1 that could underlay pathomechanisms 
of NRG1/ErbB4 hyperstimulation, crude synaptosomal fractions were prepared from 
Stop-Nrg1*NEX-Cre mice at 4 months of age and tested for changes in the 
LIMK1/cofilin pathway. 
A synaptosomal purification method was adapted (Biesemann et al., 2014), which 
included homogenization of fresh tissue in 0.32 M sucrose buffer, followed by 
differential centrifugation and sucrose gradient ultracentrifugation to extract a crude 
synaptosomal fraction with intact resealed synaptic terminals (Fig. 32A, see Methods 
for details). Purification steps for the preparation of crude synaptic membranes were 
skipped. Instead, gradient purified synaptosomes were used (Biesemann et al., 
2014). An additional centrifugation step was applied to wash and pellet 
synaptosomes out of solution, to concentrate the solution, and redissolve in 0.32 M 
homogenization buffer. To confirm the purification of synaptosomes, samples from 
purification steps were tested by western blotting for synaptic (synaptophysin, 
VGluT1) and glial markers (GLT-1, MBP) (Fig. 32B). 
Synaptosomal preparations of Stop-Nrg1*NEX-Cre mice and controls were tested for 
enrichment of HA-NRG1 by western blotting using an anti-HA antibody. As expected, 
HA-NRG1 was present in synaptosomes of Stop-Nrg1*NEX-Cre mice but not in 
controls. Both full length and processed HA-NRG1 was detected in synaptosomes 
(Fig. 32C). Preliminary analyses failed to detect phosphorylated ErbB4 receptors 
(Tyr1284) and LIMK1 (Thr508) in the synaptosomal fraction of transgenic mice or 
controls (data not shown). In contrast, phosphorylated cofilin (Ser3) was present in 
synaptosomes and clearly reduced in Stop-Nrg1*NEX-Cre mice, in contrast to total 
protein lysates from hippocampus (see Fig. 31C). This indicates differences in the 
subcellular targeting of phosphorylated cofilin to synapses under conditions of 






Fig. 32: HA-NRG1 is enriched in synaptosomes of Stop-Nrg1*NEX-Cre
 
mice and 
regulates cofilin phosphorylation. (A) Schematic illustration of synaptosomal preparation 
as described in the methods section 6.4.3. (B) Western blot analysis of fractions of the 
synaptosomal preparation reveals concentration of synaptosomes, indicated by 
synaptophysin and VGluT1 immunoreactivity, and reduction of myelin (myelin basic protein, 
MBP) contamination in final synaptosomes (Syn). Glial glutamate transporter (GLT)-1 is also 
enriched in synaptosomal fractions, in line with the tripartite synapse theory. GAPDH was 
used as a loading control. (C) Western blot analysis of synaptosomal preparations reveals 
enrichment of full length and N-terminal fragment (NTF) of HA-CRD-NRG1 in synaptosomes 
of Stop-Nrg1*NEX-Cre
 
mice. -actin was used as a loading control. (D) Western blot analysis 
of synaptosomes reveals HA-NRG1 enrichment and reduction of cofilin phosphorylation in 
Stop-Nrg1*NEX-Cre
 
mice compared to WT controls. -actin was used as a loading control. 





Human NRG1 and ErbB4 genes are possible genetic risk factors for schizophrenia 
(SZ) (Stefansson et al., 2002; Nicodemus et al., 2006; Silberberg et al., 2006; Law et 
al., 2007). NRG1/ErbB4 signaling regulates multiple aspects of nervous system 
development, including myelination, interneuronal migration and synaptic plasticity 
(Mei and Xiong, 2008). Most NRG1 at-risk haplotypes are located in the non-coding 
region of the gene (Stefansson et al., 2002; Weickert et al., 2012), suggesting that 
rather than disturbed protein function, altered NRG1 expression could underlay a 
pathomechanism with relevance for SZ. Indeed both increased and decreased NRG1 
expression has been observed in postmortem brain of SZ patients (Law et al., 2006; 
Bertram et al., 2007). The icelandic haplotype (HapICE) has been associated with 
increased expression of NRG1 type III (CRD-NRG1), the most abundant NRG1 
isoform in the human brain (Liu et al., 2011), and was correlated with an earlier onset 
of the disease (Weickert et al., 2012). However, the contribution of NRG1/ErbB4 
signaling to disease pathology and the precise pathomechanisms underlying SZ 
remain elusive. Together, these findings suggest a working hypothesis according to 
which NRG1/ErbB4 hyperstimulation causes neuronal network dysfunctions with 
relevance for SZ. 
The aim of this study was to address this working hypothesis by analyzing different 
loss- and gain-of-function mouse models of NRG1, with a special focus on 
interneuron development and behavioral functions. In addition, a novel conditional 
transgenic mouse line was employed, which allowed Cre-dependent stage- and cell 
type-specific activation of HA epitope-tagged CRD-NRG1. This mouse line was used 
to investigate the role of NRG1 in early embryonic versus postnatal development, 
and to model acute changes of NRG1/ErbB4 signaling in the adult brain. Histological, 
biochemical and behavioral experiments were performed to identify and compare the 
functional involvement of stage-specific NRG1 overexpression in the generation of 
schizophrenia-relevant phenotypes. Data derived from this Ph.D. project have 
recently been published in the journal Cell Reports (Agarwal et al., 2014). 
 
4.1 Embryonic NRG1 signaling is dispensable for interneuron migration 
Reduced numbers of GABAergic interneurons have been reported in the post 
mortem brain of SZ patients (Benes et al., 1991; Chance et al., 2005; Holt et al., 
2005; Levitt, 2005; Lewis et al., 2005; Heckers and Konradi, 2014), and the ErbB4 




reduction of GABAergic interneurons in the cortex (Neddens and Buonanno, 2009). 
This suggests that NRG1 (via signaling to ErbB4) serves a role in interneuron 
development and migration, and that diminished NRG1 signaling could contribute to 
inhibitory network dysfunctions in SZ. This hypothesis was tested by breeding 
conditional NRG1 knockout mice (Li et al., 2002) to Emx1-Cre driver mice (Gorski et 
al., 2002), which eliminate NRG1 from glutamatergic neurons, astrocyes and 
oligodendrocytes, but not interneurons, beginning at E10. Unexpectedly, these 
NRG1 mutants survived into adulthood and showed no difference in the number or 
cortical position of GAD67+ interneurons. Moreover, inhibitory neurotransmission in 
the adult hippocampus was increased, not diminished, in the absence of NRG1 
(Agarwal et al., 2014), in contrast to findings in ErbB4 mutants (Fazzari et al., 2010). 
Thus, NRG1 expression in the embryonic cortex is dispensable for the development 
and migration of GABAergic interneurons, but is required for the fine-tuning of 
excitatory and inhibitory (E/I) neurotransmission. The discrepancy to findings in 
ErbB4 mutants suggests compensatory functions by other ErbB4 ligands, such as 
NRG2 (Carraway et al., 1997) or NRG3 (Zhang et al., 1997) during the regulation of 
inhibitory circuits. This idea is supported by the absence of obvious brain 
abnormalities in NRG2 null mutants (Britto et al., 2004) and could be genetically 
addressed in compound mutants of NRG family members.  
 
4.2 CRD-NRG1 overexpression hyperstimulates ErbB4 receptors and 
alters inhibitory neurotransmission 
Elevated expression of CRD-NRG1 has been reported in a postmortem cohort of SZ 
patients carrying the HapICE haplotype (Weickert et al., 2012), associated with SZ 
(Stefansson et al. in 2002). To model chronically elevated CRD-NRG1 expression, 
Thy1.2 promoter-driven NRG1 transgenic mice (Nrg1-tg; Michailov et al., 2004) were 
examined, which express CRD-NRG1 in neurons of the neocortex and hippocampus, 
but also in subcortical regions and the PNS (Agarwal et al., 2014). ErbB4 
hyperphosphorylation has been observed in postmortem brain of SZ patients (Hahn 
et al., 2006). In line with this, we found sustained ErbB4 hyperphosphorylation at 
Tyr1284 in hippocampal protein lysates of CRD-NRG1 transgenic mice, making 
CRD-NRG1 transgenic mice a suitable tool to study the consequences of 
NRG1/ErbB4 hyperstimulation in vivo. 
CRD-NRG1 has been reported to serve as a permissive guidance signal for the 




However, total numbers of GAD67+ and PV+ interneurons were unaltered in the 
cortex and hippocampus of Nrg1-tg mice at P14, but when numbers of GAD67+ 
interneurons were assessed based on their position within cortical layers, a 
significant reduction in layer IV of Nrg1-tg mice was observed. Cortical layer IV (or 
internal granular layer of the cortex) receives its main input from thalamocortical and 
intra-hemispheric corticocortical afferents (Jones, 1998). Tangential migration of 
cortical interneurons and the outgrowth of thalamocortical axons functionally interact 
in the ventral telencephalon and are co-regulated by NRG1 signaling (López-Bendito 
et al., 2006). Thus, abnormal NRG1 signaling in the subcortical regions could alter 
thalamocortical axon pathfinding, thereby preferentially affecting interneuron 
migration into layer IV. Distinct from findings in postnatal brains, in vivo imaging of 
PV+ interneurons in adult Nrg1-tg*PV-GFP mice by 2P-LSM revealed a reduction of 
PV (GFP+) interneurons in layer II/III and V of the cortex. A similar reduction of PV 
(GFP+) interneurons was observed in a second mouse line (HA-Nrg1-tg*PV-GFP), 
strongly supporting the absence of transgene integration-associated effects. Taken 
together, overexpression of CRD-NRG1 impairs the normal intergration and/or 
maintenance of PV+ interneurons in the neocortex. However, in the absence of 
obvious neuroinflammation and -pathology (Brinkmann et al., 2008; Velanac et al., 
2011; Agarwal et al., 2014), it is currently unclear if the reduction of PV (GFP+) 
interneurons is due to reduced cell numbers, e.g. following apoptotic cell death, or 
changes in the expression of the PV promoter, as GFP expression was used for 
quantification. To address these questions and to establish a possible link between 
postnatal and adult findings, further studies, including immunostaining and 2P-LSM 
at different time points are required. 
Altered neurotransmission could contribute to dysregulation of calcium-binding 
proteins, such as PV, or a reduction in the expression of GAD67 (Akbarian et al., 
1995; Hashimoto et al., 2003; Ongür et al., 2010). This idea is supported by 
electrophysiological recordings of pyramidal neurons in Nrg1-tg mice, which showed 
disrupted plasticity (STP and LTP) at the Schaffer collateral-CA1 synapse and a shift 
of the excitatory/inhibitory (E/I) balance towards enhanced inhibition. This effect 
could be due to increased number of synaptic inputs from GABAergic interneurons or 
increased GABA release from inhibitory presynapses (Agarwal et al., 2014). These 
data suggest stage-specific deficits in GABAergic interneuron intergration and 
maintenance, and an imbalance of the E/I ratio. Impaired interneuron functions in 
cortical layers II/III and V could influence cortical connectivity and output to 





4.3 CRD-NRG1 transgenic mice show SZ-relevant behavioral 
dysfunctions 
CRD-NRG1 overexpression in the PNS severely compromises the neuromuscular 
junction in Nrg1-tg mice (W.J. Thompson, personal communication), which prevents 
behavioral analysis. Therefore, we examined instead a mouse line (HA-Nrg1-tg) in 
which HA epitope-tagged CRD-NRG1 is expressed under control of the same Thy1.2 
cassette as in Nrg1-tg mice. HA-Nrg1-tg mice displayed pronounced anxiety-like 
behavior in the open field test, indicating that NRG1 overexpression might change 
circuits involved in emotional states. In line with this assumption, increased CRD-
NRG1 expression was observed in the amygdala of HA-Nrg1-tg mice. Moreover, 
broad expression of ErbB4 receptors was reported in PV-negative cells of the 
amygdala, and ErbB4-/- mice, but not conditional PV-ErbB4-/- mice exhibit reduced 
anxiety (Shamir et al., 2012). The anxiogenic effect seems to be isoform-specific, as 
Ig-NRG1 transgenic mice show no increase in anxiety-like behavior in the open field 
test (Deakin et al., 2009). Prepulse inhibition (PPI) is an operational measure of 
sensorimotor gating and PPI deficits are frequently observed in neuropsychiatric 
disorders (Kohl et al., 2013), possibly reflecting abnormalities in frontal-cortical-
striatal circuitry (Swerdlow and Geyer, 1998; Young et al., 2010). When analyzed in 
the PPI test, HA-Nrg1-tg mice exhibited an increased startle response and reduced 
PPI. Reduced PPI was also observed in Ig-Nrg1 transgenic mice (Deakin et al., 
2009; Yin et al., 2013), indicating that Ig-NRG1 and CRD-NRG1 may serve similar 
roles in the regulation of PPI circuitry. Deficits in PPI (which were absent in 
conditional NRG1 mutants) are a hallmark for schizophrenia, further supporting the 
hypothesis that NRG1/ErbB4 hyperstimulation contributes to SZ pathology. 
Taken together, histological, physiological, and behavioral studies in NRG1 mutants 
and transgenic mice suggest that an “optimal” level of NRG1 signaling is required for 
efficient synaptic neurotransmission and possibly  higher brain functions, thereby 
extending an ‚inverted U-shaped’ model (Role and Talmage, 2007) to a ‚bell-shaped’ 
model (Agarwal et al., 2014). In addition, these data imply that human NRG1 at-risk 
polymorphisms exert a gain-of-function effect. 
 
4.4 Conditional overexpression of CRD-NRG1 in transgenic mice 
The NRG1 gene encodes at least 30 different isoforms. NRG1 isoforms are 




developing and adult nervous system (Liu et al., 2011). Results obtained in Thy1.2 
promoter-driven NRG1 transgenic mice suggest that hyperstimulated NRG1/ErbB4 
signaling, rather than NRG1 hypofunction, could contribute to SZ pathology. SZ is 
believed to be a neurodevelopmental disorder (Harrison, 1999), but it is not clear 
how altered NRG1/ErbB4 signaling could increase susceptibility for SZ. To address 
the complexity of endogenous NRG1 signaling, a novel transgenic mouse line was 
generated, which allows conditional CRD-NRG1 overexpression based on the Cre-
loxP system. The transgene cassette (Stop-Nrg1) contained a fragment of the 
chicken -actin promoter, driving expression of CRD-NRG1 after Cre-mediated 
removal of a ‚floxed’ Stop-cassette encoding GFP. Virtually all tissues expressed 
GFP, including brain, spinal cord, muscles and heart. Thus, Stop-Nrg1 mice could 
serve as a genetic tool to study NRG1 functions also outside the nervous system, 
e.g. during heart development, or in Hirschsprung disease (HSCR), a congenital 
disorder of the gastrointestinal tract, characterized by the absence of intramural 
ganglion cells, for which increased NRG1 expression has been reported (Garcia-
Barcelo et al., 2009; Tang et al., 2011, 2012a, 2012b; Luzón-Toro et al., 2012; 
Phusantisampan et al., 2012; Gui et al., 2013). 
Fluorescent immunostainings for cell type-specific markers revealed that not all 
neural cell types in the brain expressed the Stop-Nrg1 transgene (based on GFP 
expression). The GFP cassette was predominantly expressed in pyramidal neurons 
and oligodendrocytes, but only by few interneurons, micro- and astroglia, similar to 
findings by others (M. Rossner, personal communication). Thus, the chicken -actin 
promoter fragment is not well suited for expression in interneurons, which prevented 
studies on NRG1 autocrine signaling in ErbB4+ interneurons. The main glial cell type 
expressing the transgene were oligodendrocytes (80-90 % GFP+), whereas only 
40-50 % of microglia and astrocytes were GFP+. Taken together, the chicken -
actin promoter fragment used for the generation of Stop-Nrg1 mice appears not to be 
suitable for studies in interneurons, astrocytes and microglia. A possible alternative 
approach would be to target the Rosa26 locus using homologous recombination, as 
in the case of the R26R-floxtdTomato reporter mouse line (Madisen et al., 2010). 
 
4.5 Modeling stage-specific CRD-NRG1 overexpression in cortical 
projection neurons 
Endogenous CRD-NRG1 is predominantly expressed by glutamatergic projection 




cortical projection neuron-restricted overexpression of HA-NRG1 beginning at 
embryonic stages (E12), Stop-Nrg1 mice were bred to NEX-Cre driver mice 
(Goebbels et al., 2006). Fluorescent immunostaining confirmed projection neuron-
restricted HA-NRG1 expression, starting at early embryonic stages. Immunostaining 
for the N- (HA-tag) and C-terminus of HA-NRG1 showed overlapping signals, which 
accumulated inside and on the surface of the somatodendritic compartment and 
apical dendrites of projection neurons, indicating either trafficking of full length HA-
NRG1 or coordinated transport of the cleaved N- and C-terminus fragments to these 
subcellular domains. To which extend HA-NRG1 (or cleaved fragments) are 
transported to presynaptic sites is under current investigation, but preliminary results 
support limited axonal and presynaptic transport, similar to findings in the PNS 
(Velanac et al., 2011). Biochemical analysis by western blotting of hippocampal 
protein lysates from Stop-Nrg1*NEX-Cre mice confirmed expression of full length 
and proteolytically processed HA-NRG1, as two protein bands (140 kDa, 60 kDa) 
were detected, albeit at lower levels compared to Thy1.2 promoter-driven mouse 
lines. In line with our working hypothesis, conditional overexpression of HA-NRG1 
lead to increased steady state levels of ErbB4 phosphorylation. 
In a complementary approach CamKII-Cre driver mice (Minichiello et al., 1999) were 
used to direct HA-NRG1 overexpression to cortical projection neurons starting at 
postnatal stages (P5). This approach aimed at modeling a postnatal onset of 
hyperstimulated NRG1/ErbB4 signaling, according to the late neurodevelopmental 
onset hypothesis of SZ (Harrison, 1999). Similar to the NEX-Cre model, HA-NRG1 
expression was restricted to projection neurons of the cortex and hippocampus. 
However, Stop-Nrg1*CKII-Cre mice displayed additional recombination in subcortical 
regions, e.g. striatum, thalamus, and hypothalamus. Western blot analysis confirmed 
expression of full length and processed HA-NRG1 and ErbB4 hyperphosphorylation. 
Taken together, Stop-Nrg1 transgenic mice in combination with different Cre-driver 
lines allow stage- and cell type-specific CRD-NRG1 overexpression and ErbB4 
hyperstimulation. 
 
4.6 Embryonic and postnatal HA-NRG1 overexpression is not associated 
with neuropathology or –inflammation at adult stages 
NRG1 is a growth and differentiation factor involved in many neurodevelopmental 
processes, including neuronal migration and myelination, but has also been 




Transgenic overexpression of a growth factors could have pathological and 
neurotoxic effects. Stop-Nrg1 mice also permanently express GFP in most cells of 
their body, and GFP expression was shown to trigger pronounced hypomyelination 
and axonal pathology in transgenic mice, which express GFP under control of the 
CNP promoter (Millet et al., 2012). To identify possible signs of neuroinflammation or 
-degeneration, an immunohistochemical analysis was performed, which included a 
quantification of interneuron numbers in embryonic (Stop-Nrg1*NEX-Cre) and 
postnatal (Stop-Nrg1*CKII-Cre) models at four months and one year of age. 
Postnatal onset of HA-NRG1 overexpression in Stop-Nrg1*CKII-Cre mice had no 
effect on GAD67+ and PV+ interneuron numbers. 
When cell numbers were quantified in Stop-Nrg1*NEX-Cre mice, a tendency for 
reduced cell numbers was counted in Stop-Nrg1*NEX-Cre but also in NEX-Cre mice. 
In addition, a modestly increased cortical width was observed in both Stop-
Nrg1*NEX-Cre and NEX-Cre mice. Together, increased cortical width and slightly 
reduced cell numbers resulted in significantly reduced cell densities in Stop-
Nrg1*NEX-Cre and NEX-Cre mice. Thus, effects on interneuron numbers were not 
derived from CRD-NRG1 overexpression.  
Furthermore, a mildly increased area of IBA1+ microglia was noticed in the 
hippocampus of NEX-Cre mice at 1 year of age, suggesting microglial activation. 
This effect was significant when compared to the other genotypes, except for Stop-
Nrg1*NEX-Cre mice, which themselves were not significantly different from other 
controls, indicating that HA-NRG1 overexpression was even beneficial and may 
counteract microglia activation. Since microglia activation was not detected in CKII-
Cre mice, changes in IBA1+ microglia were not simply the result of Cre expression. It 
is currently unclear if the loss of one functional gene copy in NEX-Cre mice, which 
causes NEX haploinsufficiency, could effect cortical size, e.g. by reducing tissue 
stability during the processing of brain sections. Impaired neuronal development was 
not reported for the NEX null mutation (Schwab et al., 1998; Goebbels et al., 2006), 
however aged heterozygous and homozygous NEX-Cre mutants will be studied in 
more detail, as this is a widely used Cre driver line. 
These histological studies demonstrate absence of neurotoxic, inflammatory or 
mitogenic effects resulting from conditional CRD-NRG1 overexpression or 
permanent expression of GFP in conditional transgenic mice. This is consistent with 
findings in Thy1.2 promoter-based transgenic mice with much higher NRG1 
expression, which also lack signs of neuroinflammation or –degeneration. Different 




changes in the number or location of cortical interneurons in Stop-Nrg1*NEX-Cre or 
Stop-Nrg1*CKII-Cre mice, consistent with the finding that subcortical NRG1 
expression domains play an important role in mediating interneuron migration 
(Flames et al., 2004).  
In stark contrast to cortical neurons, overexpression of different NRG1 variants, 
including CRD-NRG1, in Schwann cells of the PNS causes severe Schwann cell 
hyperplasia (Huijbregts et al., 2003; R. Stassart, personal communication), possibly 
as a result of autocrine signaling to glial ErbB2/ErbB3 receptors. A comparable 
experiment of CRD-NRG1 overexpression in interneurons (with prominent ErbB4) is 
currently not possible due to limited expression of the conditional transgene in 
interneurons. 
 
4.7 Thy1.2-driven CRD-NRG1 mice have enlarged ventricles and reduced 
body weight 
Enlarged ventricles are the most replicated endophenotype in SZ (Harrison, 1999) 
and variants of the NRG1 gene have been associated with increased lateral ventricle 
volume (Mata et al., 2009). Alterations in ventricular sizes were observed in loss- and 
gain-of-function mouse models by MRI imaging, with Emx-Cre*Nrg1f/f mice having 
reduced, and Nrg1-tg mice enlarged lateral ventricles (Agarwal et al., 2014). 
Interestingly, ventricular enlargment seems to result from isoform-specific functions, 
as Ig-Nrg1 transgenic mice have normal ventricular sizes (P. Harrison, personal 
communication). A comparative histological examination of ventricular sizes in all 
available CRD-NRG1 transgenic mouse lines revealed enlarged lateral ventricles in 
HA-Nrg1-tg mice, similar to Nrg1-tg mice (Agarwal et al., 2014). Interestingly, HA-
Nrg1GIEF mice and conditional transgenic mice (Stop-Nrg1*NEX-Cre and Stop-
Nrg1*CKII-Cre mice) had normal lateral ventricles. This suggests that the 
backsignaling-deficient HA-Nrg1GIEF is not capable to trigger ventricular enlargement, 
even though it is expressed at even higher levels than full length HA-NRG1 in HA-
Nrg1-tg mice. The finding that cortical-restricted HA-NRG1 overexpression had no 
effect on ventricular sizes, indicates that subcortical CRD-NRG1 overexpression is 
required to induce ventricular enlargement. The general overexpression level in 
conditional mice is lower than in Thy1.2-driven mice, however Stop-Nrg1*CKII-Cre 
mice, which show expression in striatal and thalamic regions, are not significantly 
different from HA-Nrg1-tg mice. Overexpression of CRD-NRG1 in cells of the choroid 




choroid plexus in conditional Stop-Nrg1*NEX-Cre and Stop-Nrg1*CKII-Cre mice, 
however HA-Nrg1-tg mice show positive signals in chromogenic immunostaining for 
the HA tag in the choroid plexus, and expression of the Thy1.2 promoter in the 
choroid plexus has been reported (Campsall et al., 2002). In addition, ErbB4 
expression has also been shown for large cells in the choroid plexus (Bean et al., 
2014). If CRD-NRG1 overexpression in the choroid plexus plays a role in regulating 
ventricular sizes requires further investigations. Taken together, subcortical or 
choroid plexus overexpression of NRG1 (via currently undefined signaling pathways) 
could lead to ventricular enlargement in Nrg1-tg and HA-Nrg1-tg mice. 
Since Nrg1-tg mice appeared to have reduced body weight, a comparative analysis 
of body weight was performed for all CRD-NRG1 mouse lines. Reduced body weight 
was observed in Nrg1-tg, HA-Nrg1-tg and Stop-Nrg1*CKII-Cre mice. However, Stop-
Nrg1*CKII-Cre mice were only significantly different from Stop-Nrg1*NEX-Cre mice, 
which showed normal body weight compared to controls. Again, subcortical 
overexpression of CRD-NRG1 seems to affect body weight. The mechanisms 
underlying these weight reductions could involve NRG1-mediated effects on leptin 
levels, as injection of the recombinant EGF-like domain of NRG1 was shown to affect 
leptin levels, food intake and body weight in normal-weight mice (Ennequin et al., 
2015). ErbB4 expression was found in the hypothalamus and the Raphe Nuclei 
(Bean et al., 2014), and reduced preweaning bodyweight has been reported in 
conditional Nestin-Cre*ErbB4null mice (Golub et al., 2004). The Raphe Nuclei regulate 
food intake, memory retention and anxiety (Carlini et al., 2004). Thus, Raphe Nuclei 
could be an important target for the regulation of body weight or the generation of 
anxiety-like behavior observed in HA-Nrg1-tg mice. The hypothalamus is also known 
to control metabolism, thermoregulation, and stress response. Expression of ErbB4 
in GAD67+ interneurons has been reported in the hypothalamus (Bean et al., 2014), 
and could serve as a link between altered body weight and stress levels in HA-Nrg1-
tg mice. However, whether hyperstimulated NRG1/ErbB4 signaling ultimately alters 
food intake in transgenic mice needs further evaluation. 
 
4.8 Embryonic HA-NRG1 overexpression induces hyperactivity, but no 
anxiety-like behavior or PPI deficits 
‘Global’ CRD-NRG1 overexpression in HA-Nrg1-tg mice lead to pronounced anxiety-
like behavior and impaired PPI (Agarwal et al., 2014), as well as working memory 




the temporal and spatial aspects of NRG1 overexpression on behavior, Stop-
Nrg1*NEX-Cre and Stop-Nrg1*CKII-Cre mice were analyzed in the same set of 
behavior tests.  
Unexpectedly, no signs of anxiety-like behavior were found in both conditional 
models. Instead, both lines showed hyperactivity, which is thought to correspond to 
psychomotor agitation in schizophrenic patients and is considered a schizophrenia-
relevant behavior (Snyder, 1973; Yin et al., 2013a). Hyperactivity was found in the 
open field and the hole board test and was more pronounced in Stop-Nrg1*NEX-Cre 
mice. In the hole board test hyperactivity even seemed to prevent mice from 
exploring the new environment, as they showed tendencies to reduced exploration 
time and hole visits. Also in the tail suspension test Stop-Nrg1*NEX-Cre mice fought 
more against the aversive situation, in line with hyperactivity. Stop-Nrg1*NEX-Cre 
mice showed the strongest hyperactivity always at the beginning of a test, arguing for 
novelty-induced hyperactivity. In line with these findings, hypoactivity was observed 
in conditional CKII-Cre*Nrg1f/f (Agarwal et al., 2014) and Nestin-Cre*ErbB4null 
mutants (Golub et al., 2004). Hyperactivity was also described in conditional 
transgenic mice with modest Ig-NRG1 overexpression in the cortex (Yin et al., 
2013a), interestingly, these mice also show no anxiety-like behavior. However, 
transgenic mice with Thy1.2-driven strong cortical and subcortical Ig-NRG1 
overexpression show normal motor behavior with initial hypoactivity (Deakin et al., 
2009). These contrasting findings in transgenic mice expressing the same NRG1 
isoform. Indicate that differences in expression levels (and thereby ErbB4 
stimulation) or cortical versus subcortical functions play an important role in NRG1-
mediated regulation of motor behavior. NRG1 expression level differences might 
differentially regulate serotonine and/or dopamine signaling in the striatum and basal 
ganglia, including the Nucleus accumbens, thought to be involved in regulation 
hyperlocomotion (Taepavarapruk et al., 2000; Bishop and Walker, 2003; Brus et al., 
2004; Fadda et al., 2005). Interestingly, these circuits might also be involved in the 
regulation of anxiety levels in these mice (Scott et al., 2006; Jiang et al., 2015). 
No PPI impairments were observed in Stop-Nrg1*NEX-Cre and Stop-Nrg1*CKII-Cre 
mice, in contrast to HA-Nrg1-tg mice (Agarwal et al., 2014). In addition to unaltered 
PPI, both lines exhibited normal startle responses. Absence of PPI impairments 
could be related to lower cortical overexpression of HA-NRG1 in both lines compared 
to HA-Nrg1-tg mice, which is associated with a lower level of ErbB4 
hyperphosphorylation. This idea is supported by the finding that administration of 
spironolactone ameliorates the PPI deficits in HA-Nrg1-tg mice. Spironolactone is a 




phosphorylation in the brain of HA-Nrg1-tg mice (Wehr et al., in preparation). In 
addition, absence of HA-NRG1 overexpression from subcortical regions in 
conditional mouse lines, notably the striatal, could explain normal PPI as striatal 
projections have been considered important for the generation of PPI (Baldan 
Ramsey et al., 2011). PPI deficits appear not to be NRG1 isoform-specific as both 
Thy1.2 promoter-driven (Deakin et al., 2009) and conditional transgenic mice with Ig-
Nrg1 overexpression exhibit impaired PPI (Yin et al., 2013). Finally, in line with a bell-
shaped model of NRG1-mediated regulation of sensorimotor gating, PPI deficits also 
occur in heterozygous CRD-NRG1 mutants (Chen et al., 2008). Stop-Nrg1*NEX-Cre 
and Stop-Nrg1*CKII-Cre mice also showed no deficits in working memory, as 
measured in the Y-maze test. This is in contrasts to reduced performance of HA-
Nrg1-tg mice in this test. Similar to PPI, administation of spironolactone to HA-Nrg1-
tg mice ameliorates this deficit (Wehr et al., in preparation), suggesting that the level 
of NRG1/ErbB4 hyperstimulation is critical for the magnitude of working memory 
deficits. 
Finally, deficits were observed in cued fear memory in Stop-Nrg1*NEX-Cre mice. A 
tendency to reduced contextual fear memory was also observed. Impaired contextual 
and cued fear conditioning was also found in CKII-Cre*Nrg1f/f mice (Agarwal et al., 
2014), again supporting a bell-shaped model of NRG1 functions in hippocampal 
learning. However, considering the hyperactivity observed in Stop-Nrg1*NEX-Cre 
mice, deficits in fear conditioning could be independent from hippocampal learning 
deficits, but simply linked to hyperactivity-mediated reduction in freezing behavior. 
In contrast to HA-Nrg1-tg mice (Wehr et al., in preparation), Stop-Nrg1*NEX-Cre and 
Stop-Nrg1*CKII-Cre mice showed normal pain sensitivity in the hotplate test, arguing 
for effects of Thy1.2 promoter-driven expression of HA-Nrg1 in the PNS. 
Similar to Stop-Nrg1*NEX-Cre mice, Stop-Nrg1*CKII-Cre mice displayed a tendency 
for hyperactivity in the open field and hole board test, but performance in all other 
tests was unaltered. Thus, postnatal overexpression of HA-NRG1 exerts only minor 
effects on mouse behavior. However, as the Stop-Nrg1*CKII-Cre sample was small 
(n=7 Stop-Nrg1*CKII-Cre mice), this experiment can only be considered as a pilot 






4.9 Stop-Nrg1*NEX-CreERT2 mice allow acute NRG1 overexpression in 
the adult brain 
Acute stimulation of NRG1/ErbB4 signaling may provide a better insight into 
‘physiological’ functions of NRG1 in the brain. To model acute stimulation of 
NRG1/ErbB4 signaling in the brain, NEX-CreERT2 driver mice were used, which 
allow tamoxifen-induced activation of Cre recombinase in cortical projection neurons 
(Agarwal et al., 2011). 
Tamoxifen injection (for 10 days at 100 mg/kg bodyweight, defined as the maximum 
recombination treatment) of Stop-Nrg1*NEX-CreERT2 mice and harvest of protein 
samples one month later resulted in approximately half of the HA-NRG1 expression 
observed in Stop-Nrg1*NEX-Cre mice. Reduced HA-NRG1 expression in Stop-
Nrg1*NEX-CreERT2 mice could be due to incomplete recombination in projection 
neurons and absent Cre activity in adult dentate gyrus granule cells (Agarwal et al., 
2011). In contrast to HA-Nrg1-tg and Stop-Nrg1*NEX-Cre mice, when Stop-
Nrg1*NEX-CreERT2 mice were tamoxifen injected for maximum recombination for 5 
days, and tissue was collected the day after the last injection, MAPK signaling 
(based on increased Erk1/2 phosphorylation) was induced. This is the first example 
for NRG1-mediated activation of a signaling pathway in a transgenic mouse model. 
Under conditions of chronic overexpression in HA-Nrg1-tg and Stop-Nrg1*NEX-Cre 
mice, feedback mechanisms seem to effectively downregulated activation of this 
signaling pathway. Subsequently, increased Erk1/2 phosphorylation was also found 
in HA-Nrg1GIEF mice, in line with the hypothesis that BACE1 processing activates 
NRG1, such that NRG1-mediated Erk1/2 activation overrides negative feedback 
mechanisms, even under chronic conditions. In summary, Stop-Nrg1*NEX-CreERT2 
mice open up a way to analyze acute NRG1/ErbB4 signaling in the adult brain and 
therefore could be used as a model to test late onset hyperstimulation of this 
signaling module in the development of SZ. A comparable approach of acute 
activation of Ig-NRG1 signaling has recently shown the development and regression 
of SZ-relevant phenotypes upon activation or inactivation of Ig-Nrg1 overexpression 
(Yin et al., 2013a). 
Using sensitive R26R-floxtdTomato Cre reporter mice, parameters were established 
for the production of small numbers of recombined cortical neurons based on limited 
tamoxifen administration. This should have provided the basis for single-cell 
genetics. Unexpectedly, administration of low doses of tamoxifen to Stop-Nrg1*NEX-
CreERT2*tdTomato mice to examine individual tdTomato+/HA-NRG1+ projection 




same time. Similar observations were made in PLP-CreERT2 mice (A. Agarwal, 
personal communication), the reason for this, however, remains unclear. In addition, 
many tdTomato+ neurons in the hippocampus maintain GFP fluorescence, indicating 
insufficient concomitant recombination of the Stop-Nrg1 transgene. 
 
4.10 Possible roles of NRG1-mediated forward and backsignaling in 
cortical network dysfunction 
Several CRD-NRG1 transgenic mouse lines are available, which express different 
levels of CRD-NRG1 in the brain. Compared to Thy1.2-driven transgenic models, 
conditional Stop-Nrg1 mice show more physiological expression levels. Importantly, 
sustained ErbB4 hyperphosphorylation at Tyr1284 was detected in the cortex of all 
analyzed NRG1 transgenic mouse lines, and correlated with the level of NRG1 
overexpression over a wide range of expression levels. This shows that ErbB4 is not 
rate limiting for NRG1 signaling in the brain, consistent with findings in the PNS, 
where heterozygous NRG1 mutants, but not heterozygous ErbB2/ErbB3 mutants are 
hypomyelinated (Michailov et al., 2004). The finding of permanently increased 
steady-state levels of hyperphosphorylated ErbB4 in hippocampal protein lysates 
under conditions of chronic NRG1 overexpression also implies that mechanisms for 
the downregulation of ErbB receptor activity, e.g. dephosphorylation by 
phosphatases, including receptor phosphotyrosine phosphatase β (RPTPβ), or 
PTPN21, both of which have been associated with SZ (Buxbaum et al., 2008; Plani-
Lam et al., 2015), or receptor inactivation by proteolysis or internalization, are not 
sufficient to compensate for NRG1-mediated activation. In line with this, it was shown 
that ligand-mediated endocytosis of ErbB4 receptors via the clathrin pathway is slow 
compared to the EGF receptor, and that hippocampal interneurons predominantly 
express the TACE-mediated cleavage-resistant JMb ErbB4 receptor isoforms, and 
thus, maintain a high level of ErbB4 at the cell surface (Longart et al., 2007). 
However, we found reduced levels of total ErbB4 protein in hippocampus protein 
lysates of all analyzed NRG1 transgenic mouse lines. In line with this, it was shown 
that internalization of stimulated ErbB4 receptors is important and necessary for 
downstream signaling (Liu et al., 2007), and ErbB4 receptor levels can be regulated 
by ubiquitination by neuregulin receptor degradation protein-1 (Nrdp1), that was 
shown to suppress ErbB3 and ErbB4 receptor levels when coexpressed in COS7 
cells (Diamonti et al., 2002). 




a SHC1 adapter protein binding site, involved in MAPK signaling (Schulze et al., 
2005). Whether other tyrosine residues are also hyperphosphorylated, e.g. Tyr984 
(STAT5-binding) or Tyr1056 (PI3K-p85 binding) (Schulze et al., 2005; Kaushansky et 
al., 2008), remains to be analyzed in future studies and could reveal activation of 
additional signaling pathways. 
Previous histological studies in HA-Nrg1-tg and HA-Nrg1GIEF mice revealed 
differential subcellular localization of full length and BACE1-processed CRD-NRG1 
(HA-NRG1GIEF). While full length CRD-NRG1 was observed mainly in the somato-
dendritic compartment, HA-Nrg1GIEF was also found in distal dendritic processes and 
in axons (see also Velanac et al., 2011). Moreover, whereas full length CRD-NRG1 
can mediate forward and backsignaling, HA-NRG1GIEF lacks backsignaling activity. In 
combination with different subcellular localization, full length CRD-NRG1 and HA-
NRG1GIEF might exhibit different signaling properties. Based on these findings a 
comparative biochemical analysis of several NRG1 transgenic lines was performed 
to examine whether distinct CRD-NRG1 variants, associated with different levels of 
NRG1/ErbB4 hyperstimulation, recruit different signaling pathways. 
Western blot analysis of HA-Nrg1-tg, Stop-Nrg1*NEX-Cre and HA-Nrg1GIEF mice 
revealed that only in HA-Nrg1GIEF mice MAPK and PI3K signaling pathways were 
hyperactivated, supporting the hypothesis that BACE1 processing activates NRG1 
and is a limiting factor for NRG1 signaling in the brain. As aforementioned, in acute 
Stop-NRG1*NEX-CreERT2 mice that were collected directly the day after the last 
tamoxifen injection, activated MAPK signaling was also found, indicating that under 
acute stimulation of NRG1 signaling the activation of forward signaling by proteolytic 
cleavage might be different than under chronic conditions, and in addition, 
downregulation of signaling pathways via feedback mechanisms might be involved 
under chronic full length CRD-NRG1 overexpression conditions. To further address 
this hypothesis and to rule out signaling effects simply due to higher HA-NRGGIEF 
expression, homozygous HA-Nrg1-tg mice with very high HA-CRD-NRG1 expression 
could be produced and tested for activated MAPK and PI3K signaling. It is however 
interesting that HA-NRGGIEF induces these pathways even under chronic 
overexpression, which could also be due to the differential trafficking of the two 
variants. To which extend differential activation of these signaling pathways has 
further morphological or functional (physiological and behavioral) consequences in 
HA-NRGGIEF mice requires further investigations. Accordingly, examination of 
dendritic spines by STED microscopy and electrophysiological analysis of synaptic 
plasticity in the hippocampus of HA-Nrg1GIEF mice have been initiated. In summary, 




mediated forward signaling. 
In addition to canonical forward signaling, backsignaling mediated by the ICD of 
NRG1 was already described more than 10 years ago (Bao et al., 2003), however 
not much is known about its role in the regulation of cortical development. Similar to 
ErbB4, -secretase-mediated cleavage in the intramembrane region of NRG1 
releases the NRG1-ICD, which can translocate into the nucleus, where it has been 
implicated in the regulation of neuronal survival (Bao et al., 2003), oligodendroglial 
differentiation (Pirotte et al., 2010), and PSD95 expression in the mouse cochlea 
(Bao et al., 2004). In line with this, it was shown that a substitution at the 
intramembranous valine 321 to leucine, that was previously linked to SZ (Walss-Bass 
et al., 2006), disrupted intramembranous proteolytic cleavage by -secretase and 
abolished ICD signaling of CRD-NRG1, which resulted in defects of growth and 
branching of dendrites. This function was shown to be even independent of ErbB 
kinase activity (Chen et al., 2010). In addition, loss of the -secretase subunit Aph1B 
was shown to impair synaptic neurotransmission and plasticity, and dendritic spine 
development, and this effect was rescued by co-expression of NRG1-ICD in a cell-
autonomous fashion (Fazzari et al., 2014). In addition to the proposed transcription 
factor-like functions of the NRG1-ICD, a direct interaction of the NRG1-ICD with 
LIMK1 was reported in a yeast two-hybrid screen (Wang et al., 1998). LIMK1 is a 
major regulator of cytoskeleton remodeling (Arber et al., 1998; Yang et al., 1998) and 
spine dynamics (Meng et al., 2002, 2003; Sarmiere and Bamburg, 2002). 
Overexpression of Ig-Nrg1 in transgenic mice was shown to recruit LIMK1 into 
synaptosomes, to enhance cofilin phosphorylation, and to impair glutamatergic 
neurotransmission (Yin et al., 2013a). We found dysregulated expression of 
cytoskeleton remodeling proteins and abnormal spine growth in Thy1.2 promoter-
driven CRD-NRG1 mice (Agarwal et al., 2014). Together, this suggested a possible 
interaction of CRD-NRG1 backsignaling with LIMK1. Biochemical analysis showed a 
reduction in LIMK1 phosphorylation in hippocampal lysates of Stop-Nrg1*NEX-Cre 
mice, but not in HA-Nrg1-tg and HA-Nrg1GIEF mice. Levels of total LIMK1 protein 
were similar in all groups. In addition, increased levels of cofilin phosphorylation were 
observed in all of these transgenic mice. HA-Nrg1GIEF mice showed the strongest 
induction of cofilin phosphorylation, whereas HA-Nrg1-tg mice displayed only a 
modest increase. These results are currently difficult to interpret as the textbook 
knowledge claims that phosphorylation activates LIMK1, which leads to increased 
cofilin phosphorylation, thereby inhibiting cofilin and stabilizing filamentous actin 




LIMK1 phosphorylation in Stop-Nrg1*NEX-Cre mice is consistent with the idea that 
selective accumulation of full length CRD-NRG1 in the (postsynaptic) 
somatodendritic compartment may trigger abnormal backsignaling to LIMK1, thereby 
affecting its phosphorylation status. Importantly, western blot analysis of 
synaptosomal fractions showed a decrease of phosphorylated cofilin in Stop-
Nrg1*NEX-Cre mice compared to controls. This finding is in contrast to our 
observations in total hippocampal lysates, but indicates subcellular 
compartmentalization with regard to NRG1 regulated downstream signaling. Thus, 
upregulation of CRD-NRG1 under disease conditions may alter subcellular trafficking 
(and processing) of the full length protein, resulting in accumulation in the 
somatodendritic compartment and abnormal backsignaling. This could include local 
reduction in LIMK1 and cofilin phosphorylation. In line with this, it has been shown 
that other actin-binding proteins, including debrin, profiling II and N-catenin are 
recruited into dendritic spines upon synaptic activity. Accumulation of profilin II in 
dendritic spines for instance, was shown to persist for hours beyond initial 
stimulation, depends on postsynaptic Ca2+ levels, and stabilizes spine morphology in 
a mature state (Ackermann and Matus, 2003). To further address the potential 
subcellular differences in LIMK1 and cofilin localization, primary neuronal cell 
cultures of NRG1 transgenic mice will be used in future studies. 
Increased cofilin phosphorylation in backsignaling-deficient HA-Nrg1GIEF mice in the 
absence of altered LIMK1 phosphorylation strongly suggests that forward signaling in 
HA-Nrg1GIEF mice triggers mechanisms that ultimately regulate cofilin 
phosphorylation via distinct mechanisms, for instance inhibition of slingshot 
phosphatases (Niwa et al., 2002; Spratley et al., 2011; Mizuno, 2012). In addition, 
the Ras family GTPases and their downstream MAP kinase signaling pathways are 
known to also regulate dendritic spine morphology (Wu et al., 2001; Gärtner et al., 
2005), thus, in HA-Nrg1GIEF mice with enhanced MAPK signaling cofilin 
phosphorylation could be regulated via MAPK signaling (with low expression of 
ErbB4 in projection neurons). Differential stimulation of cofilin phosphorylation in 
Stop-Nrg1*NEX-Cre and HA-Nrg1-tg mice indicates that different levels of CRD-
NRG1 overexpression might trigger distinct signaling pathways or differentially 
activate distinct feedback-loops. In the future, it will be important to further analyze if 
direct interactions of the NRG1-ICD and LIMK1 indeed take place, thereby bypassing 
upstream members of the signaling cascade, e.g. p21-activated kinase 1 (PAK1) or 
Myosin light chain 2 (MLC2) (Scott and Olson, 2007; Barnes and Polleux, 2009). A 
direct interaction of the NRG1-ICD with LIMK1, depended or independent of ErbB4, 




pathomechanism underlying SZ pathogenesis and would underline the importance of 
multimodal NRG1 signaling properties.  
Taken together, the current working model suggests that NRG1 forward signaling is 
executed by the N-terminal product (NRG1GIEF) of BACE1 cleavage, which activates 
ErbB4 receptors mainly in GABAergic interneurons to modulate inhibitory 
neurotransmission. Backsignaling via the NRG1-ICD, partly independent from ErbB4, 
regulates gene expression and morphological changes in pyramidal cells, including 
dendritic spines. This could influence synaptic plasticity and integrity, and potentially 
involve interactions with LIMK1, but also other interaction partners, for instance 
microtubule-associated serine/threonine kinases (MAST) and syntrophin-associated 
serine/threonine kinase (SAST) kinases (Cary Lai, unpublished data). Other data 
suggest an ErbB4-independent mechanism regulating spine dynamics via kalirin-7, a 
key regulator of spine remodeling (Cahill et al., 2013). In line with this, loss of kalirin-
7 was also shown to influence locomotor activity and PPI in kalirin-7 mutant mice 
(Cahill et al., 2009). Kalirin-7 is a brain-specific GEF for Rho-like small GTPases, and 
by directly activating Rac1, and subsequent regulation of PAK1 activity it can be 
linked to LIMK1/cofilin signaling (Scott and Olson, 2007; Penzes and Jones, 2008). 
However, by direct interaction with LIMK1, NRG1 could directly impact on the actin 
cytoskeleton and spine dynamics. 
In summary, considering the complexity of NRG1 signaling further studies of NRG1 
isoforms under chronic and acute situations, as well as in different cortical areas and 
cell types, will be of great importance for the understanding of pathomechanisms of 
SZ. In this sense, Thy1.2-driven HA-Nrg1-tg mice serve as an „easy access“ model 
for hyperstimulated NRG1/ErbB4 signaling, which is suitable for drug screening 
(Wehr et al., in preparation). Stop-Nrg1 mice on the other hand, allow the 
investigation of specific pathomechanisms associated with Cre-mediated stage- and 
cell type-specific HA-NRG1 overexpression. Thus, ‚global’ and conditional NRG1 
transgenic mice are valuable research tools for a better understanding of the 






5.1 Kits and chemicals 
All chemicals were purchased from Sigma-Aldrich and Merck unless stated 
otherwise. All molecular biology and DNA purification kits were purchased from 
Qiagen, Invitek, BIORAD, Applied Biosystems, Promega, Stratagene, Sigma-Aldrich, 
Macherey-Nagel and nexttecTM. General laboratory materials were purchased from 
Gilson, Sarstedt, Molecular Bio Products, Greiner Bio One, Falcon and Eppendorf. 
 
5.2 Websites referred for online protocols 
Neuroscience             http://mrw.interscience.wiley.com/emrw/9780471142300/home/  
Molecular biology  http://mrw.interscience.wiley.com/emrw/9780471142720/home/  
Protein  http://mrw.interscience.wiley.com/emrw/9780471140863/home/ 
 
5.3 Equipment 
Lab water systems 
Sartorius Arium 611 
Pipettes 
Hirschmann Laborgeräte pipetus-akku 
Gilson Pipetman (2 μl, 10 μl, 20 μl, 100 μl, 200μl, 1000 μl) 
Deep-freeze storage 
New Brunswick Scientific Co. UltraLow Temperature Freezer U725 
DNA preparation and analysis 
Advanced Biotechnologies Ltd. CombiThermosealer 
Biometra Thermocycler T3 
Biometra TGradient 96-well 
Eppendorf Centrifuge 5415 R 
Eppendorf Thermomixer T3 
Heraeus Biofuge Pico 
INTAS UV-system with Camera and printer 
Memmert waterbath 
ÖTTI waterbath 
New Brunswick Scientific Innova 4000 Inkubator Shaker 
Heidolph Titramax 1000 T-shaker with Incubator 1000 




Scientific Industries Inc. G-560E Vortex Genie-2 
Sharp R-202 microwave 
Qiagen Sigma 4K15C centrifuge 
Proteinbiochemistry  
Beckman Ultra Centrifuge 
Bertin Technologies Precellys 24 Lysis & Homogenization with Peqlab Tubes  
BIORAD PowerPac 300 Powersupply 
BIORAD Mini Protean 3 electrophoresis chamber 
BIORAD Mini Trans-Blot cell  
Beckman Centrifuge Tubes 
Hecht Assistant 348 RM5 Rotating mixer  
IKA KS 260 basic shaker 
Intas ChemoCam Imager ECL HR-16-3200 
New Brunswick Scientific Co. TC-7 Tissue culture roller 
Pharmacia LKB-EPS 500/400 Powersupply 
Sartorius S 5ml Glas-Teflon Potter and B.Braun Potters Homogenisator 
Sorvall Centrifuge 
Sorvall Rotor SS-34  
SW-41Ti swing out bucket rotor 
ThermoMax Molecular Devises Microplate Reader 
Perfusion of mice 
Heidolph Pump Drive PD 5101 Peristaltic Pump 
In-house made preparation platform with drainage 
ÖTTI waterbath 
Pharmacia Fine Chemicals Peristaltic Pump P-1 
Histology 
Daewoo microwave 
Inolab wtw Series pH720 pH-meter 
Leica Jung Cryocut CM3000 
Leica Mikrotom VT1000S vibratome 
Microm AP280-1/-2/-3 paraffin embedding centre 
Microm HM400 sliding microtome 
Microm HMP110 embedding station 
PFM waterbath 1000 




Microscope and binoculars 
Leica Confocal AOBS SP2 inverted CLSM 
Leica MZ16F fluorescent stereomicroscope 
Zeiss Imager.Z1 with Power Supply 231, XBO 75W HBO 100W lamp,  
AxioCam MRc camera and Zeiss Zen 2012 (blue edition) software 
Zeiss Observer.Z1 AX10, HXP120 UV-lamp, Power Supply 23, SMC 2009  
stage control, ApoTome.2, AxioCam MRm camera and Zeiss Zen 2012 (blue 
edition) software  
2P-LSM custom-made, equipped with an fs-pulsed titanium-sapphire laser  
(Chameleon Ultra II, Coherent, Glasgow, UK) and a long-distance 20x/1.0 NA 
water immersion objective (Zeiss, Jena, Germany) 
Mouse behaviour 
Digital video camcorder (Sony) 
Fear conditioning setup (TSE Systems, Bad Homburg, Germany) 
Light dark preference test chamber - inhouse build 
Open field test Plexiglas arena with hole board inserts and ActiMot Software   
 (TSE Systems, Bad Homburg, Germany) 
San Diego Instruments’ SR-Lab startle response system 
Ugo Basile Series 46000 Fear Conditioning System 
Y-maze continuous alteration test – inhouse build 
Panasonic Lumix DMC-TZ31 digital camera 
Computers and Softwares 
Apple MacBook 13“, 2.4 GHz Intel Core 2 Duo with Mac OS X Version 10.6.8 
Adobe Illustrator CS3, Version 13.0.2 
Adobe Photoshop CS3, Version 10.0.1 
(FIJI Is Just) ImageJ, Version 1.0 
GraphPad Prism 5 for Mac OS X, Version 5.0b 
Mekentosj Papers, Version 1.9.3 
Microsoft Excel 2008 (Version 12.3.6) and 2011 (Version 14.0.0) for Mac 










5.4 Molecular biology buffers and stock solutions 
 
50x Tris-Acetat EDTA (TAE) buffer 
 2.0 M    Tris-Acetate, pH 8.0  
 50 mM    EDTA 
 57.1 ml    Glacial acetic acid 
Adjust volume to 1000 ml with H2O. 
 
1x Tris-EDTA (TE) buffer 
10 mM   Tris-HCl, pH 8.0  
1 mM   EDTA 
 
10x modified Gitschier buffer (MGB) 
6.7 ml   1 M Tris-HCl, pH 8.8   
1.66 ml   1 M (NH4)2SO4  
650 μl   1 M MgCl2 
Adjust final volume to 10 ml with H2O. 
 
1x MGB buffer (Working solution) 
 1 ml    10x MGB  
 500 μl    10 % Triton X-100  
 8.4 ml   H2O 
 
Proteinase K (Stock 10 mg/ml in ddH2O) 
 
10 mM dNTP (50x Stock) 
2.5 mM each Nucleotide (dATP, dCTP, dGTP, dTTP) (Boehringer) 
200 μM Final concentration per PCR-reaction (50 μM each Nucleotide) 
 
 
5.5 Protein biochemistry buffers and solutions 
Phosphatase inhibitors 
 1 Tablet    PhosStop phosphatase inhibitor cocktail (Roche) 







 1 Tablet   Complete Mini protease inhibitor (Roche)  
Added freshly to 10 ml of protein lysis buffer before use. 
 
Modified Ripa buffer (protein lysis buffer) 
 50 mM    Tris-HCl (pH 7.4) 
 150 mM   NaCl 
 1.0 mM    EDTA 
 0,1 %    SDS 
 1,0 %    Sodium deoxycholate 
 1,0 %    Triton X-100 
Phosphatase and protease inhibitors were added freshly to the buffer before use. 
 
Sucrose homogenization buffer (protein lysis buffer) 
 0.32 M  Sucrose 
0.01 M   Tris-HCl (pH 7.4) 
0.01 M   NaHCO3 
0.01 M   MgCl2 
Phosphatase and protease inhibitors were added freshly to the buffer before use. 
 
0.32 M Sucrose homogenization buffer (synaptosomal extraction buffer) 
 0.32 M   Sucrose  
4.0 mM   HEPES/NaOH (pH 7.4) 
Phosphatase and protease inhibitors were added freshly to the buffer before use. 
Steril filtered and stored at 4 °C up to 4 weeks. 
 
0.8 M Sucrose gradient solution 
 0.8 M   Sucrose  
4.0 mM   HEPES/NaOH (pH 7.4) 
Phosphatase and protease inhibitors were added freshly to the buffer before use. 
Steril filtered and stored at 4 °C up to 4 weeks. 
 
1.2 M Sucrose gradient solution 
 1.2 M   Sucrose  
4.0 mM   HEPES/NaOH (pH 7.4) 
Phosphatase and protease inhibitors were added freshly to the buffer before use. 




5.6 SDS PAGE and Western Blotting 
5x SDS sample buffer 
 100 mM  Tris, pH 6.8  
 5 % (w/v)   SDS 
 10 % (v/v)   0.4 % Bromphenolblue (in EtOH) 
 50 % (v/v)   Glycerol 
 
4x LDS sample buffer (NuPAGE) 
4.0 ml   100 % Glycerol (f.c. 40 %) 
0.682 g  Tris base (f.c. 564 mM) 
0.666 g  Tris-HCl (f.c. 424 mM) 
0.8 g  LDS (Lithium dodecyl sulfate) 
250 µl  1 % Phenol red solution (f.c. 2.5  % (v/v)) 
750 µl  1 % Serva Blue G250 solution (f.c. 7.5 % (v/v)) 
0.006 g  EDTA (f.c. 2 mM) 
Filled up to 10 ml with ddH2O. 1x buffer had a pH of 8.5. No pH adjustment 
necessary. For working solution added 20 µl of 1 M DTT to 50 ml 4x LDS sample 
buffer. 
 
1 M Dithiothreitol (DTT) 
1.5425 g  DTT 
Filled up to 10 ml with ddH2O. 
 
4x Tris-HCl (Separation gel buffer) 
 1.5 M  Tris-HCl pH 8.8 
 
4x Tris-HCl (Stacking gel buffer) 
1.0 M  Tris-HCl pH 6.8  
 
20x Tris buffered saline (TBS) 
1.0 M  Tris base 
3.0 M  NaCl 







1x TBS with Tween-20 (TBST) 
50 mM  Tris-HCl (pH 7.4) 
0.05 %  Tween-20 
 
Blocking Buffer 
5 %  Non-fat dry milk-powder in 1x TBST 
Not stored longer than one week at 4 °C. 
 
Western blot stripping buffer 
0.2 M  Glycine-HCl (pH 2.5) 
0.1 %  Tween-20 
Alternatively used 0.5 M NaOH solution to strip western blots. 
 
8.0 % Polyacrylamide separating gel (4 gels of 0.75 mm thickness)  
 9.3 ml   ddH2O 
 5.3 ml   30 % Acrylamide/bis-acrylamide (29:1) - Sigma  
 5.0 ml   1.5 M Tris Separation gel buffer 
 0.2 ml   10 % Sodium dodecyl sulfate (SDS)  
 0.2 ml   10 % Ammonium persulphate (APS) 
 0.012 ml   TEMED (Biorad) 
  
12 % Polyacrylamide separating gel (4 gels of 0.75 mm thickness)  
 6.6 ml   ddH2O 
 8.0 ml   30 % Acrylamide/bis-acrylamide (29:1) - Sigma  
 5.0 ml   1.5 M Tris Separation gel buffer 
 0.2 ml   10 % Sodium dodecyl sulfate (SDS)  
 0.2 ml   10 % Ammonium persulphate (APS) 
 0.008 ml   TEMED (Biorad) 
 
15 % Polyacrylamide separating gel (4 gels of 0.75 mm thickness)  
 4.6 ml   ddH2O 
 10.0 ml   30 % Acrylamide/bis-acrylamide (29:1) - Sigma  
 5.0 ml   1.5 M Tris Separation gel buffer 
 0.2 ml   10 % Sodium dodecyl sulfate (SDS)  
 0.2 ml   10 % Ammonium persulphate (APS) 





Polyacrylamide stacking gel (4 gels of 0.75 mm thickness) 
 5.5 ml   ddH2O  
 1.3 μl   30 % Acrylamide/bis-acrylamide (29:1) - Sigma  
 1 ml    1 M Tris Stacking gel buffer 
 0.08 ml   10 % Sodium dodecyl sulfate (SDS)  
 0.08 ml   10 % Ammonium persulphate (APS)  
 0.008 ml   TEMED (Biorad) 
 
5x Trisglycine electrophoresis buffer 
 125 mM  Tris base 
1.25 mM  Glycine 
0.5 %  Sodium dodecyl sulfate (SDS) 
Working solution (1x)  
200 ml  5x Trisglycine electrophoresis buffer 
800 ml  ddH2O. 
 
10x Trisglycine transfer buffer 
250 mM  Tris base 
1.92 M  Glycine 
Working solution (1x with 20 % methanol) 
100 ml  10x Trisglycine transfer buffer 
200 ml  100 % Methanol 
700 ml  ddH2O 
 
Coomassie blue (Staining solution) 
2 g  Coomassie brilliant blue (G-250)  
1 l  100 % Methanol 
200 ml  Acetic acid 
800 ml  ddH2O 
Stirred overnight and filtered through Whatman paper. 
 
Enhanced Chemiluminescence (ECL) Western-blot detection kit  
 Western LightningTM Plus-ECL, Oxidizing reagent plus and Enhanced  
 luminol reagent plus (Perkin Elmer Life Sciences, Inc.) 
 





5.7 DNA and Protein markers 
GeneRuler 1 kb DNA ladder       Fermentas 
GeneRuler 100 bp DNA ladder      Fermentas 
LabAid PageRuler Prestained Protein Ladder 10-170 kDa   Fermentas 
 
 
5.8 Immunohistochemistry buffers and solutions 
Avertin (Anesthetic) 
1 g  Tribromethanol (2,2,2-Tribromethanol, 99 %) 
0.81 ml  Amyl alcohol 
71.49 ml  ddH2O 
Heated ddH2O up to 40 °C and added to the tribromethanol and amylalcohol and 
stirred for 10 min. Sterilefiltered, aliquotted and frozen at -20 °C. Protected from light. 
Mice were intraperitoneal (IP) injected with 0.2 ml per 10 g of body weight. 
 
Phosphate buffer (Stock Solutions)  
 0.2 M   Sodiumdihydrogenphosphate (NaH2PO4)  
 0.2 M   Di-Sodiumhydrogenphosphate (Na2HPO4)  
Working Solution (pH 7.4) 
 20 ml   0.2 M Sodiumdihydrogenphosphate (NaH2PO4) 
 80 ml     0.2 M Di-Sodiumhydrogenphosphate (Na2HPO4) 
 100 ml    ddH2O 
 
10x Phosphate buffered saline (PBS) 
 1.7 M    NaCl 
 34 mM    KCl 
 40 mM    Na2HPO4*2H2O 
 18 mM    K2HPO4 
pH adjusted to 7.2 with 1 N NaOH. 
 
1x PBS (Working solution) 
 100 ml   10x PBS 







Bovine Serum Albumin (PBS/BSA) 
 20 ml    0.2 M Sodiumdihydrogenphosphate (NaH2PO4)  
 80 ml    0.2 M Di-Sodiumhydrogenphosphate (Na2HPO4) 
 1.8 g    NaCl   
 1.0 g    Bovines Serum Albumin (BSA) 
 100 ml   ddH2O 
 
16% Paraformaldehyde (PFA, Stock solution) 
 80 g   Paraformaldehyde 
 450 ml   ddH2O 
Heated up to 65 °C while stirring and then stirred for another 20 min. Droplets of 5 N 
NaOH added until solution turned clear. Filled up to a final volume of 500 ml with 
ddH2O and left to cool down. Filtered through 500 ml Nalgene sterile filter unit. 
Aliquotted and frozen at -20 °C. 
 
4% Paraformaldehyde (PFA) 
 100 ml    0.2 M Sodiumdihydrogenphosphate (NaH2PO4) 
 400 ml    0.2 M Di-Sodiumhydrogenphosphate (Na2HPO4)  
 250 ml    16 % PFA 
 8.0 g    NaCl  
 250 ml    ddH2O 
 
Citrate Buffer (Stock Solutions)  
 0.1 M   Citric acid (C6H8O7*H2O)  
 0.1 M   Sodium citrate (C6H5O7Na3*2H2O)  
Stored at 4°C.  
Working Solution (0.01 M pH 6.0) 
 9.0 ml    0.1 M Citric acid (C6H8O7*H2O)  
 41 ml    0.1 M Sodium citrate (C6H5O7Na3*2H2O)  
 450 ml    ddH2O 
Always prepared freshly. 
 
Tris-buffer (Stock Solution)  
 0.5 M   Tris base  






Working Solution  
 100 ml   0.5 M Tris base (pH 7.6)  
 9.0 g    NaCl  
Filled up to a final volume of 1000 ml with ddH2O. Always prepared freshly. 
 
2% Milk-powder in Tris-buffer  
 20 g    Non-fat dry milk-powder 
Filled up to a final volume of 1000 ml with Tris-buffer working solution. 
 
 
5.9 Buffers for immunohistochemisty of vibrotome and cryo sections 
0.1 % Triton X-100 in 1x PBS 
40 µl   4 % Triton X-100 
960 µl   1x PBS 
 
4 % Horse-Serum, 0.1 % Triton X-100 in 1x PBS 
40 µl   Horse Serum 
960 µl   0.1 % Triton X-100 in 1x PBS 
 
1 % Horse-Serum, 0.1 % Triton X-100 in 1x PBS 
10 µl   Horse Serum 
990 µl   0.1 % Triton X-100 in 1x PBS 
 
1.5 % Horse Serum in 1x PBS 
15 µl   Horse Serum 
 985 µl    1x PBS 
 
 
5.10 Mounting media 
Eukit    (Kindler) 
Aqua polymount   (Polyscience) 








5.11 Histological stains and reagents 
Mayer’s Haematoxylin solution 
 1 g    Haematoxylin  
Dissolved in 1000 ml ddH2O, then added:  
 0.2 g   Sodium iodate  
 50 g    Potassium aluminium sulphate  
under constant shaking. Then added:  
 50 g    Chloralhydrate  
 1 g    Citric acid  
Filtered before use. 
 
Eosin Stock solution (10x)  
 10 g    Eosin 
Dissolved in 100 ml of ddH2O and left to mature. 
Eosin working solution 
 2.5 ml   Eosin Stock solution  
Filled up to 250 ml with ddH2O and finished by adding 12 drops of glacial acetic acid. 
 
Scott’s solution 
 2 g  KHCO3  
 20 g  MgSO4 
Filled up to a final volume of 1000 ml with ddH2O. 
 
HCl-Alcohol 
 1.25 ml   Conc. HCl  
 350 ml   100 % Ethanol  
 150 ml   ddH2O 
 
-Gal Staining buffer (stock solutions) 
500 mM  Potassium ferricyanid (in PBS) 
500 mM  Potassium ferrocyanid (in PBS) 
2 mM  MgCl2 








5 mM  Potassium ferricyanid 
5 mM  Potassium ferrocyanid 
2 mM  MgCl2 
600 μl  X-Gal (f.c. 1.2 mg/ml) 




All oligonucleotides (primers) were synthesized at “Oligo Syntesys Lab” of the Max 
Planck Institute of Experimental Medicine. They were provided at 50 pM stock 
concentrations. In house identification numbers are displayed in brackets. 
 
 
5.13 Genotyping primer 
CKII-Cre               In house No. 
Forward: 5'-CGAGTGGCCCCTAGTTCTGGGGGCAGC-3'  (7964) 
Reverse: 5’-CGTTGCATCGACCGGTAATGCAGGC-3’  (7963) 
 
Emx1-Cre 
Forward: 5’-CAGGGTGTTATAAGCAATCCC-3’   (4192) 
Reverse: 5'-CCTGGAAAATGCTTCTGTCCG-3'    (4193) 
 
Nrg1f/f 
Forward: 5’-TCCTTTTGTGTGTGTTCAGCACCGG-3’  (6744) 
Reverse: 5'-GCACCAAGTGGTTGCGATTGTTGCT-3'  (6743) 
 
NEX-Cre and NEX-CreERT2 
Forward: 5'-GAGTCCTGGAATCAGTCTTTTTC-3'   (3131) 
Reverse: 5'-CCGCATAACCAGTGAAACAG-3'   (2409) 
Reverse: 5'-AGAATGTGGAGTAGGGTGAC-3'   (3132) 
 
PV-GFP 
Forward: 5’-GACACTGCAGCGCTGGTCAT-3’   (6895) 






Forward: 5’-TACGGCATGGACGAGCTGTACAAGTAA-3’  (21027) 
Reverse: 5'-CAGGCGAGCAGCCAAGGAAA-3'   (21028) 
 
R26R-floxLacZ 
Forward: 5'-AAAGTCGCTCTGAGTTGTTAT -3'   (3735) 
Reverse: 5'-GCGAAGAGTTTGTCCTCAACC -3'   (3736) 
Reverse: 5'-GGAGCGGGAGAAATGGATATG -3'   (3737) 
 
Stop-Nrg1 
Forward: 5’-GTCCACAAATACCCACTTTAGGCCAGC-3’  (11980) 
Reverse: 5’-GGTGGCTATAAAGAGGTCATCAG-3’   (15762) 
 
Thy1.2-driven Nrg1-tg, HA-Nrg1-tg and HA-Nrg1GIEF  
Forward: 5’-GTCCACAAATACCCACTTTAGGCCAGC-3’  (11980) 




REDTaq DNA Polymerase Sigma-Aldrich 




5.15.1 Primary Antibodies 
Antibody Cat. No. Species Company Dilution Purpose 
Actin MAB1501 mono-ms Millipore 1000 WB 
AKT #9272 poly-rb Cell Signaling 5000 WB 
AKT #4691 poly-rb Cell Signaling 5000 WB 
phospho-AKT (Ser473) 
(D9E) 
#4060 poly-rb Cell Signaling 5000 WB 
phospho-AKT (Ser473) 
(736E11) 
#3787 poly-rb Cell Signaling 5000 WB 
Cofilin #3312 poly-rb Cell Signaling 1000 WB 
phospho-Cofilin 1 (hSer 3)-
R 
sc-12912-R poly-rb Santa Cruz 1000 WB 




Antibody Cat. No. Species Company Dilution Purpose 
ErbB4 mAb10 mono-rb A. Buonanno 1 µg/ml WB 
ErbB4 (E200) ab32375 mono-rb abcam 1000 WB 
GAD67 MAB5406 mono-ms Chemicon 100 IHC 






Rockland 500 IHC 
GLT-1 AB1783 poly-gp Chemicon 20000 WB 
HA ab9110 poly-rb abcam 500 IHC, WB 
HA.11 MMS-101P mono-ms Covance 250 IHC, WB 
IBA1 019-19741 poly-rb Wako 700 IHC 
Krox-20 PRB-236P poly-rb Covance 100 IHC 
LIMK1 #3842 poly-rb Cell Signaling 1000 WB 
phospho-LIMK1 (Thr508) ab38508 poly-rb abcam 500 WB 
phospho-LIMK1 
(Thr508)/LIMK2 (Thr505) 
#3841 poly-rb Cell Signaling 1000 WB 
MBP A0623 poly-rb Dako 500 WB 
NeuN MAB377 mono-ms Chemicon 100 IHC 
Neuregulin-1a/b1/2 (C-20) SC-348 poly-rb Santa Cruz 100 / 500 IHC, WB 
Neurogranin AB1763 poly-rb Chemicon 1000 IHC 






#4757 mono-rb Cell Signaling 1000 WB 
p44/42 MAPK (Erk1/2) 
(137F5) 




#4376 poly-rb Cell Signaling 5000 WB 
Parvalbumin 28 PV-28 poly-rb Swant 200 IHC 




Tubulin T 5168 mono-ms Sigma 1000000 WB 
 
 
5.15.2 Secondary Antibodies 
    Species Company Dilution Purpose 
-goat-Alexa488   donkey  Dianova  1:500   IHC 
-guinea pig-cy3   goat   Dianova 1:500   IHC 
-guinea pig-cy5   goat   Dianova 1:500   IHC 




-mouse-AF555   donkey  Dianova  1:1000  IHC 
-mouse-Biotin   goat   Acris   1:100   IHC 
-mouse-cy2    goat   Dianova  1:100   IHC 
-mouse-cy3    goat   Dianova  1:1000  IHC 
-mouse-cy5    donkey  Dianova  1:500   IHC 
-mouse-DL488   goat   Dianova  1:100   IHC 
-mouse-DL633  goat   Dianova  1:250   IHC 
-mouse-HRP   goat   Dianova  1:5000  WB 
-rabbit-Alexa488   goat   Dianova  1:100   IHC 
-rabbit-Alexa555   donkey  Dianova  1:500   IHC 
-rabbit-Biotin   goat   Novus-Bio  1:100   IHC 
-rabbit-cy2    goat   Dianova  1:100   IHC 
-rabbit-cy3    goat   Dianova  1:1000  IHC 
-rabbit-cy5    donkey  Dianova  1:500   IHC 
-rabbit-DL488   goat   Dianova  1:100   IHC 
-rabbit-HRP    goat   Promega  1:5000  WB 
 
 
5.16 Mouse lines 
Stop-Nrg1 
conditional -actin eGFP-Stop-flox 2HA-Nrg1 type III1a transgenic mouse 
(Unterbarnscheidt et al., in preparation) 
Nrg1-tg 
Thy1.2 promtor-driven Nrg1 type III1a transgenic mouse  
(Wolpowitz et al., 2000) 
HA-Nrg1-tg 
Thy1.2 2HA-Nrg1 type III1a transgenic mouse  
(Velanac et al., 2011) 
HA-Nrg1GIEF  
Thy1.2 2HA-Nrg1GIEF transgenic mouse 
(Velanac et al., 2011) 
Nrg1f/f 







Cre driver mouse line, generated by homologous recombination of Cre into 
the NEX locus (Goebbels et al., 2006) 
NEX-CreERT2  
Cre driver mouse line, generated by homologous recombination of Tamoxifen 
inducible CreERT2 into the NEX locus (Agarwal et al., 2011) 
CKII-Cre  
Cre driver mouse line, expressing Cre as a transgene under control of 
CamKII promoter (Minichiello et al., 1999) 
Emx1-Cre  
Cre driver mouse line, generated by homologous recombination of IREScre 
into the exon encoding the 3’ untranslated region of the mouse Emx1 gene 
(Gorski et al., 2002) 
R26R-floxtdTomato 
Rosa26 knock-in floxed tdTomato Cre-reporter mouse line  
(Madisen et al., 2010) 
R26R-floxLacZ 
Rosa26 knock-in floxed LacZ Cre-reporter mouse line  
(Soriano, 1999) 
PV-GFP  
Bac-transgenic mouse expression eGFP under regulatory elements of the 






6.1 Animal maintenance, handling and treatment 
6.1.1 Generation of conditional Stop-Nrg1 transgenic mice 
Stop-Nrg1 mice were generated by cloning the HA-NRG1FL cDNA used for the 
generation of HA-Nrg1-tg mice (Velanac et al., 2011) via SpeI and XhoI restriction 
digest into the polylinker of the -actin Stop-eGFP-flox cassette in a pBluescriptKS 
vector. The vector backbone harbored a fragment of a chicken -actin promoter, an 
eGFP-Stop cassette flanked by two loxP sites, and a bovin growth hormone polyA 
site. The transgene cassette was excised from the plasmid via SalI and injected into 
C57bl6n oocytes. Initial cloning of the vector backbone was performed by Maike 
Gummert and HA-NRG1FL cDNA insertion and linearization was conducted by 
Viktorija Velanac at the Max-Planck-Institute of Experimental Medicine in Göttingen. 
One positive founder was born. The transgenic line was maintained on a C57/Bl6N 
background. 
 
6.1.2 Breeding of mouse mutants 
Mice mutants were bred starting at 8 weeks of age. To maintain and expand the 
mutant lines, mutant mice were bred to WT mice of the C57/Bl6N strain. 
 
6.1.3 Animal maintenance and handling 
All mouse mutants used in this study were maintained and bred in the animal facility 
of the Max-Planck-Institute of Experimental Medicine. Animals were kept and 
handled in compliance with animal policies of the Max-Planck-Institute of 
Experimental Medicine and approved by the German Federal State of Lower Saxony. 
 
6.1.4 Tamoxifen injection 
For the acute activation of NRG1 overexpression, the NEX-CreERT2 mouse line was 
used. The CreERT2 sequence in this mouse line is an improved version of the 
original tamoxifen-inducible Cre recombinase (Feil et al., 1997; Metzger and 
Chambon, 2001), which is fused to a mutated human oestrogen receptor (ER) 
ligand-binding domain (LBD) (Feil et al., 1997). In the absence of tamoxifen, a 
synthetic ligand of the ER, the CreERT2 variant is located in the cytoplasm and is 
inactive. Addition of tamoxifen induces nuclear transfer and site-specific 
recombination of loxP-flanked genomic DNA (Feil et al., 1997). Tamoxifen was 




postnatally by IP injection of the mother and transmission of tamoxifen via milk. 
Concentrations used ranged from 25 to 100 mg/kg of body weight and from 2 to 10 
consecutive days of injection (full induction = 10 days of 100 mg/kg body weight). 
 
6.1.5 Phenotyping of tail biopsies of Stop-Nrg1 mice 
For routine genotyping of Stop-Nrg1 mice the fluorescence of the loxP sites-flanked 
eGFP-Stop-cassette of the transgene cassette was used. In unrecombined cells, e.g. 
in the tailbiopsie it can be used to genotype mice. For fluorescent phenotyping of 
transgenic mice, tail biopsies were examined under fluorescent light of 488 nm 
excitation under a fluorescent microscope (Leica), prior to DNA extraction and 
genotyping for Cre recombinase transgenes by PCR (see section: Preparation of 
mouse genomic DNA, below). 
 
 
6.2 Preparation of mouse genomic DNA 
6.2.1 Standard method of genomic DNA isolation 
Routine genotyping of transgenic mouse lines was performed on genomic DNA 
isolated from 5 mm pieces of tail biopsies. Each tail was lysed in a tightly closed tube 
with 200 µl of lysis buffer, that contained 180 µl of 1x MGB (working solution) and 20 
µl of proteinase K (10 mg/ml). Lysis was carried out over night (ON) at 52 °C and 
vigorous shaking. Digested tails where centrifuged 5 min at 5000 rpm followed by 
heat inactivation of the proteinase K at 95 °C for 10 min. Lysates were then mixed by 
shaking and centrifuged at 5000 rpm for 10 min at room temperature (RT). 1 μl of 
supernatant was used in genotyping PCR reactions (see below). Alternatively 
surface phase of the supernatant was diluted with ddH2O (1:5) for increased purity of 
PCR results. 
 
6.2.2 nexttecTM Tissue & Cells kit-based genomic DNA isolation 
The standard method was used to isolate genomic DNA from mouse tail biopsies in 
the beginning of this study. Meanwhile, a kit-based isolation method was aquired and 
established in the lab. Routine genomic DNA extraction was from then on performed 
by using nexttecTM’s 1-Step Tissue & Cells kit. The DNA isolation was performed 
according to the manufactures protocol. Briefly, tail biopsies were lysed in 300 µl 
lysis buffer, containing 265 µl of buffer G1, 10 µl buffer G2 and 25 µl buffer G3, by 
vigorous shaking for 30 min at 12.000 rpm and 62 °C. Meanwhile nexttecTM 




centrifuged for 1 min at 350 xg. 120 µl of the tail lysate were then loaded onto 
columns and incubated for 3 min at RT before eluation by centrifugation at 750 xg for 
1 min into fresh tail tubes. Lysate were diluted 1:5 in ddH2O. 1 µl of the lysate was 
used in genotyping PCR reactions (see below). 
 
 
6.3 DNA modification and analysis 
6.3.1 DNA amplification in vitro by polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR), originally reported by (Mullis et al., 1986), is a 
standard method that enables in vitro enzymatic amplification of selected DNA 
sequence. The reaction requires a thermostable DNA polymerase from the 
termophilic bacterium Thermus aquaticus (Taq Polymerase), that is stable at the 
melting temperature of the double stranded DNA and has an optimal activity at 72 
°C. In the reaction a template sequence for amplification is defined by primers, single 
stranded oligonucleotides that complementary bind to the sense and antisense 
strands on the opposite ends of the template. The DNA amplification is carried out in 
a thermocycler (Thermocycler T3, Biometra) through multiple repetitions of three step 
PCR cycles. In the first step of the PCR reaction the double stranded DNA template 
is broken up at 95 °C. In the second step the primers anneal to the complementary 
sequences of the template DNA at their specific annealing temperature. In the last 
step each strand of the template is replicated by elongation of the primer sequence 
by the Taq Polymerase, which adds nucleotides complementary to the template. 
In this study standard PCR master mix were setup with RedTaq polymerase (Sigma) 
as follows: 
   1μl   DNA (100 pg-100 ng)  
   1μl   sense primer (10 pM) 
   1μl   antisense primer (10 pM) 
   2μl   dNTP mix (2 mM) 
   2μl   10x RedTaq buffer 
   1μl   RedTaq polymerase (1 U/μl)  
   12μl   ddH2O 
PCR products were then separated on agarose gels for visualization. 
 
6.3.2 Primer design 
All primers were designed manually, based on the template sequence information 




(http://mbcf.dfci.harvard.edu/docs/oligocalc.html). They where designed to have at 
least 20 bp overlap with the template sequence, and a melting temperature of ~60 
°C. Oligonucleotides were synthesized in-house at the ‘Oligo Synthesis Lab’ of the 
Max-Planck-Institute of Experimental Medicine at a stock concentration of 50 pM and 
diluted 1:5 in ddH2O before use. 
 
6.3.3 Agarose gel electorphoresis for the size separation of DNA 
fragments 
To separate DNA fragments, resulting from genotyping PCRs, based on their size 
agarose gel electrophoresis was used (Voytas, 2001). For the separation, gels of 1 
% - 2 % agarose in 1x TAE buffer were used. For DNA visualization 2 to 3 µl of 10x 
GelREDTM (Biotium) were added to 20 µl DNA sample. Gels were placed into the 
electrophoresis chambers and filled with 1x TAE buffer until the gel surface was 
covered by buffer and the wells were filled. Standard DNA marker (100 bp or 1 kb 
ladder) and DNA samples (containing glycerol and tracking dye) were loaded into the 
wells. The chamber was then connected to a power supply and voltage was set to 70 
V for the first run-in of the samples. Negatively charged DNA migrates to the 
positively charged cathode and smaller DNA fragments migrate faster through the 
gel than bigger fragments. When probes had successfully entered the gel, the 
voltage was increased to 100 V. The gel was run until the desired fragment 
separation was achieved. For documentation, snapshots of UV-trans-illuminated gels 
were taken. 
 
6.3.4 Genotyping of mouse mutants 
At 3 weeks of age a tail biopsy was taken from mutant mice. DNA for genotyping was 
prepared with either the standard procedure or the nexttecTM Tissue & Cells kit. The 
genotype was determined by performing genotyping PCRs with mutant specific 
genotyping primers described in the material section (Section 5.13). An example for 
a PCR master mix is given in the section above. PCRs were incubated in the 










6.3.5 PCR programs: 
Stop-Nrg1  
1. 95 °C  5 min 
2. 95 °C  45 sec 
3. 56 °C  30 sec  
4. 72 °C  1 min 
 2 to 4 for 36 cycles 
5. 56 °C  1 min 
6. 72 °C  10 min 
7. 4 °C  pause 
 
Nrg1-tg, HA-Nrg1-tg and HA-Nrg1GIEF 
1. 95 °C  3 min 
2. 95 °C  45 sec 
3. 58 °C  30 sec  
4. 72 °C  1 min 
 2 to 4 for 35 cycles 
5. 72 °C  10 min 
6. 4 °C  pause 
 
Nrg1f/f 
1. 94 °C  3 min 
2. 60 °C  30 sec 
3. 72 °C  50 sec  
4. 94 °C  45 sec 
 2 to 4 for 39 cycles 
5. 60 °C  1 min 
6. 72 °C  10 min 
7. 4 °C  pause 
 
NEX-Cre and NEX-CreERT2  
1. 94 °C  3 min 
2. 54 °C  30 sec 
3. 72 °C  1 min  
4. 94 °C  30 sec 
 2 to 4 for 39 cycles 
5. 54 °C  1 min 
6. 72 °C  5 min 








1. 95 °C  3 min 
2. 94 °C  30 sec 
3. 58 °C  30 sec  
4. 72 °C  30 sec 
 2 to 4 for 35 cycles 
5. 58 °C  1 min 
6. 72 °C  5 min 
7. 4 °C  pause 
 
Emx1-Cre  
1. 94 °C  3 min 
2. 55 °C  30 sec 
3. 72 °C  30 sec  
4. 94 °C  30 sec 
 2 to 4 for 35 cycles 
5. 55 °C  1 min 
6. 72 °C  5 min 
7. 4 °C  pause 
 
R26R-floxtdTomato 
1. 95 °C  3 min 
2. 60 °C  30 sec 
3. 72 °C  1.5 min 
4. 95 °C  30 sec 
 2 to 4 for 45 cycles 
5. 60 °C  1 min 
6. 72 °C  10 min 
7. 4 °C  pause 
 
R26R-floxLacZ 
1. 95 °C  3 min 
2. 56 °C  30 sec 
3. 72 °C  1 min  
4. 95 °C  30 sec 
 2 to 4 for 36 cycles 
5. 56 °C  1 min 
6. 72 °C  10 min 








1. 95 °C  3 min 
2. 57 °C  40 sec 
3. 72 °C  45 sec  
4. 95 °C  30 sec 
 2 to 4 for 40 cycles 
5. 56 °C  1 min 
6. 72 °C 10 min 
7. 4 °C  pause 
 
 
6.4 Protein biochemistry methods 
6.4.1 Radioimmunoprecipitation assay (RIPA) buffer protein extraction 
For the analysis of proteins of mouse nervous system tissue, brains of mice at 
different ages were dissected and cortices (Cx), prefrontal cortices (PFC), 
hippocampi (Hipp) and thalamus (Thal) were micro-dissected on ice and afterwards 
frozen on dry ice and stored at -80 °C. To prepare protein samples, the frozen tissue 
was homogenized in 900 μl (Cx) or 200 μl (PFC, Hipp, Thal) RIPA buffer with 
protease and phosphatase inhibitors (Roche), respectively. Homogenization was 
carried out with the Precellys homogenizer (5500 rpm, 2x10 sec, Bertin 
Technologies), followed by lyses on ice for 20 min. Lysed tissue was centrifuged for 
10 min at 8000 rpm at 4 °C in order to spin down the beads and unlysed material. 
The supernatant was transferred into a new Eppendorf cup and centrifuged for 30 
min at maximum speed at 4 °C. The supernatant containing the soluble proteins was 
transferred to a new Eppendorf cup. Supernatant and pellets were kept at –80 °C 
until use. Protein concentration measurement was performed on dilutions (1:1 up to 
1:20 in RIPA buffer) of the supernatant fraction. 
 
6.4.2 Sucrose buffer protein extraction 
To analyze the phosphorylation status of ErbB receptors and downstream effectors, 
and to improve the western blot quality for transmembrane proteins, sucrose buffer-
based protein extraction was used. Micro-dissected frozen mouse brain material from 
one hemisphere (Cx, PFC, Hipp, Thal) was homogenized in 900 µl (Cx) or 200 µl 
(PFC, Hipp, Thal) sucrose homogenization buffer with protease and phosphatase 
inhibitors (Roche), respectively. Homogenization was carried out with the Precellys 
homogenizer (5500 rpm, 2x10 sec, Bertin Technologies). 130 µl of the resulting 
homogenate were added to 70 µl of 4x LDS sample buffer (NuPAGE) working 




and frozen and stored at -80 °C. The leftovers of the homogenates were frozen and 
stored at -80 °C. Protein concentration measurement was performed on dilutions (1:1 
up to 1:20 in sucrose homogenization buffer) of these leftovers.  
 
6.4.3 Synaptosomal preparation 
Many different protocols for the isolation of synaptosomes have been developed 
since its first description in 1958 (HEBB and WHITTAKER, 1958). Synaptosomes are 
resealed nerve terminals separated from axons and dendrites (Whittaker, 1993), they 
are very small (50 nm in diameter) and homogeneous in shape and size, and can be 
isolated by size fractionation techniques. The protocol used in this study was 
adapted from protocols described by Hell and Jahn (2006), Huttner et al. (1983) and 
Biesemann et al. (2014).  
To isolated synaptosomes the tissue was prepared freshly. Mice were sacrificed by 
cervical dislocation followed by decapitation. The brain was immediately removed 
from the skull and the forebrain was dissected on ice. The cerebellum and olfactory 
bulb were removed and after separation of the two hemispheres, the midbrain was 
pinched out using a pair of bend tweezers and a dissection spatula. White matter 
was removed and the forebrains were transferred into ice-cold 0.32 M sucrose 
homogenization buffer (synaptosomal extraction buffer) with protease and 
phosphatase inhibitors (Roche) and kept on ice. All used solutions were prepared 
with protease and phosphatase inhibitors (Roche) to ensure phospho-specificity for 
later analyses (Fig. 33).  
The two forebrain hemispheres of each mouse were homogenized in 4 ml of fresh 
ice-cold homogenization buffer with 12 gentle up and down strokes at 900 rpm using 
a loosely fitting 5 ml glass-Teflon potter in the 4 °C cold room. After transfer of the 
homogenate to a centrifuge tube the potter was rinsed with additional 4 ml of 
homogenization buffer in 9 up and down strokes. These 8 ml of homogenate (H) 
were centrifuged for 10 min at 1000 xg at 4 °C in the SS-34 rotor (with adaptors) in 
the Sorvall centrifuge. This centrifugation step removed large cell fragments and 
nuclei from the solution. The supernatant (S1) was removed carefully from the pellet 
(P1). P1 was carefully resuspended in 4 ml of homogenization buffer and centrifuged 
again for 10 min at 1000 xg at 4 °C in the SS-34 rotor (with adaptors) in the Sorvall 
centrifuge. The supernatant (S1.2) was added to S1 and centrifuged for 15 min at 
12.500 xg at 4 °C in the SS-34 rotor (with adaptors). The supernatant (S2) was 
removed completely and the synaptosome-enriched pellet (P2) was resuspended in 
1 ml of homogenization buffer. The P2 fraction was then carefully layered on top of a 




sucrose gradient solutions. After carefully balancing the tubes, the gradient was 
centrifuged for 2 h at ~50.000 xg (18.000 rpm) at 4 °C in a SW-41Ti swing-out bucket 
rotor in the Beckman ultracentrifuge with accel: 5 and deccel: 5 settings. The 
resulting gradient consisted of the three sucrose gradient steps (0.32 M, 0.8 M and 
1.2 M sucrose solutions) containing low amounts of protein, two interfaces and a 
pellet. A myelin-containing fraction ‘A’ was enriched at the border of 0.32 M to 0.8 M 
sucrose. Synaptosomes were enriched in the interface ‘B’ of 1.2 M and 0.8 M 
sucrose and recovered by carefully removing the layers of the gradient step by step. 
The resulting fraction was referred to as synaptosome fraction or gradient-purified 
synaptosomes. 900 µl of fraction B were then diluted with 900 µl of 0.32 M sucrose 
homogenization buffer and centrifuged for 20 min at 20.000 xg (10.800 rpm) at 4 °C 
in the SW-41Ti swing-out bucket rotor in the Beckman ultracentrifuge, to wash and 
concentrate the synaptosomal fraction. The pellet (P3) was resuspended in 200 µl of 
0.32 M sucrose homogenization buffer and referred to as final synaptosomes. 
Aliquots of all fractions were frozen and stored at -80 °C. The pellet fractions P1.2 
and the gradient pellet were resuspended in 800 µl and 200 µl 0.32 M sucrose 
homogenization buffer, respectively, for protein concentration measurement and 
western blot analyses. 
 
 









6.4.4 Protein concentration measurement with the Lowry assay 
To determine the protein concentration of samples the Bio-Rad DC Protein Assay kit 
was used. The working principal of this kit is based on the Lowry assay described in 
1951 (LOWRY et al., 1951). The two step assay is based on the reaction between 
protein and an alkaline copper tartrate solution, followed by the reduction of Folin 
reagent that produces several reduced species of characteristic blue color with a 
maximum absorbance at 750 nm. Hereby the color development is primarily due to 
oxidation of the amino acids tyrosine and tryptophan, and to a lesser extent cystine, 
cysteine, and histidine (LOWRY et al., 1951; Peterson, 1979). The assay was 
performed in a 96-well plate (flat bottom) according to the manufacturer’s “micro 
plate” assay protocol and absorbance was measured at 650 nm with a microtitre 
plate reader (ThermoMax Molecular Devises). A standard curve, using dilutions of 
bovine serum albumine (BSA), was used to estimate protein concentrations. Protein 
samples were pre-diluted before measurement and concentrations were calculated 
with regard to the dilution factor. 
 
6.4.5 Preparation of protein samples for SDS electrophoresis 
6.4.5.1 RIPA buffer protein samples 
RIPA buffer extracted protein samples were set up with final concentrations ranging 
between 2.5 to 5 µg/µl in 5x SDS sample buffer with 1 % -mercaptoethanol. 
Volumes of the samples were equalized with RIPA buffer. Samples were mixed 
carefully by pipetting up and down and afterwards denatured at 95 °C for 10 min. For 
storage samples were kept at -80 °C. 
 
6.4.5.2 Sucrose buffer protein samples 
Since sucrose buffer extracted samples were set up and denatured in 4x LDS 
sample buffer directly after homogenization, the protein concentration measurement 
was carried out on the leftover of the homogenate. Using the measured 
concentrations, denatured samples were then diluted to equal concentrations 
(ranging between 1 and 3 µg/µl protein) using a similar mixture of 4x LDS samples 
buffer with DTT and sucrose homogenization buffer as used in the denatured 
sample. Diluted and undiluted samples were stored at  -80 °C until use. 
 
6.4.5.3 Synaptosomes 
Samples of the different fractions of the synaptosomal preparation were set up for 




using same volumes (20µl) of the fractions in 4x LDS sample buffer with DTT. In the 
second approach samples were set up in equal concentrations (1 µg/µl protein) in 4x 
LDS sample buffer with DTT. Volumes of samples were equalized with 0.32 M 
sucrose homogenization buffer. In both cases samples were denatured at 70 °C for 
10 min. 
 
6.4.6 Discontinous SDS polyacrylamide gel electrophoresis 
To separate proteins by size from a sample, discontinuous SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed (Laemmli, 1970). SDS polyacrylamide 
gels were casted between Bio-Rad glass plates and 0.75 mm or 1.75 mm spacer 
plates that were assembled according to the company’s instructions. The separation 
gel acrylamide solution of the desired percentage was poured between the glass 
plates, separated from air by a layer of isopropyl alcohol and left to polymerize for 30 
min at RT. After rinsing the isopropyl alcohol with ddH2O, the stacking gel solution 
was added onto the separation gel. A Teflon comb (10 or 15 teeth) was immediately 
inserted into the stacking gel solution and the gel was left to polymerize for 30 min. 
Polymerized gels were kept up to one week at 4 °C. The chamber for electrophoresis 
(Bio-Rad mini protean 3) was assembled according to the manufacturer’s manual 
and the inner gasket was filled with the electrophoresis buffer to check for leakiness 
of the chamber. The combs were carefully removed and the wells were washed with 
electrophoresis buffer by pipetting up and down. 3-30 μg of denatured protein 
samples and 10 μl of prestained protein marker (Fermentas) were loaded onto the 
gel. The chamber was filled with electrophoresis buffer and connected to a power 
supply (Bio-Rad). The gel was run under a constant voltage of 100 mV until samples 
aligned at the border of stacking and separation gel. The voltage was then increased 
to 150 mV and the gel was run until the tracking dye reached the end of the gel. The 
gel was carefully removed from the glass plates and proceeded with Coomassie 
staining or western blot analysis. 
 
6.4.7 Coomassie staining 
To verify the protein transfer, SDS-PAGE gels were stained with Coomassie solution. 
Briefly, the gel was covered with Coomassie solution and coocked in a microwave for 
30 sec. Afterwards gels were washed with ddH2O at RT under constant gentle 






6.4.8 Western Blotting 
6.4.8.1 Electrophoretic transfer 
For immunological detection of proteins resolved by SDS-PAGE, proteins were 
transferred onto PVDF membranes by electrophoresis, as originally described by 
Towbin and colleagues (Towbin et al., 1979). By applying an electric current to the 
blotting module, the negatively charged proteins migrate from the cathode to the 
anode and are retained on a PVDF membrane by electrostatic and hydrophobic 
interactions. PVDF membranes (Roche, pore size 0.2 µm) were activated for 1 min in 
100 % methanol, washed twice in ddH2O and then placed into transfer buffer. 
Blotting pads and Whatman papers were pre-soaked in transfer buffer and the 
blotting sandwich was assembled in the following way: 
 
Fig. 34: Bio-Rad Mini Trans-Blot western blot sandwich 
 
The protein transfer was performed using Bio-Rad Mini Trans-Blot cells under a 
constant voltage of 38 V and a maximum current of 275 mA, for 90-180 min 
(depending on the size of the protein and the thickness of the gel) at 4 °C. 
 
6.4.8.2 Immunological detection of proteins on PVDF membranes 
After electrophoretic transfer of proteins to PVDF membranes, membranes were first 
blocked for 60 min at RT in blocking buffer and then placed into 50 ml falcons with 3 
ml of the primary antibody diluted in blocking buffer. Incubation was carried out ON at 
4 °C with constant rotation. On the next day membranes were washed four times for 
10 min TBST and incubated with the HRP-conjugated secondary antibody diluted in 
blocking buffer for 1 hr at RT. The membranes were again washed four times with 
TBST for 10 min at RT, followed by 1 min incubation with a 1:1 dilution of the two 
Enhanced Chemiluminescence Detection (ECL) solutions. After drying the 
membranes on tissue, they were placed into a transparent plastic foil and placed into 
the Intas ChemoCam Imager. The membranes were scanned for 20 min, the protein 
standard fotographed and the images saved digitally for later analyses and 
quantifications. 




stripping buffer for 1 hr at 60 °C or in 0.5 M NaOH for 15 min at RT with vigorous 
shaking. After washing in TBST and blocking, membranes were incubated in the next 
antibody. 
 
6.4.8.3 Densitometric quantification of band intensity 
For densitometric analyses of western blot bands, raw images acquired with the Intas 
ChemoCam Imager were opened with FIJI, converted to 8-Bit and inverted (to have 
black bands on white background). The densities of bands of interest were measured 
using FIJI’s gel analyzing function. Results were normalized to loading controls (e.g. 
-actin or -tubulin) and normalized values (±SEM) were analyzed for statistical 
significance using the GraphPad Prism software package. 
 
 
6.5 Histology and immunohistochemistry 
6.5.1 Analysis of fluorescent organs 
The transgene cassette of Stop-Nrg1 mice contains a loxP sites-flanked eGFP Stop-
cassette. This element allows for Cre-dependent stage-specific activation of the HA-
CRD-NRG1 overexpression, but can also be used to genotype mice and to visualize 
transgenic cells. To check which organs of the mice expressed the transgene 
cassette, different organs (brain, heart, liver, muscles, tailtips, spinal cord and sciatic 
nerves) were examined for eGFP fluorescence. Mice were sacrificed by cervical 
dislocation and decapitation, organs were dissected from the mice and after short 
rinsing in 1x PBS, they were examined with the Leica MZ16F fluorescent 
stereomicroscope. Images of brightfield and fluorescent light were taken and 
analyzed by FIJI software. 
 
6.5.2 Perfusion fixation of mouse tissue for histology 
To perform histology on mouse brain tissue, mice were perfusion fixed to better 
preserve the tissue for later processing. Mice were deeply anesthetize by IP injection 
of Avertin with a dose of 0.2 ml per 10 g of body weight. Once the mouse was 
anesthetized, it was fixed onto a preparation platform with drainage (ventral side up). 
Two pieces of tail were cut for later re-genotyping and the abdomen and the 
diaphragm were opened, and the rib cage was cut laterally on both sides to the top 
and above the sternum. It was then fully removed to expose the heart. A 27 gauge 
needle butterfly connected to a peristaltic pump was carefully inserted into the left 




a small cut to ensure the perfusion flow. The peristaltic pump was started and the 
blood was flushed out of the circulatory system with 20 ml of pre-warmed HBSS at a 
flow rate of 1 ml/min. Afterwards the mouse was perfused with 30-40 ml of ice-cold 
4% PFA fixative at a flow rate of 1 ml/min. After perfusion, fixed brains were 
dissected and placed into cold fixative for post-fixation. Post-fixation was carried out 
ON at 4 °C. Tissue for vibratome sectioning was sectioned directly after ON post 
fixation. For cryosectioning of brain tissue, post-fixed tissue was cryo protected in 
sucrose solutions (see section 6.5.4). Tissue for paraffin embedding was changed to 
1 % PFA, after post-fixation, for prolonged storage at 4 °C, or immediately proceeded 
for embedding (see section 6.5.5). 
 
6.5.3 Vibratome sectioning of tissue 
For vibratome sectioning, tissue was, after post-fixation, washed in 1x PBS and 
immediately sectioned at the vibratome. Therefore the brains were sliced coronally 
into 3 three pieces of 4 mm thickness, a PFC, a hippocampal and a cerebellar 
section. These pieces were glued onto the specimen holder of the vibratome using 
instant glue. The specimen holder was fixed onto the stage of the vibratome that was 
filled with ice cold 1x PBS. Coronal sections of 50 µm thickness were sectioned and 
collected in 24-well plates in 1x PBS. The sections were kept at 4 °C and were 
immediately proceeded with immunohistological stainings. 
 
6.5.4 Cryo protection, embedding and cryosectioning of tissue 
For cryo sectioning, mouse brains were cryo protected by incubations in a row of 
sucrose solutions with accending sucrose concentrations. First tissue was shortly 
rinsed in 1x PBS and then submersed in a 10 % (w/v), a 20 % (w/v) and finally a 30 
% (w/v) sucrose solution at 4 °C, until the tissue had sunk to the bottom of the tube in 
each solution. Brains were sectioned into three 4 mm thick coronal pieces (a PFC, 
hippocampal and cerebellar piece) using a brain slicer, and frozen on aluminum foil 
on dry ice, then wrapped in aluminum foil and stored until sectioning at -80 °C. 
Embryonic brains of Stop-Nrg1*NEX-Cre mice, that were used to determine the early 
embryonic onset of HA-Nrg1 overexpression, were, due to the tissue size, embedded 
in Shandon cryomatrix in aluminum foil molds. A layer of Shandon cryomatrix was 
filled into the labeled molds at RT and the cryo protected tissue was placed into the 
molds with the cutting surface facing to the bottom of the mold. Molds were carefully 
filled with Shandon cryomatrix and placed onto dry ice to freeze. For sectioning 




sectioning. Shandon cryomatrix-embedded embryonic tissue blocks were trimmed to 
size using razor blades. Afterwards brain pieces or cryomatrix blocks were glued 
onto a specimen holder with Shandon cryomatrix embedding medium and fixed into 
the cryostat. 14 µm to 20 µm thick sections were cut using a knife-angle of 4 °, a 
chamber temperature of -21 °C and an object temperature of -19 °C. Sections were 
either collected on positively charged ultrafrost microscope slides, dryed ON at RT in 
an exsiccator and used for „on slide“ immunohistochemistry, or collected in 1x PBS 
in multi-well plates and processed for stainings on free-floating cryo sections. 
 
6.5.5 Paraplast impregnation, embedding and sectioning of tissue 
For paraplast embedding, tissue was, after ON post-fixation, shortly rinsed in 1x PBS 
and sliced into three 4 mm thick pieces (a PFC, hippocampal and cerebellar section). 
The three pieces were given into tissue cassettes and using the paraplast 
embedding station (see embedding scheme below), dehydrated and infiltrated with 
paraplast, and then embedded into paraplast blocks, using the paraplast embedding 
centre and metall molds. After cooling down harden the fresh paraplast, blocks were 
removed from the molds and stored at RT until sectioning. 
Paraplast blocks were sectioned using a sliding microtome and the 5 µm thick 
sections were collected on ice-cold destilled water. After transfer to a 42 °C 
waterbath and straigthening, sections were mounted onto charged microscope 
slides. For parallel processing, sections of multiple genotypes were mounted per 
slide (for instance Cre and Stop-Nrg1 parental controls next to a Stop-Nrg1*Cre 
double transgenic mouse). Sections were dried at RT between each animal, and 
after the last section, slides were dried ON at 37 °C and then stored at RT or 
proceeded with fluorescent and chromogenic immunohistological stainings. 
Embedding scheme of the paraplast embedding centre: 
           Solution        Incubation time 
EtOH 50 %  1 hour  
EtOH 70 %  2 hours 
EtOH 70 %  2 hours  
EtOH 96 %  1 hour  
EtOH 96 %  1 hour  
EtOH 100 %  1 hour  
EtOH 100 %  1 hour  
Isopropanol  1 hour  
Xylol   2 hours  
Xylol   2 hours 
Paraplast  2 hours 




6.5.6 Histological staining procedures 
6.5.6.1 Haematoxylin-Eosin (H+E) staining 
Haematoxylin-Eosin (H+E) staining is widely used as a histological staining method 
that gives information of the overall tissue structure. Haematoxylin stains basophilic 
nuclei in dark purple and Eosin stains eosinophilic cytoplasm pink.  
For the H+E staining, paraffin sections were deparaffinised by two 10 min 
incubations in Xylol and one for 10 min in Xylol/Isopropanol (1:1), followed by 
rehydratation in descending ethanol dilutions (100 %, 90 %, 70 %, and 50 %) for 5 
min each. After washing for 5 min in ddH2O, sections were stained with 0.1 % 
Haematoxylin for 5 min and washed with ddH2O. The dark purple color was 
differentiated by a short wash in HCl-Alcohol solution. To stop the differentiation 
process and properly develop the color, sections were incubated for 5 min in Scott’s 
solution. After a short rinse in ddH2O, sections were counterstained in 0.1 % Eosin 
for 3-5 min. Excess dye was washed off with ddH2O. After dehydration in an 
ascending row of ethanol dilution (50 %, 70 %, 90 %, and 100 %) by short incubation 
steps (10-30 sec, depending on the stability of the Eosin stain), sections were 
incubated once for 10 min in Xylol/Isopropanol (1:1) and twice for 10 min in Xylol, 
and finally mounted with the Xylol based mounting medium Eukitt and dried at RT. 
 
6.5.6.2 DAB immunostaining of paraffin sections 
DAB immunostaining is based on the enzymatic reaction of horseradish peroxidase 
(HRP) attached to a secondary antibody with DAB substrate, which forms a stable 
brown precipitate that can be visualized by light microscopy (Harlow and Lane, 
1988). 5 µm thick paraffin sections were incubated at 60 °C for 10 min and 
deparaffinized and dehydrated as for the H+E staining. Afterwards, sections were 
incubated for 5 min in ddH2O followed by 5 min incubation in citrate buffer. 
Meanwhile citrate buffer was heated up in a microwave. Sections were cooked for 10 
min in boiling citrate buffer at 650 W in the microwave for antigen retrieval. Eventual 
evaporation was replenished with ddH2O, to maintain the buffer molarity. After a cool 
down at RT for 20 min or longer, sections were washed for 5 min in Tris-buffer with 2 
% milk powder and then mounted with plastic cover-plates for the following steps of 
the protocol. To test if cover-plates were mounted properly and the flowrate was 
optimal, sections were washed with Tris-buffer with 2 % milk powder. Then 
endogenous peroxidases were inactivated by 5 min incubation with 100 μl of 3 % 
hydrogen peroxide followed by blocking with 100 μl of blocking buffer for 20 min at 




incubated ON at 4 °C. On the next day, sections were washed with Tris-buffer with 2 
% milk-powder, followed by incubation with 100 μl of the biotinylated secondary 
antibody (Dako LSAB2, yellow bottle solution A) for 10 min at RT. After washing in 
Tris-buffer with 2 % milk-powder, 100 μl of Steptavidine conjugated to Horseradish 
Peroxidase (Dako LSAB2, red bottle solution B) were added to the sections and 
incubated for another 10 min at RT. After washing with Tris-buffer without milk-
powder for 10 min at RT, plastic cover-plates were removed and slides were placed 
into a box for staining with 100 μl of DAB substrate solution (1 ml Dako Substrate 
buffer with two drops of DAB) for 10 min, followed by washing twice in ddH2O for 5 
min. Depending on the purpose of the staining, sections were either counterstained 
with Haematoxylin for 30 sec and then washed once in ddH2O for 5 min, or sections 
were, without counterstaining, directly proceeded with dehydration in the ascending 
alcohol row and mounting in Eukitt, as for the H+E staining. 
 
6.5.6.3 DAB immunostaining of paraffin sections using the Ventana 
staining machine 
For quantification of neuronal numbers, paraffin sections were stained 
chromogenically using the Ventana Discovery XT Staining Module for standardized, 
automated stainings, that provide higher comparability between different sections. In 
addition, the staining procedure in an oil-based medium at 37 °C also speed up the 
staining process. First, microscope slides were labeled with a barcode sticker, 
encoding staining informations. Staining was carried out using the Research IHC 
DAB Map XT protocol with the Research IHC DAB Map XT kit according to the 
manufacturer’s informations. Primary antibodies and biotin-conjugated bridging 
antibodies were titrated by hand. Primary antibodies were incubated for 60 min, 
secondary biotin-conjugated antibodies for 20 min at 37 °C. Afterwards, sections 
were collected from the machine and rinsed with soapy water in a glas cuvette, to 
remove the residual oil from the slides. After dehydration by short incubations in an 
ascending row of alcohol solutions, followed by one incubation for 10 min in 
Xylol/Isopropanol (1:1) and twice for 10 min in Xylol, sections were mounted with 
Eukitt mounting medium and dried at RT. 
 
6.5.6.4 Fluorescent immunostaining of paraffin sections 
The protocol for fluorescent immunostaining of paraffin sections is similar to the DAB 
staining protocol until the steps after antigen retrieval. After cooling down, sections 




humidified chamber. 150 μl of blocking buffer were pipetted onto each slide and 
slides were covered with a piece of parafilm to ensure equal distribution of the 
blocking solution, allowing application of low (as low as 100 μl) volumes to the slides. 
Blocking was carried out for 20 min at RT. After decanting the blocking buffer, 150 μl 
of primary antibody were applied, slides were again covered with parafilm and 
incubated ON at 4 °C in the humidified chamber. On the next day, slides were 
washed 3x for 5 min in Tris-buffer with 2 % milk-powder, followed by application of 
150 μl dilution of fluorescent secondary antibody (incl. DAPI) in PBS/BSA and 
covering with parafilm. Incubation was carried out for 1 hour at RT in the humidified 
chamber, followed by 3x washing in Tris-buffer without milk-powder for 5 min, 
mounting with AquaPolymount, and storage at 4 °C. 
 
6.5.6.5 Fluorescent staining of vibratome sections 
Free floating vibratome sections were stained in a 24-well plate, starting with a 30 
min permeabilization in 200 µl of 0.4 % Triton X-100 in 1x PBS at RT. Afterwards, 
solution was carefully removed with a pipette and 200 µl of blocking solution were 
applied (4 % Horse-Serum, 0.1 % Triton X-100 in 1x PBS) for 30 min at RT. Primary 
antibodies (150 µl per slide) were diluted in 1 % Horse-Serum, 0.1 % Triton X-100 in 
1x PBS and incubated ON at 4 °C. On the next day sections were washed 3x for 5 
min in 1x PBS (500 µl), before application of 150 µl of the fluorescent secondary 
antibodies and Dapi (1 mg/ml), diluted in 1.5 % Horse-Serum in 1x PBS, and 
incubation for 2 hours at RT. From this step on slides had to be protected from light. 
After three more washing steps with 1x PBS, sections were carefully transferred with 
a soft brush to a deep petridish filled with tap water and pulled onto charged 
microscope slides. After a short first drying, sections were mounted with 
AquaPolymount and stored at 4 °C. 
 
6.5.6.6 Fluorescent staining of cryo sections 
Free floating cryo sections were stained, using the similar protocol as for free floating 
vibratome sections. Staining of slide-mounted cryo sections, was carried out on lying 
slides in a humidified box. Shandon cryomatrix was washed off by 10 min incubation 
in 1x PBS at RT in a cuvette, prior to permeabilization and blocking. Slides were 
placed into a humidified chamber and 200 µl of 4 % Horse-Serum, 0.1 % Triton X-
100 in 1x PBS were applied onto the slides for combined permeabilization and 
blocking for 30 min at RT. Afterwards 150 µl of the primary antibodies (diluted in 1 % 




parafilm, incubation was carried out ON at 4 °C. On the next day the staining was 
proceeded with three washing steps of 10 min in 1x PBS at RT in a cuvette, followed 
by application of 150 µl of the secondary antibodies and Dapi diluted in 1.5 % Horse-
Serum in 1x PBS, covering with parafilm, and incubation for two hours at RT in the 
humidified chamber. Afterwards, slides were washed 3x in 1x PBS in a cuvette, 
protected from light, then mounted in AquaPolymount and stored at 4 °C. 
 
6.5.6.7 Detection of β-galactosidase in tissue sections (X-Gal staining) 
The X-Gal staining method is based on the bacterial enzyme β-galactosidase’s (β-
gal) catalytic cleavage β-galactosides into monosaccharides. The enzyme has a 
broad substrate specificity and can thus also be used to cleave organic compounds 
such as 5-bromo4-chloro-3-indolyl-β-D-galactoside (X-Gal), resulting in a colorful 
indigo-colored precipitate (5-bromo-4-chloro-3-hydroxyindole) under oxidizing buffer 
conditions. Placed under the appropriate regulatory elements, the enzyme can 
furthermore be expressed in mammalian cells and is usually well tolerated. In 
transgenic mice this property of the enzyme allows the use of β-gal as a reporter to 
detect transgene or promoter activity of endogenous genes in ‘knock-in’ approaches 
(Goring et al., 1987; Sanes, 1994). 
To visualize β-gal activity in transgenic reporter mice, 50 μm vibratome brain sections 
were incubated in 'β-gal staining buffer' for 10 min to 24 hours at 37 °C in the dark. 
Sections were washed 3x for 10 min in 1x PBS at RT, to stop the X-Gal reaction. 
Sections were mounted onto charged microscope slides, shortly dried, then mounted 
with AquaPolymount and stored at 4 °C. 
 
6.5.7 Imaging and image analysis 
6.5.7.1 Cell counting of chromogenic stainings 
To quantify neuron numbers in the cortex and hippocampus of transgenic mice, 5 µm 
thick coronal paraffin sections (bregma -1.7) were stained chromogenically (see 
section 6.5.6.2-3) for neuronal markers and then imaged as tiles overviews at 10x 
magnification using a Zeiss Imager.Z1 microscope. Cortical and hippocampal cell 
numbers were blindly counted using the cell counter plugin for FIJI software 
(http://fiji.sc/Cell_Counter). Counted cell numbers were expressed as cell densities 
(cells per area counted (mm2)). Cell numbers of both hemispheres were averaged 





6.5.7.2 Quantification of GFAP+ and IBA1+ areas in chromogenic 
stainings 
To determine the GFAP+ or IBA1+ area in chromogenically stained coronal brain 
sections of transgenic mice, a semi-automatic analysis, using a plug-in for the FIJI 
software (available online at http://www1.em.mpg.de/gfap), was conducted. Briefly, 
10x overview pictures, acquired with the Zeiss Imager.Z1 microscope, were blindly 
loaded into the software. Regions of interest (cortex, hippocampal grey matter, 
fimbria and the corpus callosum) were marked in both hemispheres and the software 
analyzed the DAB-positive area over the total area quantified. Area fractions of both 
hemispheres were averaged and the data was analyzed using Excel and GraphPad 
Prism software. 
 
6.5.7.3 Two-Photon laser scanning microscopy 
For 2P-LSM, transgenic mice of 6-8 weeks of age were anesthetized using a gas 
mixture of O2:N2O (1:1) loaded with 5 % isoflurane in a closed box (flow rate: 1000 
ml/min). After initial sedation, anesthesia was maintained by a mask, on a heated 
plate and reduced flow rate (N2O: 100-200 ml/min; O2: 200-300 ml/min; 1.5-2 % 
isoflurane). The respiration rate was kept below 2 per second by adjusting the 
isoflurane dosage and the body temperature was kept constant (36-38 °C) 
throughout the experiment. The skull was attached to a custom-made ring using 
cement to reduce respiratory-induced movements. A cranial window close to the 
sagittal suture through the parietal bone was opened using a small dentist drill. The 
exposed cortex was covered by a glass coverslip.  
With a custom-made 2P-LSM equipped with an fs-pulsed titanium-sapphire laser 
(Chameleon Ultra II, Coherent, Glasgow, UK) and a long-distance 203/1.0 NA water 
immersion objective (Zeiss, Jena, Germany), in vivo imaging was performed. For 
excitation, the laser was set at 925 ± 5 nm. The fluorescence signal of PV-GFP+ 
interneurons was collected by a photomultiplier tube (Hamamatsu, Japan) through a 
510 ± 42 nm band-pass filter (Semrock). Uniformly spaced (0.8 µm) planes of 500 x 
500 µm2 regions of the cerebral cortex were recorded and processed to obtain z-
stacks of images (512 x 512 or 1024 x 1024 pixels in size). Image processing and 3D 
cell counting was performed using ImageJ (NIH; http://rsbweb.nih.gov/ij). For 3D 
visualization of image stacks as volumes, Java-based ImageJ 3D viewer plugin 






6.5.7.4 Data analysis and statistics 
Data organization, processing and analysis was performed using Microsoft Excel for 
Mac 2008 software. Statistical analyses were performed using GraphPad Prism 
software. Quantified values were grouped by animals and genotypes and averages 
with standard deviations (SD) and SEM (Standard error of the mean) were 
calculated. Statistical significance was analyzed with GraphPad Prism software using 




6.6 Behavioral experiments 
Mice were brought to the behavioral unit at least one week before the experiments, 
to allow them to adapt to the new environment. Mice were kept group housed with 
their littermates, with feed and water ad libitum, air ventilation and under a constant 
12 hour light-dark-cycle. Cage maintenance was done before and after the 
experimental phase, to reduce stress and handling during this phase. Animals were 
weighted before and after the experimental phase. Behavioral experiments were 
carried out during the light phase, with mice labeled only with default numbers to 
ensure blinding of the experimentator (blind to genotype). Animals were decoded and 
sorted into their respective groups only at the end of the study. Data was analyzed 
with Microsoft Excel for Mac 2008 and GraphPad Prism software. The majority of 
experiments performed in this study were performed according to standard protocols 
(Crawley, 2007). Unless stated otherwise, behavioral test apparatuses of TSE 
Systems (Bad Homburg) were used. Test chambers and apparatuses were cleaned 
with 70 % Ethanol p.A. prior to the experiment and between each trial, to minimize 
olfactory cues and ensure equal conditions for every mouse. 
 
6.6.1 Open field test 
The open field test is a widely used test to monitor spontanious locomotoric activity 
and anxiety in rodents (Hall, 1934; Broadhurst, 1961). Animals were allowed to 
explore an open field arena (size: 45 x 45 x 55 cm), with transparent walls and grey 
PVC floor (Fig. 35), for 10 min with automatic tracking by an x-y-z infrared 
observation system. Data was recorded using ActiMot software of TSE Systems. The 
following parameters were recorded: distance travelled in m, time spend in the center 
(70 % of the area) or the periphery (30 % of the area) of the arena, travel speed, time 




6.6.2 Hole board test 
To analyze the curiosity of mice, the hole board test (Bradley et al., 1968) was used. 
Holes in the floor of the experimental chambre triggered exploratory behavior, e.g. 
nos poking. The test was performed in the same apparatus as the open field test, 
only a second floor with 16 holes (diameter: 2 cm) was inserted into the arena (Fig. 
35). In this case, the x-y-z detectors of the system monitored nose pokes. Again the 
mice had 10 min to explore the arena. The system automatically tracked the distance 
travelled, number of nose pokes, and exploration time. 
 
 
Fig. 35: TSE Systems open field and hole board system. (A) Arena with infrared detector 
system. (B) Arena in open field test mode and (C) with hole board inserts. (Pictures in B and 
C were kindly provided by M. Brzózka). 
 
6.6.3 Hot plate test 
The hot plate test (O’Callaghan and Holtzman, 1975) was used to monitor the pain 
sensitivity of mice. Similar pain sensitivity in transgenic and control mice is crucial for 
certain learning tests, such as the fear conditioning test. 
Pain sensitivity was analyzed by placing mice onto a 55 °C hot plate surrounded by a 
plexiglass cylinder (Fig. 36) and measuring the time until they started licking their 
hindpaws (‚latency to lick the hindpaws (s)’). As soon as mice started to show this 
reaction, they were removed from the hot plate and placed onto a cool metal surface 
to cool down and were then transferred back into their homecages. Animals that 






Fig. 36: Hot plate test setup. 55 °C hot plate and a plexiglass cylinder to prevent mice from 
escaping. 
 
6.6.4 Light-Dark preference test 
The conflict between the drive to explore a novel environment and the aversion 
toward a light room was used for the light-dark preference test (Crawley and 
Goodwin, 1980). The in-house build experimental chamber consisted of two parts, a 
light compartment (LC) that was surrounded by transparent walls and a dark 
compartment (DC), with dark walls (Fig. 37). Both compartments were connected by 
a small open door. The test started by placing a mouse into the light compartment, 
facing towards the outside wall. The time until the mouse first entered the dark 
compartment was stopped (‚latency to enter the dark compartment’). From this point 
on, the time spend in either one of the compartments and the number of crossings 
was measured over a period of 5 min. 
 
 
Fig. 37: Light-Dark preference test setup. Light (LC) and dark compartment (DC) are 






6.6.5 Y-maze spontaneous alternation test 
The Y-maze spontaneous alternation test was used to measure working memory 
deficits in transgenic mice. Because of the inate drive of a rodent to investigate a 
new enviroment, mice will explore a new arm of the Y-maze rather than returning to 
one that was previously visited. Thus, over the course of multiple arm entries, normal 
mice show a tendency to more likely enter a less recently visited arm. Many parts of 
the brain, including the hippocampus, septum, basal forebrain, and prefrontal cortex, 
are involved in this task.  
The test apparatus consisted of a three armed Y-shaped maze (at an angle of 120°) 
(Fig. 38). A mouse was introduced into the starting arm and was allowed to freely 
explore the maze for 10 min. The experiment was recorded with an overhead video 
camera and the number of arm entries and their order was scored to calculate the 
percentage of alternation. An entry to an arm was counted when all four limbs were 
within the arm. 
 
 
Fig. 38: Y-maze spontaneous alternation test setup. Mize were introduced into the starting 
arm and were allowed to freely explore the maze for 10 min with overhead video recording. 
 
6.6.6 Tail suspension test 
The tail suspension test is used assess moot levels and motivational behavior in 
rodents. Mice were hung by the tail for 6 min (Fig. 39) and the time in which they 
actively tried to get free or hung passively was quantified. Mice with high motivation 
were expected to fight longer to escape the uncomfortable situation. Mice, which 






Fig. 39: Tail suspension test. Mice are hung by the tail for 6 min to access motivational 
states. 
 
6.6.7 Prepulse inhibition test 
Prepulse inhibition is phenomenon in which under normal conditions a weaker pre-
stimulus inhibits the reaction to a subsequent strong startling stimulus. The reduction 
of the amplitude of startle reflects the ability of the nervous system to temporarily 
adapt to a strong sensory stimulus when a preceeding weaker signal is given to warn 
the organism. Deficits in prepulse inhibition manifest in the inability to filter out the 
unnecessary information, have been linked to abnormalities of sensorimotor gating 
and are well described in schizophrenia (Geyer and Braff, 1982; Braff et al., 1992). 
The startle response was measured using San Diego Instruments’ SR-Lab startle 
response system. Mice were placed into a tubular enclosure on a detector platform in 
the test chamber, recording vertical movements of the enclosure (Fig. 40). The 
startle reaction to an acoustic stimulus (body muscles contraction, jumping) evoking 
a movement of the platform and a transient force, was recorded with a computer 
during a time window of 100 ms (beginning with the onset of the acoustic stimulus) 
and stored for further evaluation. Since restraining is stressful for mice and could 
influence the read-out, animals were habituated with similar enclosures for at least 5 
days prior to the experiment. With two experimental setups, always two mice were 
recorded at a time. It was ensured that genotypes always altered between the 
recorded pairs and setups. The protocol used was based on the protocol published in 
Brzózka et al. (2010). Briefly, the test started with an initial two minutes habituation 
phase to 65 dB background white noise (continuous throughout the session), 
followed by baseline recording for 1 min. Startle reflexes were evoked by acoustic 
stimuli delivered from a loudspeaker. After the baseline recordings, six pulse-alone 




decrease influence of within-session habituation and scale down the initial startle 
response to a stable plateau. For tests of prepulse inhibition, the 120 dB startle pulse 
of 40 ms duration was applied either alone or preceeded by a non-startling prepulse 
stimulus of 70, 75 or 80 dB intensity and 20 ms duration. An interval of 100 ms with 
background white noise was employed between each prepulse and pulse stimulus. 
The trials were presented in a pseudorandom order with inter-trial intervals ranging 
from 8 to 22 s. The amplitude of the startle response (expressed in arbitrary units, 
AUs) was defined as the difference between the maximum force detected during a 
recording window and the force measured immediately before the stimulus onset. 
Maximum amplitudes were averaged for each individual animal, separately for all 
types of trials (i.e. stimulus alone or stimulus preceded by a prepulse). Prepulse 
inhibition (expressed in %) was calculated as the percentage of the startle response 
using the following formula: 
 
Prepulse inhibition (%)  =  100   –   (startle amplitude after prepulse and pulse)  
            startle amplitude after pulse only) × 100 
 
 
Fig. 40: San Diego Instruments’ SR-Lab startle response system. Mice were placed into 
plastic restrainers on a detector platform recording vertical movements of the enclosure. 
 
6.6.8 Fear conditioning 
In this study two cohorts of conditional NRG1 transgenic mice were tested 
individually in the fear conditioning paradigm. In between these two tests a new fear 




the old TSE Systems setup, while the Stop-Nrg1*NEX-Cre cohort was tested in the 
new Ugo Basile Series 46000 Fear Conditioning System. The basic principle of the 
experiment was similar for both setups, the differences between the two will be 
explained as follows. 
In this experiment the freezing behavior, defined as a lack of movement (excluding 
respiratory movements of the chest), is considered as a measure of memory. The 
experiment consists of three experimental trials, conducted over the course of three 
consecutive days. On the first day the mice were conditioned in the conditioning 
chamber. In the TSE Sytems setup the conditioning took place in a plexiglas 
conditioning chamber (36 x 20 x 20 cm) with a loudspeaker, a lamp (12 V) and a 
removable shock grid floor made of stainless rods (4 mm diameter, spaced 6 mm 
apart). The grid was connected to the shock-scrambler unit applying an electrical 
shock of defined intensity and duration. The system had an overhead video camera 
connected to a monitor (Fig. 41C). The Ugo Basile setup, had a square conditioning 
box with a 15 x 15 cm grid floor. In contrast to the TSE Systems setup, the walls of 
the chamber were covered with black and white striped pannels and the chamber 
was placed in a soundproof box with an infrared overhead camera (Fig. 41A). In the 
TSE System only one mouse was tested at a time, while in the Ugo Basile setup, two 
mice were tested at a time, in two setups. Here a white noise tone was played during 
the experiment. 
The training for the contextual and cued fear memory took place at the same time. A 
mouse was placed into the conditioning box and its behavior (freezing rate) was 
observed as an initial baseline phase of 2 min. In the TSE System setup, freezing 
was scored every 4 s during 2 min (context baseline) by the blind to genotype 
experimenter, while in the Ugo Basile setup the freezing events and durations were 
scored by the software, in both experiments the whole session was recorded by a 
camera for later rescoring. After the 2 min pre-exposure time (= context baseline) a 
tone was played for 30 sec (conditioned stimulus (CS); 10 kHz, 75 dB). Directly after 
the tone a mild electrical foot shock was applied (0.4 mA, 2 s duration). After a 30 
sec pause the tone and shock were repeated with same intensity and duration. After 
the second foot shock each mouse was allowed to stay in the conditioning box for 30 
sec to avoid the association of aversive stimuli with the experimenter. Afterwards 
animals were placed back into their home cages. The conditioning box was cleaned 
with 70 % ethanol p.A. between trials. On the second day, contextual fear memory 
was assessed by scoring the freezing response for 2 min in the conditioning box in 
the absence of tone and shock. Another 24 h later mice were placed into a new 




plastic chamber (36 x 20 x 20 x 20 cm) that was placed onto a different table, while 
the conditioning chamber was covered by white sheets (Fig. 41D). In the Ugo Basile 
experiment a transparent plastic cylinder (36 x 20 cm) was placed onto a grey plastic 
floor into the soundproof box (Fig. 41B). Baseline freezing behavior was scored for 2 
min, followed by 2 min of the cue tone (CS) and scoring of freezing response as a 
measure of cued fear memory. The ‘cue’ box was cleaned with water between trials 
to avoid olfactory cues resembling conditioning. In both cases the whole experiment 
was video recorded for second rescoring. 
 
 
Fig. 41: Ugo Basile Series 46000 and TSE Systems fear conditioning setups. The Ugo 
Basile system used a conditioning and contextual fear memory box with grid and striped walls 
(A) and a round plastic cylinder on a grey floor for cued fear memory (B) inside a soundproof 
test apparatus. In the TSE Systems setup a bigger gridded box was used for conditioning and 
assessment of contextual fear memory (C), while the cued fear memory was measured in a 
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